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Abstract 
Kinetic target-guided synthesis (TGS) and in situ click chemistry are among 
unconventional discovery strategies having the potential to streamline the development of 
protein-protein interaction modulators (PPIMs). In kinetic TGS and in situ click 
chemistry, the target is directly involved in the assembly of its own potent, bidentate 
ligand from a pool of reactive fragments. Herein, we report the use and validation of 
kinetic TGS based on the sulfo-click reaction between thio acids and sulfonyl azides as a 
screening and synthesis platform for the identification of high-quality PPIMs. Starting 
from a randomly designed library consisting of nine thio acids and nine sulfonyl azides 
leading to eighty one potential acylsulfonamides, the target protein, Bcl-XL selectively 
assembled four PPIMs, acylsulfonamides SZ4TA2, SZ7TA2, SZ9TA1, and SZ9TA5, 
which have been shown to modulate Bcl-XL/BH3 interactions. To further investigate the 
Bcl-XL templation effect, control experiments were carried out using two mutants of Bcl-
XL. In one mutant, phenylalanine Phe131 and aspartic acid Asp133, which are critical for 
the BH3 domain binding, have been substituted by alanines, while arginine Arg139, a 
residue identified to play a crucial role in the binding of ABT-737, a BH3 mimetic, has 
been replaced by an alanine in the other mutant. Incubation of these mutants with the 
reactive fragments and subsequent LC/MS-SIM analysis confirmed that these building 
block combinations yield the corresponding acylsulfonamides at the BH3 binding site, 
the actual “hot spot” of Bcl-XL. These results validate kinetic TGS using the sulfo-click 
reaction as a valuable tool for the straightforward identification of high-quality PPIMs. 
x 
 
Protein-protein interactions of the Bcl-2 family have been extensively 
investigated and the anti-apoptotic proteins (Bcl-2, Bcl-XL, and Mcl-1) have been 
validated as crucial targets for the discovery of potential anti-cancer agents. At the outset, 
Bcl-2 and Bcl-XL were considered to play an important role in the regulation of 
apoptosis. Accordingly, several small molecule inhibitors targeting Bcl-2 and/or Bcl-XL 
proteins were primarily designed. A series of acylsulfonamides targeting these proteins 
were reported by Abbott laboratories, ABT-737 and ABT-263 being the most potent 
candidates. Remarkably, these molecules were found to exhibit weaker binding affinities 
against Mcl-1, another anti-apoptotic protein. Further experimental evidence suggests 
that, inhibitors targeting Mcl-1 selectively or in combination with other anti-apoptotic 
proteins would lead to desired therapeutic effect. As a result, numerous small molecules 
displaying activity against Mcl-1 have been identified so far. Specifically, 
acylsulfonamides derived from structure activity relationship by interligand nuclear 
overhauser effect (SAR by ILOEs), a fragment-based approach, have been recently 
reported with binding affinities in the nanomolar range. In the meantime, we have 
reported that the kinetic TGS approach can also be applied to identify acylsulfonamides 
as PPIMs targeting Bcl-XL. Taken together, structurally novel acylsulfonamides can be 
potentially discovered as Mcl-1 inhibitors using the kinetic TGS approach. Thus, a library 
of thirty one sulfonyl azides and ten thio acids providing three hundred and ten potential 
products was screened against Mcl-1 and the kinetic TGS hits were identified. 
Subsequently, control experiments involving Bim BH3 peptide were conducted to 
confirm that the fragments are assembled at the binding site of the protein. The kinetic 
TGS hits were then synthesized and subjected to the fluorescence polarization assay. 
xi 
 
Gratifyingly, activities in single digit micromolar range were detected, demonstrating that 
the sulfo-click kinetic TGS approach can also be used for screening and identification of 
acylsulfonamides as PPIMs targeting Mcl-1. 
The amide bond serves as one of nature’s most fundamental functional group and 
is observed in a large number of organic and biological molecules. Traditionally, the 
amide functionality is introduced in a molecule through coupling of an amine and an 
activated carboxylic acid. Recently, various alternative methods have been reported 
wherein, the aldehydes or alcohols are  oxidized using transition metal catalysts and are 
treated with amines to transform into the corresponding amides. These transformations 
however, require specially designed catalysts, long reaction times and high temperatures. 
We herein describe a practical and efficient amidation reaction involving aromatic 
aldehydes and various azides under mild basic conditions. A broad spectrum of 
functional groups was tolerated, demonstrating the scope of the reaction. Consequently, 
the amides were synthesized in moderate to excellent yields, presenting an attractive 
alternative to the currently available synthetic methods. 
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Chapter 1 
Various Drug Discovery Approaches and Protein-Protein Interaction Targets 
1.1 Drug discovery approaches 
 Advances in the field of molecular biology have resulted in a better understanding 
of various biochemical pathways. Consequently, a large number of proteins have been 
recognized and validated as therapeutic targets creating an urgent need for generation of 
novel drug-like molecules. Over the last two decades, conventional drug discovery 
approaches such as combinatorial chemistry and high-throughput screening (HTS) have 
been extensively explored in the quest of biologically active molecules. These approaches 
demand generation of a large library of compounds and data analysis making it expensive 
and cumbersome. Moreover, the false positives obtained during the library screening 
presents additional drawbacks thereby impeding the drug discovery and development 
process. Alternatively, a wide range of fragment-based approaches have emerged as 
promising tools towards lead discovery. These approaches can be divided into two 
categories. In the first category, the fragments with weak binding affinities are identified 
using various biophysical techniques and are subsequently converted into the drug-like 
molecules using traditional synthetic procedures. In the second category, the target serves 
as a template assembling the fragments together to yield the inhibitor of that target itself. 
These approaches are termed as template-assisted strategies or target-guided synthesis 
2 
 
(TGS). TGS can be further classified into three subcategories: (a) dynamic combinatorial 
chemistry (DCC), (b) catalyst/reagent-accelerated TGS and (c) kinetic TGS. 
1.2 Combinatorial chemistry and high-throughput screening (HTS) 
Combinatorial chemistry was developed by Merrifield in 1960s to rapidly 
generate a large number of compounds, utilizing a solid phase synthesis methodology.1 
Since then this approach has been widely used for drug discovery and development.2 
Hundreds to thousands of compounds can be synthesized and tested in much shorter time 
compared to the conventional synthetic procedures thereby increasing the chances of 
finding molecules with biological activity. Especially, mixtures of compounds are 
obtained in a mix and split method. These mixtures are directly subjected to the 
biological assays and if found active, the exact compound displaying the activity can then 
be identified via a specialized deconvolution procedure. In the HTS approach, libraries of 
compounds (> 106), primarily generated through combinatorial chemistry, are tested in an 
automated fashion against a wide range of targets to identify potential hits. Various types 
of HTS assays have been developed to detect binding of the compound to a desired 
target. Some of the commonly used assays include the fluorescence polarization (FP) 
assay3 and the amplified luminescent proximity homogeneous assay (Alpha).4 
Importantly, these strategies require huge investments since a large set of molecules 
needs to be synthesized and analyzed using automated liquid handling tools. Also, a high 
rate of false positives is observed during HTS screening especially for difficult targets 
considered to belong to the class of “undruggable” targets. This could be attributed to the 
presence of chemically reactive members in the library and/or inhibitory activity arising 
from formation of molecular aggregates, known as promiscuous inhibitors. Moreover, 
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approximately 1063 drug-like molecules consisting of up to 30 heavy atoms have been 
estimated to exist.5 Screening all of these molecules is practically impossible, presenting 
limitations in exploring the chemical space efficiently.6 As a result, although the 
pharmaceutical industry has heavily relied on combinatorial chemistry and HTS 
approaches, they have met with limited success. In order to find alternatives, modern 
approaches such as fragment-based lead discovery (FBLD) have been extensively 
exploited. 
1.3 Fragment-based lead discovery 
Recently, several fragment-based lead discovery (FBLD) approaches have been 
established as an attractive alternative to the conventional drug discovery methods.7 This 
approach involves synthesis of libraries of small molecules or fragments (molecular 
weight in the range of 150-300 Da).8 As opposed to the drug-like molecules, only 107 
fragments consisting of up to 12 heavy atoms have been estimated to exist.9 
Consequently, the fragments possess higher ligand efficiency compared to the molecules 
arising from the combinatorial libraries and HTS. Initially, the fragments exhibiting weak 
affinity (binding constants in the milli- to micromolar ranges) are identified and 
subsequently combined using synthetic procedures to develop ligands with high affinity 
(binding constants in the micro- to nanomolar ranges).8, 10 Various techniques employed 
to detect fragments with weak binding affinities include surface plasmon resonance 
(SPR),11 X-ray crystallography,12 isothermal titration calorimetry (ITC),13 nuclear 
magnetic resonance (NMR) spectroscopy14 and mass spectrometry.15 Some of the 
disadvantages of the aforementioned methods are the relatively low throughout, the 
requirement of sensitive and expensive instrumentation for the detection of small 
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molecular weight compounds, and the necessity of large amount of protein. Importantly, 
these techniques fail to provide the most critical piece of information: what is the best 
way to combine identified fragments with weak binding affinities leading to high-affinity 
ligands?16 Thus, extensive synthetic efforts have to be implemented in order to obtain 
potent inhibitors immediately after the fragments are detected. For example, Fesik et al. 
utilized a SAR by NMR approach to develop dual inhibitors of anti-apoptotic proteins, 
Bcl-2 and Bcl-XL.17 Starting from the initial fragments, more than 2300 compounds had 
to be synthesized,18 leading to ABT-737, one of the most potent inhibitor of Bcl-2 and 
Bcl-XL.19 To overcome these shortcomings, several template-assisted strategies, known 
as target-guided synthesis (TGS), have been recently established. 
1.4 Target-guided synthesis (TGS) 
 In a target-guided synthesis (TGS) approach, the biological target, a protein or an 
enzyme plays a significant role in the synthesis of its own bidentate ligand from a library 
of various building blocks derivatized with complementary reacting functional groups. 
The TGS can be broadly divided into three sets: (a) dynamic combinatorial chemistry 
(DCC) (b) catalyst/reagent-accelerated TGS and (c) kinetic TGS. 
1.4.1 Dynamic combinatorial chemistry (DCC) and its variants 
 The dynamic combinatorial chemistry (DCC) approach was first applied by Huc 
et al. in 1997 to discover inhibitors of carbonic anhydrase.20 In a DCC approach, the 
reaction combining sublibraries of building blocks into a larger library of larger 
compounds is reversible (Figure 1.1). When the biological target is added to this library, 
also known as the dynamic combinatorial library (DCL), the equilibrium is shifted 
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towards the formation of compounds possessing the strongest affinities towards the 
target, thereby enabling the identification of the most potent compounds from the DCC 
library.21  
 
Figure 1.1. Schematic representation of the dynamic combinatorial chemistry (DCC) 
approach 
Hence, the generation and isolation of the desired compound can be combined in 
a single step making the entire process simple and rapid. Especially, the DCC approach 
has been proved useful in case of library of building blocks possessing a variety of 
functional groups, which are not compatible and cannot be handled conveniently using 
the conventional combinatorial chemistry methods. For example, Hochgurtel et al. 
designed the DCL of imines derived from a highly functionalized diamine and 41 diverse 
ketones, which was screened against an influenza virus enzyme, neuraminidase.22 
Reduction of imines using NaCNBH3 yielded corresponding amines, which were 
subjected to HPLC/MS analysis for the identification of hits. Other examples of the 
reactions utilized in developing the DCLs include, the trans-esterification, the olefin 
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metathesis, the peptide-bond exchange, the boronic ester formation, the Diels-Alder 
reaction and the disulfide formation.23 The variants of DCC consist of tethering, 
pseudo-dynamic combinatorial chemistry (pDCC) and dynamic combinatorial resolution 
(DCR).  
Tethering, a DCC variant has been proved to be highly successful in the 
identification of inhibitors for numerous challenging targets such as interleukin-2 
(IL-2),24 protein tyrosine phosphatase 1B (PTP-1B),25 caspases26 and others.27 A specific 
segment of the protein template is exploited, wherein a cysteine residue in the proximity 
of the binding site actively takes part in the thiol-disulfide exchange reaction (Figure 
1.2).24, 27b  
 
Figure 1.2. Schematic representation of tethering 
Alternatively, a cysteine residue can be either incorporated through site-directed 
mutagenesis27a, 28 or extended by a thiol bearing linker.26 For example, the caspase-3 
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enzyme was modified by attaching a thiol bearing aspartate analogue and subsequently 
screened against a library of 7000 disulfides.26 The disulfides binding near the 
thiol-bearing linker would thus be exchanged through the reaction with the thiol. The 
enzyme-disulfide complex can be subsequently identified using mass spectrometry. 
Although the disulfide needs to be transformed into a chemically stable entity and large 
amounts of the biological template (close to stoichiometric amounts) are required, this 
tethering approach can be applied to various enzymes/proteins due to the readily 
available cysteine residue.6 In case of dynamic combinatorial resolution (DCR),29 an 
enzyme, when treated with the DCL, selectively transforms certain members of the 
library into structurally different products through an irreversible reaction. Ramstrom and 
co-workers have demonstrated the utility of this approach using a nitroaldol in a Henry 
reaction (Figure 1.3).29a  
 
Figure 1.3. Dynamic combinatorial resolution using nitroaldol reaction 
The DCL consisting of five different aromatic aldehydes along with 
2-nitropropane leading to ten corresponding nitroaldol products (including all the 
enantiomers) was designed and treated with lipase PS-C I in the presence of 
4-chlorophenyl acetate serving as the acyl donor. Only two β-nitroalcohols (as single 
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enantiomers) were found by 1H NMR spectroscopy to be predominantly acylated by the 
lipase after 14 days of incubation.29a On the contrary, pseudo-dynamic combinatorial 
chemistry (pDCC)30 strategy relies on an enzymatic bond cleavage reaction (Figure 1.4). 
This strategy was successfully employed by Corbett et al. utilizing pronase, a nonspecific 
protease, facilitating the hydrolysis of dipeptides. Eight dipeptides were synthesized and 
incubated with carbonic anhydrase and subsequently treated with pronase. Consequently, 
the dipeptide with highest binding affinity towards carbonic anhydrase was protected, 
whereas other dipeptides, being more susceptible to hydrolysis by pronase, were 
eliminated.30a Although the applicability of this approach is restrained by the cleavage 
reaction, requirement of the template in only catalytic amounts makes it advantageous 
over conventional DCC methods. 
 
Figure 1.4. Pseudo-dynamic combinatorial chemistry 
1.4.2 Catalyst/reagent-accelerated target-guided synthesis 
 In this two-step approach, the templated combination of two fragments with 
highest binding affinities by the protein target constitutes the first step. The second step 
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entails the addition of a catalyst or a reagent resulting in the covalent bond formation 
between the binding fragments. This approach has been successfully applied to develop 
various Vancomycin dimers,31 trimers32 or oligomers33 as inhibitors of 
vancomycin-resistant bacterial strains. Nicolaou and co-workers employed the disulfide 
bond forming reaction and/or the olefin metathesis reaction to link two Vancomycin units 
together in a back-to-back fashion generating disulfide or alkene linkages, respectively.34 
The reaction conditions for the disulfide bond formation were comprised of a 
saponification using NaOH followed by the dimerization via air oxidation, whereas the 
Grubb’s catalyst ([(PCy3)2Ru(CHPh)Cl2]) along with a phase-transfer catalyst 
(C12H25NMe3Br) were required for the olefin metathesis reaction. Several analogues with 
varied linker lengths and/or different amino acid sequences at the N-terminus were 
designed and subjected to the aforementioned reaction conditions in the presence and 
absence of the targets Ac-D-Ala-D-Ala or Ac2-L-Lys-D-Ala-D-Ala. The rate of 
dimerization was found to be accelerated by the target for selective Vancomycin 
derivatives. In accordance, these dimers displayed higher potency compared to other 
dimers against the Vancomycin-resistant bacterial strains, demonstrating the utility of this 
approach. 
1.4.3 Kinetic target-guided synthesis 
 In this particular approach, the used building blocks or fragments are decorated 
with complementary reacting functional groups. Thus, when a biological target (a protein 
or an enzyme) is introduced, it selectively templates the irreversible bond formation 
between specific building blocks with high affinity. As a result, the target-facilitated 
covalent bond formation between two building blocks yields a potent inhibitor through an 
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irreversible reaction, which ideally has characteristics of a click chemistry reaction 
(Figure 1.5).35 
 
Figure 1.5. Schematic representation of the kinetic TGS approach 
A set of criteria that must be met for a reaction to be used as a click reaction 
includes: (a) high yield, (b) sluggish reactivity profile, (c) wide scope, and (d) generate 
no or minimal amounts of byproducts.36 In addition, the reaction needs to 
stereospecifically proceed smoothly in organic as well as aqueous solvents, along with a 
simple isolation of the product.36 
 
Figure 1.6. Reactions suitable for click chemistry  
Typically, reactions leading to a carbon-heteroatom bond formation are found to 
be suitable as click reactions. Some well-known reactions used for the click chemistry 
are: (a) the 1,3-dipolar cycloaddition, (b) the hetero-Diels-Alder reaction, (c) the 
reactive
fragments
biological
target
selective
binding
reaction
formation of 
bidentate ligand
target-fragments
complex
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nucleophilic ring-opening reactions of aziridines and epoxides, (d) the non-aldol 
reactions of carbonyl moiety generating oxime ethers, the formation of hydrazones and 
aromatic heterocycles, (e) the oxidative additions to olefins such as dihydroxylations and 
epoxidations, and (f) the recently developed sulfo-click reaction between azides or 
sulfonyl azides and thio acids yielding amides or acylsulfonamides (Figure 1.6 A-D).36-37 
1.4.3.1 In situ click chemistry  
Amongst the reactions mentioned above, the Huisgen 1,3-dipolar cycloaddition 
reaction between azides and alkynes resulting in 1,2,3-triazoles, termed as in situ click 
chemistry, has been instrumental in the validation of kinetic TGS approaches due to its 
desirable reactivity profile. Conveniently, the triazoles display favorable physicochemical 
properties, take part in hydrogen-bonding, and are stable towards hydrolytic cleavage as 
well as oxidative or reductive reaction conditions.36b Various reaction conditions have 
been established to synthesize the disubstituted 1,2,3-triazoles (Scheme 1.1). For 
example, copper-(I) catalysts are generally employed to regioselectively obtain 
1,4-disubstituted triazoles (anti-triazoles),38 whereas 1,5-disubstituted triazoles 
(syn-triazoles) can be synthesized using magnesium acetylides or ruthenium catalysts.39 
On the contrary, when an azide and an alkyne are heated in the absence of solvent, 
equimolar mixture of syn- and anti-triazoles is obtained.36a, 40 Interestingly, only one of 
the regioisomers is preferentially formed in the templated reaction.41 
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Scheme 1.1. Synthesis of disubstituted 1,2,3-triazoles via Huisgen cycloaddition 
The sluggish rate of this reaction has actually been proved to be advantageous for 
its application in the kinetic TGS approach.42 Mock and co-workers investigated the 
reaction of an azide and an alkyne, each attached to an alkyl ammonium moiety. They 
reported that the rate of triazole formation was radically accelerated (by a factor of 
5.5104) in the presence of catalytic amounts of cucurbituril, a nonadecacyclic cage-like 
structure comprised of substituted urea subunits.43 Based on the NMR studies and other 
experiments, the ammonium moiety (RNH3+) was found to be involved in the hydrogen 
bonding with the urea carbonyls, placing the azide and alkyne functionalities in proximity 
within the cavity of the cucurbituril cage, thereby accelerating the triazole formation.43a 
Inspired by these results, Sharpless and co-workers extended this approach to 
acetylcholinesterase (AChE),41, 44 an enzyme which a crucial role in the functioning of 
central and peripheral nervous system by catalyzing hydrolysis of acetylcholine.45 A set 
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of azides and alkynes leading to ninety eight potential triazoles (arising from forty nine 
combinations, considering syn- and anti- regioisomers) were incubated as binary 
mixtures in the presence of an eel AChE at room temperature for 6 days (Figure 1.7).44a 
   
Figure 1.7. In situ click chemistry approach using eel AChE as a template 
Out of ninety eight potential triazoles, only one triazole, syn-TZ2PA6, was 
generated in detectable amounts in the presence of the eel AChE. It is important to note 
that, the sluggish rate of this reaction would make it impossible to generate detectable 
amount of triazole in the absence of the target, underlining the role of the templation in 
accelerating the triazole formation by bringing the azide and alkyne functionalities 
together. The dissociation constants for syn- and anti-TZ2PA6 were found be 99 fM and 
14 pM respectively.44a These results clearly indicate that the triazole syn-TZ2PA6 with 
its significantly higher potency was preferentially assembled by the enzyme. Due to its 
versatility and reliability, the in situ click chemistry approach has been successfully 
employed to discover potent inhibitors of the enzymes such as bovine carbonic anhydrase 
(bCAII),46 HIV-1 protease47 and chitinase.48 Other noteworthy examples include, 
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DNA-templated triazole formation starting from hairpin polyamide azides and alkynes,49 
and polypeptide-based antibody-like capture agents for bCAII.50 
1.4.3.2 Sulfo-click reaction 
Williams and co-workers recently developed a reaction, wherein 
electron-deficient azides (sulfonyl azides) or electron-rich azides (alkyl/aryl azides) react 
with thio acids leading to the corresponding amides.37a, b Detailed mechanistic studies 
have revealed that this reaction follows two distinct pathways depending upon the 
electronic nature of the azide used. The electron-rich azides favor the formation of 
thiatriazoline intermediate 7 directly whereas the electron-deficient azides primarily 
generate the linear intermediate 8 eventually leading to thiatriazoline 7 (Scheme 1.2).37b 
This reaction requires mild conditions, is high yielding and can be carried out in various 
organic as well as aqueous solvents. Importantly, the byproducts generated are not 
detrimental to the biological systems.  
 
Scheme 1.2. Mechanism of the amidation reaction between azides and thio acids 
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These features qualify this amidation reaction, involving sulfonyl azides (termed 
as sulfo-click reaction37c) to be applied for the kinetic TGS approach. For example, Hu et 
al. designed a proof-of-concept experiment wherein, a set of six sulfonyl azides 
(SZ1-SZ6) and three thio acids (TA1-TA3) (eighteen possible combinations) was 
incubated as binary mixtures at 37 °C for six hours with the target protein Bcl-XL, an 
anti-apoptotic protein of the Bcl-2 family (Figure 1.8).51 As a control, all eighteen 
combinations were incubated in the phosphate buffer without Bcl-XL. The samples were 
then analyzed by liquid chromatography combined with mass spectrometry using selected 
ion mode (LC/MS-SIM). Of all eighteen possible N-acylsulfonamide products, SZ4TA2, 
an inhibitor of Bcl-XL reported by Abbott laboratories,52 was identified as a kinetic TGS 
hit.  
 
Figure 1.8. Screening of sulfonyl azides and thio acids against Bcl-XL 
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Additional control experiments incorporating wildtype (WT) and mutant versions 
of pro-apoptotic BH3 peptides (Bak and Bim) were carried out to probe whether the 
fragments are being templated at the binding site of Bcl-XL or through non-specific 
binding. The WT BH3 peptides were found to compete with the fragments resulting in 
the suppression of the templated product formation, whereas the mutant BH3 peptides did 
not affect the templated reaction owing to the weaker binding affinities.51 These findings 
have suggested that the kinetic TGS approach utilizing an amidation reaction could also 
be applied to protein-protein interaction targets.  
1.4.3.3 Other reactions used for kinetic TGS 
 Apart from the reactions described above, additional reactions have also been 
found suitable for the kinetic TGS approach due to their favorable characteristics (Figure 
1.9 A-D). Inspired from the serendipitous discovery by Chase and Tubbs involving 
carnitine acetyltransferase templated C-S bond forming reaction between 
bromoacetyl-carnitine and coenzyme-A,53 Nguyen and Huc extended this approach 
against bovine carbonic anhydrase II (CA II).54 A set of five alkyl chlorides and a thiol 
consisting of a sulfonamide moiety were used for this purpose. It is important to note that 
the fragments leading to more potent sulfides were preferably templated by CA II when 
two alkyl chlorides and one thiol were simultaneously incubated. Other reactions utilized 
as click reactions include a C-N bond formation templated by glycinamide ribonucleotide 
transformylase (GAR Tfase),55 a C-C bond formation with sirtuin as a template56 and a 
multi-component Ugi reaction templated by thrombin.57 
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Figure 1.9. Other reactions explored for kinetic TGS application 
1.5 Targeting protein-protein interactions 
 Protein-protein interactions constitute an integral part of the biological system and 
are involved in the regulation of many key processes ranging from signal transduction to 
apoptosis, a programmed cell death mechanism. Therefore, targeting specific 
protein-protein interactions has been of great therapeutic interest.58 Despite enormous 
potential, identification of small molecules disrupting these interactions remains a 
challenging task.58c, 58l, 59 The challenges are mainly associated with the nature of binding 
interfaces involved during these interactions. Typically, these interfaces are large 
(1500-3000 Å2),60 flat and do not provide well-defined binding pockets or grooves.58a, b 
Additionally, the binding regions involved are noncontiguous, which complicates the 
design of synthetic peptides.58b, 58d Moreover, unlike enzymatic targets, natural small 
molecules or ligands binding to the protein-protein interfaces are hardly available posing 
difficulties during the inception.58a-c Proteins are also known to undergo significant 
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conformational changes. As a result, X-ray crystal structures may not be able to reveal 
deep cavities.58a, 58e In fact, a particular crystal structure can possibly represent merely 
one out of various conformations. It is quite possible that the conformation of the protein 
suitable for small molecule binding may not be obtained in one crystal structure.58a, 61 
Due to these hurdles, protein-protein interaction targets were thought to be 
‘undruggable’. However, Clackson and Wells demonstrated through the pioneering work, 
that only a small region of the interface composed of few amino acids in the binding 
interface heavily contribute to the free energy of binding.62 It was then envisioned that 
the small molecules targeting these small regions, termed as ‘hot spots’, would serve as 
initial drug candidates displaying reasonable binding affinities. Generally, the ‘hot spots’ 
are identified by alanine scanning62b, 63 (wherein amino acid residues are replaced by 
alanine methodically and the change in the binding free energy for each mutation is 
determined) and are mainly comprised of aromatic as well as positively charged 
residues.62b Wells and co-workers used this technique to analyze the binding interactions 
between human growth hormone (hGH) and the extracellular domain of its receptor 
(hGHbp).64 During the alanine screening, they discovered that out of thirty one side 
chains constituting the binding interface of hGH, only eight make up for approximately 
85% of the binding free energy, while eleven of the side chains did not contribute 
towards the binding affinity at all.64b These findings have tremendously triggered the 
drug discovery process towards identification of various small molecules as 
protein-protein interaction modulators. Some noteworthy examples of protein-protein 
interactions include Bcl-XL / Bak, IL-2 / IL-2Rα, MDM2 / p53, LFA-1 / ICAM-1, Mcl-1 
/ Bim and TNF / TNFRc1.58a, b, 65 
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1.5.1 Protein-protein interactions of the Bcl-2 family  
The Bcl-2 family of proteins has been validated as a central regulator of apoptosis 
through an intrinsic pathway (also known as mitochondrial pathway) and can be divided 
into two categories, namely pro-apoptotic proteins and anti-apoptotic proteins.66 The 
pro-apoptotic proteins, which can be further divided into two sub-categories, include Bak, 
Bax, Bok (multidomain proteins) and Bid, Bim, Bad and Noxa (BH3-only proteins). On 
the other hand, anti-apoptotic proteins mainly include Bcl-2, Bcl-XL, Mcl-1, Bcl-w and 
A1.66c Almost all the Bcl-2 family proteins consist of a dimerization domain, known as 
BH3 domain, represented by a 16 amino acid amphipathic α helix. The NMR structure of 
Bcl-XL bound to Bak has revealed that the latter, in the α-helical structure, binds to the 
hydrophobic groove of Bcl-XL.67 The ability of the anti-apoptotic proteins to 
heterodimerize with pro-apoptotic proteins (both, multidomain and BH3 only) through 
the BH3 domain can be correlated with their role in the suppression of cell death 
mechanism resulting in tumor progression.66a In accordance, the majority of human 
cancers display overexpression of anti-apoptotic Bcl-2 family proteins. For example, high 
levels of Bcl-2 and Bcl-XL are observed in prostate, breast and colorectal cancers.68 Some 
BH3-only proteins (e.g. Bad) antagonize the anti-apoptotic proteins making the 
multidomain pro-apoptotic proteins available during apoptosis and are known as 
sensitizers or de-repressors. Alternatively, other BH3-only proteins (such as Bid or Bim) 
can directly activate the Bak or Bax and hence are termed as activators.66c Therefore, 
small molecules mimicking the BH3 domain can be developed to induce apoptosis and 
hence have the potential as anti-cancer therapeutics.69 
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Figure 1.10. Small-molecular inhibitors of Bcl-2/Bcl-XL 
 Several combinations of drug discovery methods have been employed for 
developing potent inhibitors of the Bcl-2 and/or Bcl-XL (Figure 1.10).19, 52, 70 In 
particular, small molecules mimicking the α-helix involved in the binding interactions 
have displayed high affinities (Ki ~ 5-100 nM).71 During the last decade, Fesik and 
co-workers at Abbott laboratories designed highly potent small molecular dual inhibitors 
of Bcl-2 and Bcl-XL utilizing a fragment-based approach known as SAR-by-NMR.17, 19, 
52, 72 In this approach, small fragments were screened against 15N-labeled Bcl-XL using 
15N HSQC analysis. First, ligands with weak binding affinities targeting first and second 
site within the hydrophobic groove of Bcl-XL were identified. These fragments were then 
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optimized using NMR analysis in combination with parallel synthesis to generate 
high-affinity ligands. Moreover, these compounds retained the activity in cell-based 
assays as well as in animals (tumor xenograft models).58b The most potent compound, 
ABT-737 obtained after extensive efforts exhibited a Ki of 0.6 nM against Bcl-2, Bcl-XL 
and Bcl-w.19 ABT-263, an analogue of ABT-737 has entered in phase I/II clinical trials 
for cancer treatment.73 Interestingly, these compounds were found to be selective and 
showed lower binding affinity (Ki = 0.46 µM) against other anti-apoptotic proteins such 
as Mcl-1, Bcl-B and A1.19  Analysis of various peptides derived from Bak through 
alanine scanning has revealed that the amino acid residues Val 74, Leu 78, Ile 81, Asp 83 
and Ile 85 are responsible for the key binding interactions with Bcl-XL.67, 71b Although 
ABT-737 binds to Bcl-XL in the same domain as observed for Bak-analogous peptides, it 
captures Bcl-XL in a different conformation, exposing deeper cavities in the binding 
site.58b Remarkably, these findings have highlighted the significance of ‘hot spots’ in 
targeting protein-protein interactions.  
1.6 Development of novel reactions suitable for kinetic TGS 
As described earlier, the kinetic TGS approach has the potential to streamline the 
drug discovery process and has been successfully applied to various enzymatic as well as 
protein-protein interaction targets. Various reactions suitable for kinetic TGS have been 
identified so far. Most prominent examples include, (a) the Huisgen 1,3-dipolar 
cycloaddition reaction between azides and alkynes resulting in 1,2,3-triazoles, and (b) the 
sulfo-click reaction between sulfonyl azides and thio acids yielding amides. Importantly, 
using these reactions, biologically valuable functional moieties such as triazoles and 
amides could be incorporated generating drug-like molecules. Therefore, the 
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development of novel reactions with the potential to be applied for a kinetic TGS 
approach would be of great importance.  
1.7 Research aims 
1.7.1 Identification of protein-protein interaction modulators (PPIMs) targeting Bcl-XL 
 Although protein-protein interactions possess significant biological importance, 
identification of small molecules modulating specific protein-protein interactions remains 
challenging due to the flexible nature of proteins. Several fragment based approaches 
have been established to identify fragments with good ligand efficiencies, but fail to 
provide insights into efficient fragment linkage, making the drug discovery process 
complicated. In another type of fragment-based approach, termed as kinetic target-guided 
synthesis (TGS), the target serves as a template assembling the fragments together to 
yield the inhibitor of that target itself. This approach was recently shown to be suitable 
for the identification of PPIMs. Our research efforts were focused on utilizing the kinetic 
TGS approach based on the sulfo-click reaction between thio acids and sulfonyl azides 
for the identification of high-quality PPIMs targeting an anti-apoptotic protein, Bcl-XL. 
1.7.2 Identification of PPIMs targeting Mcl-1 
 Recently, Mcl-1, another anti-apoptotic protein of the Bcl-2 family has been 
established to be actively involved in controlling the apoptotic pathway. As a result, 
several small molecules targeting Mcl-1 selectively or in combination with other 
anti-apoptotic proteins have been reported in the past few years. After obtaining 
encouraging results with Bcl-XL, our aim was to extend the kinetic TGS approach to 
Mcl-1 utilizing the sulfo-click reaction. The key features of this research endeavor 
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involved (a) the expansion of sulfonyl azide and thio acid libraries, (b) the in situ 
generation of thio acids starting from thio esters to address the issues associated with the 
stability of thio acids, (c) the screening of the expanded libraries of sulfonyl azides and 
thio acids against Mcl-1, (d) the confirmation of the kinetic TGS hits identified using 
control experiments followed by synthesis of the same, and (e) the determination of 
biological activities (IC50 values) of these kinetic TGS hits against Mcl-1 and Bcl-XL 
using fluorescence polarization assay. 
1.7.3 Development of an amidation reaction 
 Although, the kinetic TGS has been well established as a highly reliable and 
efficient approach for the identification of novel inhibitors of various biological targets 
with therapeutic interest, only a limited set of reactions have been found to be suitable for 
this method. We identified that a set of alkyl azides (substituted benzyl azides and 
α-azido amides) can undergo a reaction with aromatic aldehydes under mild basic 
conditions generating corresponding amides. First, the reaction conditions were 
optimized and t-BuOK alone was found to be suitable for this transformation, while best 
results were obtained when DMF was used as a solvent. The potential of this reaction to 
be used for kinetic TGS approach was then probed. Unfortunately, this reaction turned 
out to be sensitive to moisture and thus cannot be applied for the TGS. Nevertheless, 
biologically relevant amidomethylarenes could be easily generated using this method. As 
a result, our efforts entailed (a) expanding the scope of the reaction with respect to both 
azides and aldehydes, and (b) designing control experiments to investigate the 
mechanistic details. 
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Chapter 2 
Screening of Protein-Protein Interaction Modulators via Sulfo-Click Kinetic 
Target-Guided Synthesis 
2.1 Introduction 
 Protein-protein interactions (PPIs) are central to a large number of vital 
biological processes and thus represent attractive targets for the development of novel 
therapies for a variety of diseases.1 Although scientists recognized the tremendous 
potential in targeting PPIs over the last two decades, the development of small 
molecules, which specifically modulate or disrupt a particular PPI, remains a 
challenging and risky undertaking.1a Commonly, protein-protein interfaces are large 
and flat, and they lack deep cavities that might serve as good binding sites for small 
molecules.2 Moreover, amino acids at the interfaces of PPIs are flexible and thus pose 
challenges at conducting computer-guided compound design.3  
 Although protein-protein interfaces bury 500–3000 Å2 of total surface area, 
which exceeds the potential binding area of low-molecular-weight compounds,4 Wells 
and co-workers demonstrated that only a fraction of the amino acid residues at the 
protein-protein interface contributes to the major portion of the binding free energy.5 
These key amino acids, defined as recognition patches or hot spots, therefore provide 
the theoretical and experimental evidence that PPIs can be disrupted or modulated by 
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low-molecular-weight compounds. In the last 15 years, numerous approaches have 
been developed for the discovery of small molecules modulating or disrupting PPIs. 
Often, small molecule design is aimed at mimicking a peptide or a protein secondary 
structure in a truncated form.6 Alternatively, fragment-based drug discovery strategies 
using biomolecular NMR, X-ray crystallography, or surface plasmon resonance (SPR) 
lead to the identification of fragments with good ligand efficiencies, which are further 
developed into potent protein-protein interaction modulators (PPIMs). Herein we 
report the expansion and utilization of kinetic target-guided synthesis (TGS) as a 
screening platform for the identification of PPIMs.  
 In the last two decades, several TGS approaches have been described, in which 
the target biomolecule assembles its inhibitory ligand from a collection of reactive 
fragments. Depending on the nature of the assembly step, TGS approaches can be 
classified into (a) dynamic combinatorial chemistry (DCC), (b) reagent-accelerated 
TGS, and (c) kinetic TGS.7 In dynamic combinatorial chemistry, the assembly process 
is reversible, whereas reagent-accelerated TGS uses building blocks, which combine 
in an irreversible fashion only in presence of an external reagent or a catalyst upon 
binding to the biological target. In kinetic TGS, a biological target accelerates the 
irreversible covalent bond formation only between complementary reacting fragments 
binding to adjacent binding sites of the target (Figure 2.1A). Kinetic TGS6b and in situ 
click chemistry7a, b have been exclusively applied for the identification of inhibitors of 
enzymatic targets with well defined binding pockets. In a recent proof-of-concept 
study with the anti-apoptotic protein Bcl-XL as the biological target, we demonstrated 
that kinetic TGS can also be used for the “rediscovery” of a PPIM previously reported 
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by the Abbott Laboratories starting from smaller fragments bearing a thio acid or a 
sulfonyl azide functional group.7d Williams and coworkers described that the 
amidation reaction between thio acids and sulfonyl azides,8 which in the meantime 
has been named as the sulfo-click reaction,9 proceeds in aqueous media. 
 
Figure 2.1. Kinetic TGS approach targeting PPIs. A) TGS approaches are based on 
the principle that multidentate interactions between a ligand and a biological target 
are collectively much stronger than the corresponding monovalent interactions of 
each of the fragments.10 Thus, target-assembled compound most likely will have a 
stronger interaction with the biological target as compared to the individual building 
blocks.10 In kinetic TGS, fragments decorated with complementary reactive groups 
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are incubated with the target biomolecule. If two fragments reside simultaneously in 
close proximity in binding pockets of the target, the two reactive functionalities react 
with each other forming a covalent linkage between the two fragments. B) 
Acylsulfonamide 1, ABT-737 and ABT-263 compounds targeting Bcl-XL. C) Proof-
of-concept study to demonstrate that the amidation between thio acids and  sulfonyl 
azides is suited for kinetic TGS targeting PPIs. 
 The proteins of the Bcl-2 family have been validated as attractive PPI targets 
for cancer therapy.11 The Bcl-2 family of proteins, which consists of both anti- and 
pro-apoptotic molecules, plays a pivotal role in the regulation of the intrinsic pathway 
of apoptosis. The anti-apoptotic Bcl-2 family proteins Bcl-2, Bcl-XL, and Mcl-1 
inhibit the release of certain pro-apoptotic factors from mitochondria. In contrast, 
pro-apoptotic Bcl-2 family members, which can be further separated into two 
subgroups, the multidomain BH1-3 proteins (i.e., Bax and Bak) and the BH3-only 
proteins (e.g., Bad, Bim, and Noxa), induce the release of mitochondrial apoptogenic 
molecules into the cytosol.12 Evidence has been accumulated that the majority of 
human cancers overexpress the pro-survival Bcl-2 family proteins, which not only 
contribute to cancer progression by preventing normal cell turnover, but also render 
cancer cells resistant to current cancer treatments.13 Although there is a controversy 
over how anti-apoptotic Bcl-2 family proteins function,14 it is generally accepted that 
apoptosis is initiated by the binding of pro-apoptotic BH3-only proteins to 
anti-apoptotic Bcl-2 family molecules in cancer cells. These interactions are mediated 
by the insertion of the BH3 domain of pro-death proteins into the hydrophobic groove 
on the surface of anti-apoptotic proteins Bcl-2, Bcl-XL, or Mcl-1.15 Therefore, small 
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molecules that mimic the BH3 domains of pro-apoptotic Bcl-2 family proteins have 
potential as anti-cancer therapeutics.  
 Previously, Abbott Laboratories developed acylsulfonamide 1, ABT-737, 
ABT-263, and other structurally related acylsulfonamides, which efficiently disrupt 
Bcl-XL-Bad interaction (Figure 2.1B).16 On the basis of these reports, we designed 
reactive fragments structurally related to ABT-737 and ABT-263 (SZ1-SZ6 and 
TA1-TA3), and incubated these as binary fragment mixtures in presence of Bcl-XL 
(Figure 2.1C). Analysis of each incubation sample by liquid chromatography 
combined with mass spectrometry detection in the Selected Ion Mode (LC/MS-SIM) 
showed that of all 18 possible products only compound SZ4TA2, which was 
developed by Abbott Laboratories, has been detected. In comparison, incubations of 
fragments in the absence of Bcl-XL or in presence of Bcl-XL and various 
BH3-containing peptides failed to yield detectable amounts of acylsulfonamide 
products. In addition, IC50 inhibitory constants in the nM range have been determined 
for SZ4TA2, while their corresponding thio acid or sulfonyl azide fragments did not 
show any inhibition up to 100 µM concentrations.  
 Herein, we successfully employed and validated the sulfo-click kinetic TGS 
approach as a straightforward yet reliable PPIM screening platform for the 
identification of Bcl-XL-protein modulators. The design of kinetic TGS incubations 
with wildtype and mutant Bcl-XL proteins provided an additional layer of 
confirmatory experiments for the delivery of high-quality PPIMs. Furthermore, 
experimental evidence has been accumulated indicating that kinetic TGS is a PPIM 
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screening and synthesis method generating only active compounds. 
2.2 Results and discussion 
2.2.1 Screening of an extended reactive fragment library  
 The proof-of-concept study motivated us to investigate whether kinetic TGS is 
also successful at generating hit compounds which have not been previously reported. 
Two sublibraries of reactive fragments, one consisting of thio acids and the other of 
sulfonyl azides, have been synthesized. The thio acids were generated from the 
corresponding acid chlorides and sodium hydrosulfide, while the sulfonyl azides were 
prepared by alkylation of amines with 4-(bromomethyl)benzenesulfonyl azide 
(Scheme 2.1A-C). A selection of acylsulfonamides has been synthesized mainly by: 
a) EDCI coupling of corresponding carboxylic acids and sulfonamides, or b) the 
previsouly reported reaction between sulfonyl azides and selenocarboxylates which 
were generated from corresponding carboxylic acids and the selenating reagent, 
LiAlHSeH (Scheme 2.1D).17 
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Scheme 2.1. Synthesis of sulfonyl azides, thio acids and acylsulfonamides. Reaction 
conditions: (a) SOCl2, DMF, reflux, 2 h (b) 2-(phenylthio)ethanamine (0.5 eq), 
K2CO3, CHCl3, 12 h, RT (c) NaN3, acetone, H2O, 0 °C, 3 h, 70% (over 3 steps) (d) 
K2CO3, CH3CN:H2O (9:1), 12 h, RT, 87% (e) 2-(phenylthio)ethanamine (0.5 eq), 
K2CO3, CH3CN:H2O (9:1), 12 h, RT, 60% (f) ICH2CN, K2CO3, CH3CN:H2O (10:1), 2 
d, 60 °C, 79% (g) 12 N HCl, 90 °C, 3 h, 66% (h) i) (COCl)2, CH2Cl2, 0 °C to RT, 8 h; 
ii) dimethylthioformamide, H2S, 15 min, 25% (i) NaSH, acetone, H2O, 2 h, RT (j) 
NaSH, neat, 0 °C to RT, 1 h (k) EDCI, DMAP, CH2Cl2, RT, 24-48 h (l) 
(CH3)2CHOCOCl, N-methyl piperidine, THF, 0 °C, 30 min (m) LiAlHSeH, THF, 0 
°C, 30 min (n) RSO2N3, THF, 0 °C to RT, 3 h. 
 The majority of the reactive fragments have been randomly selected, while a 
small fraction of the reactive fragments has been designed to be structurally related to 
ABT-737 or ABT-263. Eighty one binary mixtures containing one thio acid 
(TA1-TA9) and one sulfonyl azide (SZ1-SZ9) were incubated with the target protein 
Bcl-XL for 6 hours at 37 C (Figure 2.2).  
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Figure 2.2. Kinetic TGS screening of Bcl-XL via sulfo-click chemistry 
 In parallel, identical binary fragment mixtures were incubated in buffer 
without Bcl-XL. Similar to in situ click chemistry,7a, b all incubations were directly 
subjected to HPLC analysis with acylsulfonamide product detection by electrospray 
ionization in the positive Selected Ion Mode (LC/MS-SIM).18 Comparison of the 
LC/MS-SIM traces of identical fragment combinations with or without protein 
Bcl-XL, led to the identification of the previously reported fragment combination 
SZ4TA27d and three new combinations SZ7TA2, SZ9TA1, and SZ9TA5 with 
increased amounts of acylsulfonamide products in the incubations containing Bcl-XL 
(Figure 2.3A-B and experimental section).  
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Figure 2.3. LC/MS-SIM analysis of kinetic TGS incubations with fragments SZ7 and 
TA2 targeting Bcl-XL. The samples were incubated at 37 °C for 6 hours and subjected 
to LC/MS-SIM analysis with gradient system 1 (see experimental section). A) 
Incubation sample containing fragments SZ7 and TA2 in absence of Bcl-XL; B) 
Incubation sample containing fragments SZ7 and TA2 in presence of 2 M Bcl-XL; 
C) Incubation sample containing fragments SZ7 and TA2 in presence of 2 M Bcl-XL 
and 20 M Bim BH3 peptide; D) Incubation sample containing fragments SZ7 and 
TA2 in presence of 2 M Bcl-XL and 20 M mutant Bim BH3 peptide; E) Synthetic 
SZ7TA2 as the reference compound. 
 Prior to synthesizing the new TGS hit compounds SZ7TA2, SZ9TA1, and 
SZ9TA5, control incubations with wildtype and mutant pro-apoptotic Bim BH3 
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peptides were conducted to assess whether the hit combinations assemble at the 
targeted binding sites of Bcl-XL or randomly elsewhere on the protein surface (Figure 
2.3C-D and experimental section). These control experiments with Bak BH3 peptide 
have been previously introduced to confirm the kinetic TGS assembly of compound 
SZ4TA2.7d Wildtype Bim BH3 peptide (Bim sequence 
CEIWIAQELRRIGDEFNAYYAR), the natural Bcl-XL ligand, outcompetes the 
reactive fragments for binding at the BH3 binding site of Bcl-XL and thus suppresses 
the Bcl-XL-templated assembly of acylsulfonamides SZ7TA2, SZ9TA1, and 
SZ9TA5. Contrarily, mutant of the Bim BH3 peptide (mutant Bim sequence 
CEIWIAQEARRIGAEFNAYYAR) exhibits low affinity towards Bcl-XL and 
therefore does not significantly affect the Bcl-XL-templated assembly of SZ7TA2, 
SZ9TA1, and SZ9TA5. Since these co-incubations with wildtype and mutant BH3 
peptides strongly suggest that the formation of acylsulfonamides SZ7TA2, SZ9TA1, 
and SZ9TA5 takes place at the BH3 binding site of Bcl-XL, compounds SZ7TA2, 
SZ9TA1, and SZ9TA5 have been synthesized and subjected to LC/MS-SIM analysis. 
Comparison of the LC/MS-SIM traces of the Bcl-XL-templated reactions with the 
ones of the synthetic compounds clearly confirmed that Bcl-XL templates the 
formation of hit compounds SZ7TA2, SZ9TA1, and SZ9TA5 (Figure 2.3E and 
experimental section). 
2.2.2 Kinetic TGS with mutant Bcl-XL  
 Experiments were designed, in which mutated Bcl-XL proteins are incubated 
with reactive fragments. Alterations of the BH3 binding site directly affect the 
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binding of reactive fragments SZ4, SZ7, SZ9, TA1, TA2, and TA5 to the protein, 
which in turn will influence the rate of the protein-templated acylsulfonamide 
formation. The purpose of these mutant Bcl-XL proteins is to expand the repertoire of 
controls with Bim BH3 peptides with complementary experiments indicating whether 
the TGS reaction occurs with the help of the target protein Bcl-XL and specifically at 
the binding site of interest. The known mutant of Bcl-XL, in which phenylalanine 
Phe131 and aspartic acid Asp133 have been substituted by alanines, has been 
prepared since it fails at interacting with Bak or Bim BH3 peptides.19 In addition, a 
second mutant Bcl-XL has been prepared, in which arginine Arg139 has been replaced 
by alanine. Arginine Arg139 has been identified to be a key residue interacting with 
ABT-737 and analogues thereof.16a As a proof-of-concept, incubations of the mutant 
Bcl-XL with building blocks SZ4 and TA2 were first undertaken at various reactive 
fragment concentrations (Figures 2.4, 2.5 and experimental section). In comparison to 
the incubation with wildtype Bcl-XL, a reduction in the templation activity by 
approximately 40 or more has been observed in both mutant Bcl-XL-templated 
reactions (Table 2.1). This observation can be explained by closer examination of a 
reported NMR-structure of Bcl-XL complexed with acylsulfonamide 1, whose 
structure is closely related to the kinetic TGS product SZ4TA2.16a Comparison of the 
location of Phe131 and Asp133 with the position of compound 1 in the wildtype 
Bcl-XL binding site reveals that the residues Phe131 and Asp133, although important 
for the binding to Bak or Bim BH3 peptides, are relatively distant from the 
acylsulfonamide 1, while Arg139 appears to be closer to compound 1. Surprisingly, 
mutant R139ABcl-XL displays a slightly increased templation reaction in comparison to 
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F131A,D133ABcl-XL. Conformational changes iduced by seemingly distant amino acid 
residues are difficult to trace and may probably influence the templation effect 
observed during the incubations with wildtype and mutant Bcl-XL proteins.  
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Figure 2.4. LC/MS-SIM analysis of kinetic TGS incubations with fragments SZ4 and 
TA2 targeting the wildtype and mutant of Bcl-XL. The samples were incubated at 37 
°C for 6 hours and subjected to LC/MS-SIM analysis with gradient system 1 (see 
experimental section). A) Incubation sample containing fragments SZ4 and TA2 in 
absence of wildtype Bcl-XL; B) Incubation sample containing fragments SZ4 and 
TA2 in presence of 2 M wildtype Bcl-XL; C) Incubation sample containing 
fragments SZ4 and TA2 in presence of 2 M single mutant R139ABcl-XL; D) Synthetic 
SZ4TA2 as the reference compound. 
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Figure 2.5. LC/MS-SIM analysis of kinetic TGS incubations with fragments SZ4 and 
TA2 targeting the wildtype and double mutant of Bcl-XL. The samples were 
incubated at 37 °C for 6 hours and subjected to LC/MS-SIM analysis with gradient 
system 2 (see experimental section). A) Incubation sample containing fragments SZ4 
and TA2 in absence of wildtype Bcl-XL; B) Incubation sample containing fragments 
SZ4 and TA2 in presence of 2 M wildtype Bcl-XL; C) Incubation sample containing 
fragments SZ4 and TA2 in presence of 2 M double mutant F131A,D133ABcl-XL; D) 
Synthetic SZ4TA2 as the reference compound. 
 For TGS hit combinations SZ7TA2, SZ9TA1, and SZ9TA5, confirmatory 
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experiments have been conducted with single mutant R139ABcl-XL only, since the 
preparation of double mutant F131A,D133ABcl-XL has been cumbersome. Similar to the 
incubations of fragments SZ4 and TA2, experiments with the mutant protein leading 
to acylsulfonamides SZ7TA2, SZ9TA1, and SZ9TA5 displayed a reduction in 
acylsulfonamide formation compared to the incubations with wildtype  Bcl-XL. These 
experiments suggest that the acylsulfonamide genesis occurs in proximity to key 
amino acid residue Arg139. 
Table 2.1. Kinetic TGS incubations 
Incubation 
Fragment Combinations 
SZ4TA2 SZ7TA2 SZ9TA1 SZ9TA5 
Peak 
Area 
% 
Signal 
Peak 
Area 
% 
Signal 
Peak 
Area 
% 
Signal 
Peak 
Area 
% 
Signal 
Buffer alone 26,794 7.4 3,594 6.8 313 35.3 466 10.9 
WT Bcl-XL 363,187 100.0 52,920 100.0 887 100.0 4,275 100.0 
WT Bcl-XL and WT 
Bak BH3 59,437 16.3 n.d. n.d. n.d. n.d. n.d. n.d. 
WT Bcl-XL and 
mutant Bak BH3 181,156 49.8 n.d. n.d. n.d. n.d. n.d. n.d. 
WT Bcl-XL and WT 
Bim BH3 51,773 14.3 28,911 54.6 552 62.2 944 22.1 
WT Bcl-XL and 
mutant Bim BH3 217,813 59.9 47,728 90.2 761 85.8 2,557 59.8 
Buffer alone 44195 9.6 n.d. n.d. n.d. n.d. n.d. n.d. 
WT Bcl-XL 460532 100.0 n.d. n.d. n.d. n.d. n.d. n.d. 
F131A,D133ABcl-XL 196429 42.7 n.d. n.d. n.d. n.d. n.d. n.d. 
Buffer alone 4,733 11.0 2,046 7.2 939 25.0 726 11.4 
WT Bcl-XL 43,210 100.0 28,600 100.0 3,750 100.0 6,370 100.0 
R139ABcl-XL 25,959 60.1 16,965 59.3 2,637 70.3 4,406 69.2 
n.d. = not determined; WT = wildtype 
 
2.2.3 PPIM activity of kinetic TGS hits and additional acylsulfonamides  
 The kinetic TGS hits were subjected to dose–response studies to obtain IC50s and 
to investigate if the hit compounds are also modulating or disrupting the interaction 
between Bcl-XL and a native BH3 peptide ligand. Previously, Abbott Laboratories 
determined by their assay, that SZ4TA2 is a good PPIM with a Ki constant of 19 nM.16b, c 
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Abbott determined the dissociation constants by a competitive fluorescence polarization 
assay using a fluorescein-labeled Bad-BH3 peptide. In order to precisely compare the 
inhibitory properties of our kinetic TGS hits with the compounds reported by Abbott, we 
decided to perform binding studies by a fluorescence polarization assay implemented in 
our laboratories, which uses GST-Bcl-XL and fluorescein-labeled Bak-BH3 peptide. 
Consistently, compound SZ4TA2 has been validated by our assay as a Bcl-XL inhibitor 
against Bak-BH3 with an IC50 constant of 106 nM (Table 2.2). Kinetic TGS hit 
compounds SZ7TA2, SZ9TA1, and SZ9TA5 showed IC50s in the low M range (Figure 
2.3 and experimental section). Taken together, these results indicate that the hit 
compounds SZ4TA2, SZ7TA2, SZ9TA1, and SZ9TA5 identified through the kinetic 
TGS screening are indeed respectable ligands of the biological target, which underscores 
the utility of kinetic TGS as a valuable approach to PPIM discovery. 
Table 2.2. PPIM activity of kinetic TGS hit compounds 
Compound    IC50    Ki  
SZ4TA2 106 ± 12 nM 37.5 ± 5.0 nM 
SZ7TA2 28.4 ± 3.5 M 11.5 ± 1.4 M 
SZ9TA1 28.7 ± 4.1 M 11.6 ± 1.6 M 
SZ9TA5 36.0 ± 2.5 M 14.6 ± 1.0 M 
 
 To assess whether the kinetic TGS hits are more potent than acylsulfonamides, 
which were not identified in the kinetic TGS screening, 33 randomly selected 
acylsulfonamides were synthesized. All compounds, as well as TGS hit compounds 
SZ4TA2, SZ7TA2, SZ9TA1, and SZ9TA5 were tested at a 50 M concentration for PPI 
disruption in the Bcl-XL/Bak-BH3 fluorescence polarization assay. The 37 
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acylsulfonamides tested corresponds to 45.7 of the 81 member library. Strikingly, the 
four kinetic TGS hits were the most potent compounds tested, disrupting the Bcl-XL/BH3 
interaction with 60 inhibition or more, while the randomly selected acylsulfonamides 
demonstrated an average of 15 inhibition (Table 2.3). Only four of the 33 randomly 
selected acylsulfonamides demonstrated moderate inhibition (35–45). In contrast, all 
reactive fragments SZ1-SZ9 and TA1-TA9 have been tested in the fluorescence 
polarization assay at 100 M concentration and less than 5 inhibition was detected. 
These measurements indicate that the dissociation constants for the corresponding 
reactive building blocks SZ1-SZ9 and TA1-TA9 have to be higher than 100 M. These 
important results suggest that the amidation reaction between thio acids and sulfonyl 
azides is suitable for kinetic TGS using building blocks displaying weak binding 
affinities.  In addition, this study strongly suggests that the kinetic TGS screening 
identified the more active members of the library of potential acylsulfonamides arising 
from reactive fragments SZ1-SZ9 and TA1-TA9.  
Table 2.3. Percentage inhibition displayed by an acylsulfonamide at 50 M 
concentration. Of the 37 compounds tested, the four most potent compounds were 
identified by kinetic TGS 
Fragments SZ1 SZ2 SZ3 SZ4 SZ5 SZ6 SZ7 SZ8 SZ9 
TA1 n.d. 2 0 14 29 n.d. n.d. 19 80 
TA2 n.d. 8 n.d. 100 28 26 76 n.d. 38 
TA3 6 7 n.d. n.d. n.d. n.d. n.d. 30 22 
TA4 n.d. 25 n.d. n.d. n.d. n.d. n.d. 8 n.d. 
TA5 5 n.d. n.d. n.d. 0 n.d. 15 11 60 
TA6 4 n.d. 0 n.d. 0 n.d. 20 n.d. n.d. 
TA7 n.d. n.d. 0 n.d. n.d. n.d. 47 30 45 
TA8 n.d. n.d. 0 n.d. n.d. n.d. n.d. 38 n.d. 
TA9 3 n.d. 0 n.d. 1 n.d. n.d. 24 n.d. 
n.d. = not determined 
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2.2.4 Discussion   
 Generally, cell-permeable small modulators of PPIs have been considered to be 
desirable tools with great implications for drug discovery and development.1c, d 
Nevertheless, reliable yet straightforward techniques or approaches for the development 
of potent and effective PPIMs are currently unavailable. Over the past 15 years, a variety 
of fragment-based lead discovery approaches have been developed and successfully 
applied for the development of potent PPIMs.20 These approaches are commonly based 
on the detection of fragments binding to the target protein followed by the study of their 
binding to the protein target at atomic level resolution using X-ray crystallography or 
NMR spectroscopy. The initial hits are further optimized via fragment growing, in which 
fragments are extended into identified binding sites step-by-step, or via fragment linking, 
in which fragments identified to bind to adjacent binding sites are covalently linked 
together.20c, 21 Even though fragment-based lead discovery strategies have been very 
successful for the development of PPIMs, they are mainly limited by two constraints. 
Detection and quantification of fragment binding requires specially designed 
methodology due to the weak binding typically observed for fragments. Furthermore, the 
optimization of fragments into potent and selective compounds is not straightforward and 
not rapidly achievable, even though structural information is available.21b, 22 For example, 
though high quality NMR structures were available, the development of Bcl-XL PPIMs 
by Abbott16a, b required several design iterations, and the preparation and testing of more 
than 1000 compounds in order to yield ABT-737 and ABT-263.23  Furthermore, of the 
very first design consisting of 21 different structures containing the structural motifs of 
the initial fragments identified by NMR, most compounds bound to Bcl-XL with a 
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dissociation constant greater than 10 M.16a Thus, though the hit compounds SZ7TA2, 
SZ9TA1, and SZ9TA5 display IC50 constants of 28–37 M in the Bak-BH3 fluorescence 
polarization assay, the herein reported kinetic TGS approach suggests that the high-
quality PPIMs will be identified early on in the screening process. This outcome is 
consistent with previously reported kinetic TGS studies, in which the enzyme carbonic 
anhydrase II preferably accelerates the formation of the better inhibitory compounds from 
a pool of reactive fragments.24 Other kinetic TGS examples using exclusively in situ click 
chemistry also suggest that the triazoles generated in the protein-templated reactions are 
the more potent inhibitors.18, 24b, 25  
 Recently, fragment-based discovery strategies have been reported which involve 
the protein target directly to select and assemble its own inhibitory compounds from a 
pool of reactive fragments. These approaches, also termed as in situ click chemistry or 
kinetic TGS approaches,6b, 7b were conceptually described in the 1980s26 and are still 
relatively unexplored compared to dynamic combinatorial chemistry. Thus far, kinetic 
TGS has mainly been applied to the identification of potent enzyme inhibitors. 
Nevertheless, the herein reported kinetic TGS offers an attractive approach to PPIM lead 
discovery because it allows the protein to select and combine building blocks that fit best 
into its binding sites, thus assembling larger compounds.6b, 7b The screening method can 
be as simple as determining whether or not the PPIM product has been formed in a given 
test mixture. This is especially advantageous over a conventional high-throughput 
screening of difficult targets such as protein interfaces requiring cumbersome and time-
consuming experiments to confirm whether screening hits are true or false positives.  
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 Finally, considering that the flexible nature of protein interfaces complicates the 
development of PPIMs by conventional means, kinetic TGS has the potential to target the 
protein in a conformation, which is short-lived, undetectable or easily missed with 
present techniques. A small number of in situ click chemistry approaches targeting 
enzymatic systems lead to the identification of triazole inhibitors stabilizing the protein in 
an unprecedented and less abundant conformation.27 Thus, we speculate that the herein 
reported sulfo-click chemistry kinetic TGS approach provides medicinal chemists a 
straightforward search strategy to stabilize conformations of dynamic protein targets such 
as PPIs. 
2.3 Conclusions   
 Herein, we demonstrate that the sulfo-click kinetic TGS approach exhibits great 
promise in fragment-based PPIM discovery since it combines synthesis and screening of 
libraries of low-molecular-weight PPIMs into a single step. Samples containing the 
protein target Bcl-XL and reacting fragments leading to 81 structurally different 
acylsulfonamides have been incubated and analyzed by LC/MS-SIM for acylsulfonamide 
formation. Of the 81 possible fragment combinations, only combinations SZ4TA2, 
SZ7TA2, SZ9TA1, and SZ9TA5 yielded acylsulfonamides in the Bcl-XL-templated 
reactions. Control incubations with the four hit fragment combinations, in which the BH3 
binding site of the wildtype Bcl-XL has been competitively occupied by a Bim BH3 
peptide, generated decreased amounts of acylsulfonamides. Furthermore, control 
incubations with mutants R139ABcl-XL or F131A,D133ABcl-XL, in which amino acid residues 
at the BH3 binding site have been replaced by alanines, also failed at generating the hit 
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acylsulfonamides suggesting that the protein-templated assembly of SZ4TA2, SZ7TA2, 
SZ9TA1, and SZ9TA5 occurs at the desired BH3 binding site of Bcl-XL. Subsequent 
testing of synthesized kinetic TGS hit acylsulfonamides in a fluorescence-based 
competitive binding assay demonstrated that the kinetic TGS hit compounds indeed 
display PPIM activity. These findings have been supported by a set of 33 additional 
acylsulfonamides randomly selected from the 81-member library, which have been 
shown to fail at demonstrating potent PPIM activity in the fluorescence-based 
competitive binding assay. These results provide a general test case for the sulfo-click 
kinetic TGS approach to generate hits targeting the proteins of the Bcl-2 family and 
further validate the kinetic TGS approach to be suitable for PPIM discovery. In contrast 
to conventional screening approaches, experimental data suggests that PPIM screening 
via kinetic TGS reduces the number of false positives, cutting down the number of 
screening hits to be validated in confirmatory assays. We speculate that the herein 
reported PPIM discovery strategy for the family of the Bcl-2 proteins is general and can 
easily be implemented to lead development targeting other PPIs such as MDM2/p53, 
IAP/caspase, and others.1a, 1d, 28  
2.4 Experimental section 
2.4.1 General information 
All reagents and solvents were purchased from commercial sources and used 
without further purification. All reactions were run under an Argon atmosphere unless 
otherwise indicated. Prior to use of solvents in reactions, they were purified by passing 
the degassed solvents through a column of activated alumina and transferred by an oven-
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dried syringe or cannula. Thin layer chromatography was performed on Merck TLC 
plates (silica gel 60 F254). 1H NMR and 13C NMR were recorded on a Varian Inova 400 
(400 MHz) or a Bruker Avance DPX-250 (250 MHz) instrument. The purification of 
designated compounds was carried out using reverse phase HPLC system (Waters Prep 
LC 4000 system with Waters 996 photo-diode array detector, Agilent column Eclipse 
XDB-C18, 5 µm, 9.4 mm  250 mm). Compounds were eluted using a gradient elution of 
A:B (80:20 to 0:100) over 40 min at a flow rate of 5.0 mL/min, where solvent A was H2O 
(0.05% TFA) and solvent B was CH3CN (0.05% TFA). The HRMS data were measured 
on an Agilent 1100 Series MSD/TOF with electrospray ionization. The LC/MS data were 
measured on an Agilent 1100 LC/MSD-VL with electrospray ionization.  
The gradient used for LC/MS-SIM analysis is shown below: 
Table 2.4. Elution gradient system 1 employed for the LC/MS-SIM analysis 
Time % B* Flow rate Time % B* Flow rate 
0.00 10% 0.7 mL min-1 11.50 100% 1.0 mL min-1 
2.00 10% 0.7 mL min-1 11.51 10% 0.7 mL min-1 
10.00 100% 1.0 mL min-1 13.50 10% 0.7 mL min-1 
* eluent A: H2O (0.05% TFA); eluent B: CH3CN (0.05% TFA) 
 
Table 2.5. Elution gradient system 2 employed for the LC/MS-SIM analysis 
Time % B* Flow rate Time % B* Flow rate 
0.00 10% 0.7 mL min-1 13.01 100% 1.5 mL min-1 
4.00 20% 0.7 mL min-1 15.00 100% 1.5 mL min-1 
12.00 100% 0.7 mL min-1 15.50 20% 0.7 mL min-1 
13.00 100% 0.7 mL min-1 16.50 20% 0.7 mL min-1 
* eluent A: H2O (0.05% TFA); eluent B: CH3CN (0.05% TFA) 
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The sulfonyl azides, SZ1-SZ6, thio acids, TA1-TA3 and the acylsulfonamides SZ2TA1, 
SZ2TA2, SZ2TA3, SZ4TA1, SZ4TA2, SZ5TA1 and SZ5TA2 have been previously 
reported.7d 
2.4.2 Expression and purification of wildtype and mutant Bcl-XL fusion proteins  
 The protocols for the expression and purification of GST-tagged and His-tagged 
Bcl-XL TM fusion proteins have been previously reported.7d The F131A,D133ABcl-XL TM 
and R139ABcl-XL TM mutants were generated by PCR mutagenesis using Bcl-XL TM 
cDNA as a template as described previously.19 
2.4.3 General protocol for incubations of Bcl-XL with reactive fragments  
 In a 96-well plate, one thio acid building block (1 L of a 2 mM solution in 
methanol) and one sulfonyl azide building block (1 L of a 2 mM solution in methanol) 
were added to a solution of Bcl-XL (98 L of a 2 M Bcl-XL solution in buffer (58 mM 
Na2HPO4, 17 mM NaH2PO4, 68 mM NaCl, 1 mM NaN3, pH = 7.40)). The 96-well plate 
was sealed and incubated at 37 °C for six hours. The incubation samples were then 
subjected to Liquid Chromatography combined with mass spectrometry analysis in the 
Selected Ion Mode (LC/MS-SIM, Zorbax SB-C18 preceded by a Phenomenex C18 guard 
column, electrospray ionization and mass spectrometric detection in the positive SIM, 
tuned to the expected molecular mass of the product). The TGS hit compound was 
identified by the mass and the retention time. As a control, identical building block 
combinations were incubated in buffer without Bcl-XL and subjected to LC/MS-SIM 
analysis. Comparison of the LC/MS-SIM chromatograms of these control incubations 
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with the chromatograms of the Bcl-XL containing incubations allows us to determine 
whether the protein is templating the corresponding amidation reaction. Furthermore, 
synthetically prepared acylsulfonamide was subjected to LC/MS-SIM analysis and the 
retention time was compared with the one identified in the Bcl-XL containing incubation. 
2.4.4 General protocol for the control incubations of Bcl-XL with reactive fragments 
and Bim BH3 peptides   
 For the Bcl-XL containing incubation sample showing acylsulfonamide formation, 
control incubations with Bim peptides have been undertaken to demonstrate that the 
templation reaction occurs at the desired binding site. Thus, in a 96-well plate, one thio 
acid (1 L of a 2 mM solution in methanol) and one sulfonyl azide (1 L of a 2 mM 
solution in methanol) were added to a solution of Bcl-XL (97 L of a 2 M Bcl-XL 
solution in buffer). Finally,  Bim BH3 peptide (1 L of a 2 mM solution in DMSO) was 
added and the incubation sample in a sealed 96-well plate was incubated at 37 °C for six 
hours. Similar procedure was followed for the mutant Bim BH3 peptide incubation. 
These two incubation samples were then subjected to LC/MS-SIM analysis along with 
the wildtype Bcl-XL containing sample without any of the Bim BH3 peptides. 
2.4.5 General protocol for the control incubations of mutants of Bcl-XL with reactive 
fragments  
 Additional control experiments were carried out using the mutants of Bcl-XL. In a 
96-well plate, one thio acid (1 L of a 2 mM solution in methanol) and one sulfonyl azide 
(1 L of a 2 mM solution in methanol) were added to a solution of mutant Bcl-XL (98 L 
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of a 2 M mutant Bcl-XL solution in buffer). This control sample was incubated along 
with the wildtype Bcl-XL containing sample at 37 °C for six hours and subjected to 
LC/MS-SIM analysis.  
2.4.6 Fluorescence polarization-based competitive binding assay  
 The detailed protocol to conduct fluorescence polarization-based competitive 
binding assays has been previously reported.7d 
2.4.7 Synthesis of building blocks 
 
Sulfonyl azide SZ7: The mixture of compound 2 (664 mg, 2 mmol), SOCl2 (4 mL), and 
DMF (16 mL) was refluxed for 2 h. The reaction mixture was then treated with cold 
water (15 mL), extracted with DCM (15 mL  3), and combined organic phases were 
dried over Na2SO4. A quick filtration through a pad of silica gel, evaporation, and 
vacuum drying gave the crude product 3 according to a similar procedure.29 The sulfonyl 
chloride 3 obtained was used for the next step without further purification. A solution of 
sulfonyl chloride 3 (325 mg, 1 mmol), 2-(phenylthio)ethanamine (155 mg, 1 mmol) and 
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potassium carbonate (200 mg, 1.44 mmol) in CHCl3 (8 mL) was stirred at room 
temperature for 12 hours. The reaction mixture was then concentrated, treated with ethyl 
acetate (20 mL) and water (20 mL), and extracted with ethyl acetate (20 mL  3). The 
combined organic layers were dried over Na2SO4 and concentrated. The crude product 4 
obtained was dissolved in acetone and the solution of sodium azide (70 mg, 1 mmol) in 
water was added dropwise at 0 °C. The mixture was stirred at 0 °C for 3 hours. Ethyl 
acetate (20 mL) and saturated aqueous potassium carbonate solution (20 mL) were added 
to the mixture and after extraction with ethyl acetate (20 mL  3), the combined organic 
phases were dried over Na2SO4 and concentrated. The sulfonyl azide SZ7 (315 mg, 70% 
over 3 steps) was obtained by flash chromatography (hexane : EtOAc = 4:1; Rf = 0.6 in 
hexane : EtOAc = 1:1). 1H NMR (400 MHz, CDCl3) : 8.56 (s, 1H), 8.49 (s, 1H), 8.11 – 
8.01 (m, 4H), 7.19 – 7.10 (m, 5H), 5.37 (t, J = 6.0 Hz, 1H), 3.21 – 3.13 (m, 2H), 2.99 (t, J 
= 6.4 Hz, 2H) ppm. 13C NMR (101 MHz, CDCl3) : 139.27, 137.05, 136.80, 133.49, 
130.84, 130.25, 130.22, 130.15, 129.76, 129.44, 129.04, 126.93, 126.24, 124.59, 41.60, 
33.85 ppm. HRMS (ESI) calcd for C18H16N4O4S3 [M+H]+: 449.0406, found: 449.0410 
 
Sulfonyl Azide SZ8: A mixture of bromide 57d (276 mg, 1 mmol), amine 630 (276 mg, 1 
mmol), and potassium carbonate (200 mg, 1.44 mmol) in acetonitrile and water (9:1; 6 
mL), was stirred at room temperature for 12 hours. After treating with ethyl acetate (20 
mL) and water (20 mL), the system was extracted with ethyl acetate (20 mL 3). The 
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combined organic layers were dried over anhydrous sodium sulfate and concentrated. 
Sulfonyl azide SZ8 (404 mg, 87%) was obtained by flash chromatography (hexane : 
EtOAc = 6:1 with 0.1% triethylamine; Rf = 0.4 in hexane : EtOAc = 1:1). 1H NMR (400 
MHz, CDCl3) : 7.82 (d, J = 6.8 Hz, 2H), 7.54 (d, J = 7.3 Hz, 2H), 7.38 – 7.18 (m, 5H), 
6.62 (s, 1H), 6.20 (s, 1H), 4.57 (s, 1H), 3.84 (d, J = 10.6 Hz, 1H), 3.80 (s, 3H), 3.56 (s, 
3H), 3.39 (d, J = 14.5 Hz, 1H), 3.05 – 2.95 (m, 2H), 2.71 (d, J = 15.4 Hz, 1H), 2.58 – 
2.48 (m, 1H) ppm. 13C NMR (101 MHz, CDCl3) : 147.82, 147.18, 146.78, 143.40, 
136.27, 129.48, 129.15, 129.08, 128.04, 127.14, 127.03, 126.22, 111.36, 110.59, 68.05, 
57.90, 55.42, 47.32, 28.21 ppm. HRMS (ESI) calcd for C24H24N4O4S [M+H]+: 465.1597, 
found: 465.1597 
 
Sulfonyl azide SZ9: The sulfonyl azide SZ9 was synthesized using a procedure 
described for the synthesis of SZ8, starting from 2-(phenylthio)ethanamine (72 mg, 0.47 
mmol) and bromide 5 (260.4 mg, 0.94 mmol). The sulfonyl azide SZ9 (154 mg, 60%) 
was obtained by flash chromatography (hexane : EtOAc = 6:1; Rf = 0.2 in hexane : 
EtOAc = 4:1). 1H NMR (400 MHz, CDCl3) : 7.87 (d, J = 8.3 Hz, 4H), 7.6 (d, J = 8.1 
Hz, 4H), 7.33 – 7.09 (m, 5H), 3.72 (s, 4H), 3.07 (t, J = 7.2 Hz, 2H), 2.76 (t, J = 6.9 Hz, 
2H) ppm. 13C NMR (101 MHz, CDCl3) : 146.61, 137.36, 129.63, 129.22, 128.97, 
127.92, 127.65, 126.35, 57.91, 52.73, 31.48 ppm. HRMS (ESI) calcd for C22H21N7O4S3 
[M+H]+: 544.0890, found: 544.0887 
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Nitrile 7: To a solution of amine 630 (1 g, 3.71 mmol) and iodoacetonitrile (620 mg, 3.71 
mmol) in acetonitrile (30 mL) and water (3 mL), was added potassium carbonate (1.53 g, 
11.13 mmol) and the resulting reaction mixture was stirred at 60 °C for 2 days. After 
cooling to room temperature, the solvent was removed under reduced pressure and the 
crude was purified by flash chromatography (hexane : EtOAc = 6:1; Rf = 0.67 in hexane : 
EtOAc = 1:1) to obtain nitrile 7 with 79% yield (904 mg). 1H NMR (400 MHz, CDCl3) : 
7.33 – 7.26 (m, 5H), 6.58 (s, 1H), 6.06 (s, 1H), 4.62 (s, 1H), 3.82 (s, 3H), 3.53 (s, 3H), 
3.41 (d, J = 8.1 Hz, 2H), 3.27 – 3.16 (m, 1H), 3.09 – 2.94 (m, 2H), 2.74 (d, J = 15.7 Hz, 
1H) ppm. 13C NMR (101 MHz, CDCl3) : 147.85, 147.47, 142.24, 129.53, 128.97, 
128.38, 125.92, 115.05, 111.63, 110.89, 66.98, 56.01, 50.04, 44.00, 29.18 ppm. HRMS 
(ESI) calcd for C19H20N2O2 [M+H]+: 309.1598, found: 309.1584 
 
Acid 8: To a flask charged with nitrile 7 (100 mg, 0.32 mmol), was added 12 N HCl (1.5 
mL) and the reaction mixture was stirred at 90 °C for 3 hours. The reaction mixture was 
then cooled to room temperature and treated with 2 N NaOH solution (pH = 5). The 
crashed out white solid was filtered, washed with cold MeOH and dried to obtain acid 8 
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as a hydrochloride salt (66%, 78 mg). The analytical sample was obtained by flash 
chromatography (MeOH : EtOAc = 2:1 with 0.2% acetic acid; Rf = 0.5 in MeOH : 
EtOAc = 3:1). 1H NMR (400 MHz, DMSO-d6) δ 7.31 – 7.18 (m, 5H), 6.69 (s, 1H), 6.13 
(s, 1H), 4.95 (s, 1H), 3.71 (s, 3H), 3.44 (s, 3H), 3.07 – 2.98 (m, 1H), 2.96 – 2.81 (m, 4H), 
2.72 – 2.62 (m, 1H) ppm. 13C NMR (101 MHz, DMSO-d6) δ 174.02, 147.02, 146.60, 
144.42, 130.23, 129.29, 127.87, 126.85, 126.83, 111.98, 111.51, 64.97, 57.17, 55.44, 
55.38, 47.30, 28.31 ppm. HRMS (ESI) calcd for C19H21NO4 [M+H]+: 328.1543, found: 
328.1536 
 
Thio acid TA4: The thio acid TA4 was obtained starting from acid 8 (340 mg, 0.93 
mmol) with 25% yield via the same procedure as previously reported for the thio acid 
TA2.7d Rf = 0.6 in DCM : MeOH = 10:1. 1H NMR (400 MHz, CDCl3) : 7.35 – 7.23 (m, 
5H), 6.66 (s, 1H), 6.27 (s, 1H), 5.57 (s, 1H), 3.83 (s, 3H), 3.63 (s, 3H), 3.50 – 3.39 (m, 
2H), 3.37 (s, 2H), 3.24 – 3.01 (m, 2H) ppm. 13C NMR (101 MHz, CDCl3) : 204.67, 
149.54, 148.69, 136.42, 130.45, 129.99, 129.30, 123.44, 121.74, 111.17, 110.88, 66.16, 
63.53, 56.08, 45.27, 24.46 ppm. HRMS (ESI) calcd for C19H21NO3S [M+H]+: 344.1315, 
found: 344.1315 
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Thio acid TA5: The synthesis of thio acid TA5 was accomplished starting from acid 
chloride 9 (400 mg, 1.99 mmol) via the same procedure as previously reported for thio 
acid TA37d with 15% yield. Rf = 0.17 in hexane : EtOAc = 2:1.  1H NMR (400 MHz, 
CDCl3) : 7.00 (d, J = 2.1 Hz, 2H), 6.65 – 6.63 (m, 1H), 3.8 (s, 6H) ppm. 13C NMR (101 
MHz, CDCl3) : 190.10, 160.97, 138.57, 106.36, 105.69, 55.73 ppm. HRMS (ESI) calcd 
for C9H10O3S [M-H]-: 197.0278, found: 197.0278 
 
Thio acid TA6: To a solution of NaSH (90 mg, 1.6 mmol) in water (1mL) was added 
dropwise a solution of acid chloride 10 (200 mg, 1.07 mmol) in acetone (6 mL). The 
resulting mixture was stirred for 2 h. The solvent was removed under reduced pressure 
and resulting crude was basified using 10% NaOH solution (pH = 12).  The reaction 
mixture was then extracted with ethyl acetate to remove organic impurities. The aqueous 
layer was slowly acidified using 2 N HCl solution (pH = 1). Corresponding thio acid 
TA6 crashed out and was filtered, washed with deionized water and dried under vacuum 
to obtain pale yellow crystals of thio acid TA6 with 25% yield. Rf = 0.26 in hexane : 
EtOAc = 1:3. 1H NMR (400 MHz, CDCl3) : 8.75 – 8.72 (m, 1H), 8.50 – 8.44 (m, 1H), 
8.22 (d, J = 7.8 Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H) ppm.  13C NMR (101 MHz, CDCl3) : 
188.19, 137.96, 133.42, 130.32, 128.32, 122.96 ppm.  HRMS (ESI) calcd for C7H5NO3S 
[M-H]-: 181.9917, found: 181.9917 
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Thio acid TA7: To a solution of NaSH (90 mg, 1.6 mmol) in water (1mL) was added 
dropwise a solution of acid chloride 11 (204 mg, 1.07 mmol) in acetone (6 mL). The 
resulting mixture was stirred for 2 h. The solvent was removed under reduced pressure 
and resulting crude was basified using 10% NaOH solution (pH = 12). The reaction 
mixture was then extracted with ethyl acetate to remove organic impurities. The aqueous 
layer was slowly acidified using 2 N HCl solution and the aqueous layer was extracted 
using ethyl acetate at various pH values starting from 6 to 2, collecting organic fractions 
for every unit change in the pH. Fractions collected between pH changing from 5 to 2 
were combined and were subjected to preparative HPLC to obtain thio acid TA7 with 
27% yield. Rf = 0.24 in hexane : EtOAc = 1:1. 1H NMR (400 MHz, CDCl3) : 8.61 – 
8.50 (m, 1H), 8.35 (d, J = 7.1 Hz, 1H), 8.13 – 7.99 (m, 1H), 7.94 – 7.84 (m, 1H), 7.68 – 
7.53 (m, 3H) ppm. 13C NMR (101 MHz, CDCl3) : 188.15, 134.29, 134.00, 133.43, 
129.52, 129.09, 128.79, 128.65, 127.27, 125.41, 124.71 ppm.  HRMS (ESI) calcd for 
C11H8OS [M-H]-: 187.0223, found: 187.0218 
 
Thio acid TA8: The acid chloride 12 (500 mg, 2.22 mmol) and NaSH (149 mg, 2.66 
mmol) were stirred at 0 °C under solvent free conditions for 1 h and the thio acid TA8 
obtained, after filtering the salts, was used without further purification.  1H NMR (250 
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MHz, CDCl3) : 7.93 – 7.85 (m, 2H), 7.32 – 7.17 (m, 2H) ppm. HRMS (ESI) calcd for 
C8H5F3O2S [M-H]-: 220.9890, found: 220.9886 
 
Thio acid TA9: The thio acid TA9 was prepared following the same procedure as 
described for TA8. 1H NMR (250 MHz, CD3OD) : 7.92 (dd, J = 1.7, 0.8 Hz, 1H), 7.49 
(dd, J = 3.7, 0.8 Hz, 1H), 6.73 (dd, J = 3.7, 1.7 Hz, 1H) ppm. HRMS (ESI) calcd for 
C5H4O2S [M-H]- : 126.9859, found: 126.9863 
2.4.8 General procedure A for the synthesis of acylsulfonamides 
A solution of sulfonamide (1 eq), carboxylic acid (1 eq), EDCI (2 eq) and DMAP 
(0.2 eq) were stirred in dry DCM or THF, under inert atmosphere at room temperature 
overnight, quenched by adding water and the system was extracted with ethyl acetate. 
The combined organic layers were dried over anhydrous sodium sulfate and concentrated. 
The crude was then subjected to flash chromatography to obtain the corresponding 
acylsulfonamide. 
2.4.9 General procedure B for the synthesis of acylsulfonamides  
Synthesis of acylsulfonamide was accomplished by reacting selenocarboxylate 
(generated from corresponding carboxylic acid and selenating reagent, LiAlHSeH) with 
the sulfonyl azide according to a previously reported procedure.17 
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2.4.10 Synthesis of kinetic TGS hits 
 
Sulfonamide 14: Sodium borohydride (60 mg, 1.5 mmol) was added slowly to the 
solution of SZ7 (500 mg, 1.1 mmol) in methanol (6mL) at 0 °C. The reaction mixture 
was stirred for 30 min at room temperature, quenched using solid NH4Cl and the solvent 
was removed under reduced pressure to afford the crude product. Sulfonamide 14  (418 
mg, 90%) was obtained by flash chromatography. Rf = 0.64 in hexane : EtOAc = 1:2. 1H 
NMR (250 MHz, Acetone-d6) : 8.67 (s, 1H), 8.60 (s, 1H), 8.21 – 8.12 (m, 3H), 8.02 (dd, 
J = 8.7, 1.7 Hz, 1H), 7.28 – 7.10 (m, 5H), 6.97 (t, J = 5.8 Hz, 1H), 6.87 (bs, 2H), 3.30 – 
3.18 (m, 2H), 3.15 – 3.06 (m, 2H) ppm. 13C NMR (63 MHz, Acetone-d6)  : 143.54, 
140.22, 136.63, 135.93, 132.11, 130.57, 130.32, 130.03, 129.97, 129.74, 128.52, 127.20, 
125.86, 125.83, 43.24, 33.73 ppm. HRMS (ESI) calcd for C18H18N2O4S3 [M+H]+: 
423.0502, found: 423.0486 
 
Acylsulfonamide SZ7TA2: The acylsulfonamide SZ7TA2 was prepared following the 
general procedure A, starting from sulfonamide 14 and 4-(4,4-dimethylpiperidin-1-
yl)benzoic acid7d with 16% yield (102 mg) after purification using preparative HPLC 
system. Rf = 0.28 in EtOAc. 1H NMR (400 MHz, CDCl3) : 8.77 (s, 1H), 8.46 (s, 1H), 
8.23 (d, J = 8.2 Hz, 1H), 7.91 – 7.78 (m, 3H), 7.67 (d, J = 8.1 Hz, 2H), 7.19 – 7.01 (m, 
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5H), 6.64 (d, J = 8.0 Hz, 2H), 5.65 (bs, 1H), 3.34 – 3.15 (m, 4H), 3.12 (d, J = 5.7 Hz, 
2H), 2.96 (d, J = 5.6 Hz, 2H), 1.46 – 1.23 (m, 4H), 0.93 (s, 6H) ppm. 13C NMR (101 
MHz, CDCl3) : 164.05, 154.37, 138.41, 137.92, 136.46, 133.56, 131.23, 130.84, 130.17, 
129.94, 129.51, 129.45, 129.02, 126.88, 126.18, 125.42, 117.85, 113.03, 43.71, 41.66, 
37.76, 33.87, 28.58, 27.68 ppm. HRMS (ESI) calcd for C32H35N3O5S3 [M+H]+: 
638.1812, found: 638.1810 
 
Sulfonamide 17: A solution of sulfonamide 157d (900 mg, 3.6 mmol), benzaldehyde (381 
mg, 3.6 mmol) and p-toluenesulfonic acid (10 mg) in benzene was refluxed for 12 h 
using Dean-stark apparatus. The reaction mixture was cooled down to room temperature 
and extracted with ethyl acetate (20 mL  3). The combined organic phases were dried 
over anhydrous sodium sulfate and concentrated to afford the product 16, which was used 
without further purification. The mixture of 16 (1.22 g, 3.6 mmol), sulfonyl azide SZ6 
(1.25 g, 3.6 mmol) and potassium carbonate (1.0 g, 7.2 mmol) in acetonitrile and water 
(9:1, 20 mL), was refluxed for 24 hours. After cooling down to room temperature, the 
reaction mixture was treated with ethyl acetate (20 mL) and water (20 mL), extracted 
with ethyl acetate (20 mL  3). The combined organic phases were dried over anhydrous 
sodium sulfate and concentrated. Interestingly, hydrolysis of the imine occurred smoothly 
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under this basic condition. Sulfonamide 17 (930 mg, 50% over 2 steps) was thus obtained 
by flash chromatography (hexane : EtOAc = 2:1; Rf = 0.2 in hexane : EtOAc = 2:1). 1H 
NMR (400 MHz, CDCl3) : 7.83 (d, J = 8.2 Hz, 4H), 7.56 (d, J = 8.2 Hz, 2H), 7.47 (d, J 
= 8.2 Hz, 2H), 7.24 – 7.14 (m, 5H), 5.00 (bs, 2H), 3.67 (d, J = 3.8 Hz, 4H), 3.06 (t, J = 
6.8 Hz, 2H), 2.75 (t, J = 6.8 Hz, 2H) ppm. 13C NMR (101 MHz, CDCl3) : 147.00, 
144.11, 140.87, 137.06, 135.81, 129.61, 129.24, 129.08, 128.94, 127.50, 126.52, 126.19, 
58.11, 57.99, 53.01, 31.56 ppm. HRMS (ESI) calcd for C22H23N5O4S3 [M+H]+: 
518.0985, found: 518.0999  
 
Acylsulfonamide SZ9TA1: The acylsulfonamide SZ9TA1 was prepared following the 
general procedure A starting from sulfonamide 17 and benzoic acid with 54% yield (65 
mg). Rf = 0.77 in EtOAc. 1H NMR (400 MHz, CDCl3) : 8.09 (d, J = 8.0 Hz, 2H), 7.78 
(d, J = 8.1 Hz, 2H), 7.77 (d, J = 7.6 Hz, 2H), 7.60 – 7.51 (m, 5H),  7.47 – 7.37 (m, 3H), 
7.19 (d, J = 4.3 Hz, 3H), 7.14 – 7.08 (m, 1H), 3.67 (s, 4H), 3.04 (t, J = 7.2 Hz, 2H), 2.73 
(t, J = 7.2 Hz, 2H) ppm. 13C NMR (101 MHz, CDCl3) : 165.13, 147.07, 145.64, 137.64, 
137.16, 135.85, 133.47, 131.42, 130.22, 129.70, 129.14, 129.03, 128.86, 128.73, 128.09, 
127.64, 126.28, 58.00, 57.92, 52.84, 31.50 ppm. HRMS (ESI) calcd for C29H27N5O5S3 
[M+H]+: 622.1247, found: 622.1240 
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Acylsulfonamide SZ9TA5: was prepared following the general procedure A starting 
from sulfonamide 17 and 3,5-dimethoxybenzoic acid with 56% yield (110 mg). Rf = 0.28 
in hexane : EtOAc = 1:1. 1H NMR (400 MHz, CDCl3) : 7.97 (d, J = 6.8 Hz, 2H), 7.78 
(d, J = 7.8 Hz, 2H), 7.47 (d, J = 7.6 Hz, 2H), 7.33 – 6.92 (m, 10H), 6.42 (s, 1H), 3.66 – 
3.48 (m, 10H), 3.04 – 2.85 (m, 2H), 2.79 – 2.50 (m, 2H) ppm. 13C NMR (101 MHz, 
CDCl3) : 160.67, 147.23, 137.21, 135.98, 129.81, 129.16, 129.00, 127.72, 126.37, 
106.56, 105.27, 58.07, 57.91, 55.61, 52.89, 31.50 ppm. HRMS (ESI) calcd for 
C31H31N5O7S3 [M+H]+: 682.1458, found: 682.1440 
2.4.11 Synthesis of additional acylsulfonamides 
 
 Sulfonamide 18: To a solution of 1-phenylpiperazine (285 mg, 1.76 mmol) and bromide 
15 (400 mg, 1.59 mmol) in THF (8 mL), was added potassium carbonate (441 mg, 3.19 
mmol) and the resulting solution was stirred at room temperature overnight. The reaction 
mixture was treated with 1N potassium carbonate solution (10 mL), extracted with ethyl 
acetate (20 mL  3). The combined organic phases were dried over anhydrous sodium 
sulfate and concentrated. The sulfonamide 18 (461 mg, 87%) was thus obtained by flash 
chromatography (hexane : EtOAc = 2:1 with 0.1% triethylamine; Rf = 0.38 in hexane : 
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EtOAc = 1:2). 1H NMR (400 MHz, DMSO-d6) δ 7.80 – 7.75 (m, 2H), 7.49 (d, J = 8.1 
Hz, 2H), 7.31 – 7.28 (m, 2H), 7.16 (t, J = 7.7 Hz, 2H), 6.88 (d, J = 8.1 Hz, 2H), 6.73 (t, J 
= 7.2 Hz, 1H), 3.56 (s, 2H), 3.11 – 3.08 (m, 4H), 2.50 – 2.46 (m, 4H) ppm. 13C NMR 
(101 MHz, DMSO-d6) δ 151.41, 143.24, 142.77, 129.59, 129.32, 126.07, 119.23, 115.81, 
61.76, 52.98, 48.64 ppm. HRMS (ESI) calcd for C17H21N3O2S [M+H]+: 332.1427, found: 
332.1425 
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Acylsulfonamide SZ1TA3: was prepared following the general procedure A starting 
from sulfonamide 18 and 4-methyl-2-phenylthiazole-5-carboxylic acid with 58% yield 
(279 mg). Rf = 0.3 in EtOAc : MeOH = 20:1. 1H NMR (400 MHz, CD3OD) δ 8.16 (d, J = 
7.0 Hz, 2H), 7.76 (t, J = 10.0 Hz, 4H), 7.39 – 7.29 (m, 3H), 7.13 (t, J = 6.8 Hz, 2H), 6.84 
(d, J = 7.3 Hz, 2H), 6.79 (t, J = 6.6 Hz, 1H), 5.28 – 5.10 (m, 2H), 4.42 (s, 2H), 3.45 – 
3.23 (m, 6H), 2.46 (s, 3H) ppm. 13C NMR (101 MHz, CD3OD) δ 169.70, 161.16, 160.43, 
149.67, 141.85, 134.50, 132.22, 132.00, 131.40, 129.16, 129.12, 128.86, 126.68, 123.40, 
121.18, 116.73, 59.25, 51.80, 46.63, 16.60 ppm. HRMS (ESI) calcd for C28H28N4O3S2 
[M+H]+: 533.1676, found: 533.1668 
 
77 
 
Acylsulfonamide SZ1TA5: was prepared following the general procedure B with 45% 
yield (67 mg). Rf = 0.44 in EtOAc. 1H NMR (400 MHz, CDCl3) δ 8.24 – 7.97 (m, 2H), 
7.82 – 7.51 (m, 2H), 7.05 – 6.79 (m, 6H), 6.56 (s, 2H), 4.33 (s, 2H), 3.70 (s, 6H), 3.57 – 
3.04 (m, 8H) ppm. 13C NMR (101 MHz, CDCl3) δ 165.35, 161.11, 148.73, 140.80, 
134.11, 133.02, 132.01, 129.77, 129.57, 122.78, 117.63, 106.30, 106.07, 60.10, 55.78, 
51.89, 47.48 ppm. HRMS (ESI) calcd for C26H29N3O5S [M+H]+: 496.1901, found: 
496.1915 
 
Acylsulfonamide SZ1TA6: was prepared following the general procedure B with 33% 
yield (48 mg). Rf = 0.54 in hexane : EtOAc = 1:1. 1H NMR (400 MHz, CD3OD) δ 8.58 – 
8.55 (m, 1H), 8.40 – 8.34 (m, 1H), 8.18 (d, J = 8.3 Hz, 2H), 8.13 (d, J = 7.9 Hz, 1H), 7.77 
(d, J = 8.4 Hz, 2H), 7.67 (t, J = 8.0 Hz, 1H), 7.20 (t, J = 8.0 Hz, 2H), 6.92 (d, J = 8.0 Hz, 
2H), 6.85 (t, J = 7.3 Hz, 1H), 4.48 (s, 2H), 3.47 – 3.32 (m, 6H), 3.28 – 3.22 (m, 2H) ppm. 
13C NMR (101 MHz, CD3OD) δ 164.63, 149.76, 148.45, 141.33, 134.81, 133.89, 133.77, 
132.88, 131.95, 130.19, 129.10, 127.39, 122.99, 121.22, 116.79, 59.22, 51.88, 46.74 
ppm. HRMS (ESI) calcd for C24H24N4O5S [M+H]+: 481.1540, found: 481.1551 
 
Acylsulfonamide SZ1TA9: was prepared following the general procedure B with 15% 
yield (19 mg). Rf = 0.47 in hexane : EtOAc = 1:1. 1H NMR (400 MHz, CDCl3) δ 8.15 (d, 
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J = 8.0 Hz, 2H), 7.66 (d, J = 8.1 Hz, 2H), 7.50 (s, 1H), 7.31 – 7.23 (m, 4H), 6.97 (t, J = 
7.2 Hz, 1H), 6.90 (d, J = 8.3 Hz, 2H), 6.53 – 6.49 (m, 1H), 4.33 (s, 2H), 3.57 – 3.12 (m, 
8H) ppm. 13C NMR (101 MHz, CDCl3) δ 155.11, 149.12, 146.53, 145.08, 140.71, 
134.43, 131.97, 129.74, 129.60, 122.43, 118.81, 117.51, 113.23, 59.99, 51.87, 47.32 
ppm. HRMS (ESI) calcd for C22H23N3O4S [M+H]+ : 426.1482, found: 426.1481 
 
Acylsulfonamide SZ2TA4: was prepared following the general procedure B with 15% 
yield (55 mg). Rf = 0.56 in DCM : MeOH = 10:1. 1H NMR (400 MHz, CD3OD) δ 8.14 
(d, J = 8.4 Hz, 2H), 7.76 (d, J = 8.4 Hz, 2H), 7.46 – 7.41 (m, 3H), 7.33 – 7.24 (m, 7H), 
6.90 (s, 1H), 6.38 (s, 1H), 5.76 (s, 1H), 4.58 – 4.48 (m, 1H), 4.17 – 4.09 (m, 1H), 4.04 – 
3.98 (m, 1H), 3.88 – 3.84 (m, 4H), 3.60 (s, 3H), 3.44 – 3.40 (m, 2H), 3.20 – 3.11 (m, 4H), 
2.89 (s, 3H), 2.81 – 2.75 (m, 1H), 2.64 – 2.58 (m, 1H) ppm. 13C NMR (101 MHz, 
CD3OD) δ 167.91, 151.33, 150.33, 143.97, 137.46, 136.69, 136.11, 132.85, 132.11, 
131.45, 130.38, 130.18, 129.96, 129.91, 128.52, 124.76, 122.31, 112.66, 112.51, 67.06, 
60.19, 58.51, 56.62, 56.56, 56.01, 46.83, 40.46, 31.50, 27.98 ppm. HRMS (ESI) calcd for 
C35H39N3O5S [M+H]+ : 614.2683, found: 614.2675 
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Acylsulfonamide SZ3TA1: was prepared following the general procedure B with 11% 
yield (21 mg). Rf = 0.33 in EtOAc : MeOH = 20:1. 1H NMR (400 MHz, DMSO-d6) δ 
7.91 – 7.83 (m, 4H), 7.75 (d, J = 8.3 Hz, 2H), 7.56 (t, J = 7.1 Hz, 1H), 7.44 (t, J = 7.7 Hz, 
2H), 2.05 (s, 3H) ppm. 13C NMR (126 MHz, DMSO-d6) δ 169.54, 166.17, 144.03, 
133.86, 133.38, 132.66, 129.45, 128.94, 128.81, 118.76, 24.61 ppm. HRMS (ESI) calcd 
for C15H14N2O4S [M+H]+: 319.0747, found: 319.0744 
 
Acylsulfonamide SZ3TA6: was prepared following the general procedure A with 46 % 
yield (78 mg). Rf = 0.25 in EtOAc : MeOH = 20:1. 1H NMR (250 MHz, Acetone-d6) : 
8.61 (s, 1H), 8.32 (dd, J = 8.1, 1.5 Hz, 1H), 8.22 (d, J = 7.7 Hz, 1H), 7.91 (d, J = 8.7 Hz, 
2H), 7.75 – 7.64 (m, 3H), 1.99 (s, 3H) ppm. 13C NMR (63 MHz, Acetone-d6) : 169.69, 
149.19, 145.17, 135.18, 135.04, 134.10, 131.13, 130.49, 128.09, 123.91, 119.11, 24.37 
ppm.  HRMS (ESI) calcd for C15H13N3O6S [M+H]+: 364.0598, found: 364.0588  
 
Acylsulfonamide SZ3TA7: was prepared following the general procedure B with 14% 
yield (31 mg). Rf = 0.44 in hexane : EtOAc = 1:3. 1H NMR (400 MHz, CD3OD) δ 8.08 
(d, J = 8.8 Hz, 2H), 8.01 (d, J = 8.2 Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.91 – 7.87 (m, 
1H), 7.84 (d, J = 8.8 Hz, 2H), 7.65 (d, J = 7.0 Hz, 1H), 7.51 – 7.46 (m, 3H), 2.17 (s, 3H) 
ppm. 13C NMR (101 MHz, CD3OD) δ 170.66, 168.03, 143.78, 133.64, 133.48, 131.69, 
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130.91, 129.74, 129.18, 128.14, 127.10, 126.25, 126.18, 124.26, 124.11, 118.72, 22.66 
ppm. HRMS (ESI) calcd for C19H16N2O4S [M+H]+: 369.0904, found: 369.0904 
 
Acylsulfonamide SZ3TA8: was prepared following the general procedure B with 26% 
yield (63 mg). Rf = 0.63 in hexane : EtOAc = 1:3. 1H NMR (400 MHz, CD3OD) δ 8.01 – 
7.98 (m, 2H), 7.91 – 7.87 (m, 2H), 7.78 – 7.74 (m, 2H), 7.36 – 7.32 (m, 2H), 2.13 (s, 3H) 
ppm. 13C NMR (101 MHz, CD3OD) δ 170.62, 164.89, 152.34, 143.69, 133.35, 130.74, 
130.16, 129.22, 120.30, 118.62, 22.62 ppm. HRMS (ESI) calcd for C16H13F3N2O5S 
[M+H]+: 403.0570, found: 403.0566 
 
Acylsulfonamide SZ3TA9: was prepared following the general procedure A with 36% 
yield (52 mg). Rf = 0.23 in EtOAc. 1H NMR (400 MHz, CD3OD) : 7.97 (d, J = 8.8 Hz, 
2H), 7.75 (d, J = 8.8 Hz, 2H), 7.70 (s, 1H), 7.25 (d, J = 3.5 Hz, 1H), 6.58 (dd, J = 3.4, 1.5 
Hz, 1H), 2.13 (s, 3H) ppm. 13C NMR (101 MHz, CD3OD) : 170.87, 156.36, 147.08, 
145.63, 143.91, 133.74, 129.33, 118.85, 117.76, 112.34, 22.87 ppm. HRMS (ESI) calcd 
for C13H12N2O5S [M+H]+: 309.0540, found: 309.0547 
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Acylsulfonamide SZ5TA5: was prepared following the general procedure B with 46% 
yield (46 mg). Rf = 0.72 in EtOAc. 1H NMR (400 MHz, CDCl3) δ 8.04 (d, J = 8.2 Hz, 
2H), 7.35 (d, J = 8.1 Hz, 2H), 6.94 (d, J = 2.0 Hz, 2H), 6.61 – 6.59 (m, 1H), 3.75 (s, 6H), 
2.44 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 164.37, 161.20, 145.50, 135.56, 
133.22, 129.85, 128.83, 106.53, 105.59, 55.85, 21.91 ppm. HRMS (ESI) calcd for 
C16H17NO5S [M+H]+: 336.0900, found: 336.0904 
 
Acylsulfonamide SZ5TA6: was prepared following the general procedure B with 10% 
yield (10 mg). Rf = 0.29 in EtOAc. 1H NMR (400 MHz, CDCl3) δ 8.68 (s, 1H), 8.41 (d, J 
= 7.9 Hz, 1H), 8.17 (d, J = 7.6 Hz, 1H), 8.06 (d, J = 8.0 Hz, 2H), 7.66 (t, J = 7.9 Hz, 1H), 
7.38 (d, J = 7.9 Hz, 2H), 2.45 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 162.46, 
148.54, 145.97, 135.11, 133.80, 133.21, 130.46, 129.96, 128.98, 127.93, 123.11, 21.95 
ppm. HRMS (ESI) calcd for C14H12N2O5S [M+H]+: 321.0540, found: 321.0533 
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Acylsulfonamide SZ5TA9: was prepared following the general procedure B with 40% 
yield (32 mg). Rf = 0.4 in EtOAc. 1H NMR (400 MHz, CDCl3) δ 8.84 (s, 1H), 8.03 (d, J 
= 8.2 Hz, 2H), 7.50 (s, 1H), 7.34 (d, J = 8.1 Hz, 2H), 7.22 (d, J = 3.4 Hz, 1H), 6.53 (d, J 
= 1.8 Hz, 1H), 2.43 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 154.53, 145.97, 145.50, 
145.40, 135.71, 129.80, 128.82, 118.30, 113.26, 21.89 ppm. HRMS (ESI) calcd for 
C12H11NO4S [M+H]+: 266.0482, found: 266.0481 
 
Sulfonyl Azide 19: To a solution of sulfonyl azide SZ67d (600 mg, 1.72 mmol) and 
NaHCO3 (145 mg, 1.72 mmol) in CHCl3 (6.5 mL) was added (Boc)2O (376 mg, 1.72 
mmol) at 0 °C. The reaction mixture was then slowly warmed to room temperature and 
monitored using TLC until SZ6 was completely consumed. The reaction mixture was 
then treated with 1N NaHCO3 solution (20 mL) and extracted with CHCl3 (15 mL  3). 
The combined organic phases were dried over anhydrous sodium sulfate and 
concentrated. The crude obtained was subjected to flash chromatography (hexane : 
EtOAc = 8:1; Rf = 0.54 in hexane : EtOAc = 2:1) to obtain the corresponding sulfonyl 
azide 19 with 93% yield (717 mg). 1H NMR (400 MHz, CDCl3) δ 7.86 (d, J = 8.2 Hz, 
2H), 7.38 – 7.16 (m, 7H), 4.51 (s, 2H), 3.39 – 3.29 (m, 2H), 3.01 – 2.95 (m, 2H), 1.45 (s, 
9H) ppm. 13C NMR (101 MHz, CDCl3) δ 155.50, 146.12, 137.21, 129.52, 129.07, 
128.52, 127.99, 127.78, 126.52, 80.82, 50.48, 47.04, 31.80, 28.32 ppm. HRMS (ESI) 
calcd for C20H24N4O4S2 [M+Na]+: 471.1131, found: 471.1127 
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Sulfonamide 20: The sulfonamide 20 was prepared starting from sulfonyl azide 19 (600 
mg, 1.54 mmol) following the procedure described for synthesis of sulfonamide 14 with 
92% yield (600 mg). Rf = 0.42 in hexane : EtOAc = 1:1. 1H NMR (400 MHz, CDCl3) δ 
7.81 (d, J = 7.3 Hz, 2H), 7.30 – 7.13 (m, 7H), 5.16 (s, 2H), 4.45 (s, 2H), 3.34 – 3.27 (m, 
2H), 3.00 – 2.89 (m, 2H), 1.43 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3) δ 155.57, 
143.41, 140.98, 135.12, 129.44, 129.05, 128.08, 127.53, 126.68, 80.73, 50.37, 46.90, 
31.66, 28.34 ppm. HRMS (ESI) calcd for C20H26N2O4S2 [M+Na]+: 445.1226, found: 
445.1219 
 
Acylsulfonamide 21: was prepared following the general procedure A with 85% yield 
(576 mg). Rf = 0.54 in hexane : EtOAc = 1:1. 1H NMR (400 MHz, CDCl3) δ 8.04 (d, J = 
8.1 Hz, 2H), 7.71 (d, J = 8.9 Hz, 2H), 7.31 – 7.06 (m, 9H), 4.47 (s, 2H), 3.38 – 3.30 (m, 
6H), 3.01 – 2.90 (m, 2H), 1.59 (t, J = 5.4 Hz, 4H), 1.41 (s, 9H), 1.00 (s, 6H) ppm. 13C 
NMR (101 MHz, CDCl3) δ 163.91, 155.80, 150.97, 137.88, 135.29, 130.25, 129.72, 
129.26, 129.09, 127.97, 127.56, 126.68, 126.38, 116.78, 80.99, 50.62, 47.71, 47.23, 
37.11, 31.93, 28.52, 28.28, 27.72 ppm. HRMS (ESI) calcd for C34H43N3O5S2 [M+H]+: 
638.2717, found: 638.2693 
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Acylsulfonamide SZ6TA2: To a solution of acylsulfonamide 21 (437 mg, 0.68 mmol) in 
CHCl3 (5 mL) cooled to 0 °C, was added TFA (1.2 mL) dropwise. The reaction mixture 
was then slowly warmed to room temperature and monitored using TLC until 
acylsulfonamide 21 was completely consumed. The reaction was then treated with 
saturated K2CO3 solution (pH = 7) and extracted with CHCl3 (20 mL  3). The combined 
organic phases were dried over anhydrous sodium sulfate and concentrated. The crude 
obtained was purified using preparative HPLC to afford the acylsulfonamide SZ6TA2 
with 90% yield (330 mg). Rf = 0.69 in EtOAc : MeOH = 20:1. 1H NMR (400 MHz, 
CD3OD) δ 8.21 (d, J = 8.4 Hz, 2H), 7.77 (dd, J = 17.2, 8.7 Hz, 4H), 7.49 (d, J = 7.7 Hz, 
2H), 7.40 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.3 Hz, 1H), 7.08 (d, J = 9.1 Hz, 2H), 4.40 (s, 
2H), 3.53 – 3.44 (m, 4H), 3.41 – 3.38 (m, 3H), 1.63 – 1.52 (m, 4H), 1.37 (s, 1H), 1.10 (s, 
6H) ppm. 13C NMR (101 MHz, CD3OD) δ 165.85, 154.02, 141.32, 136.66, 133.42, 
130.61, 130.22, 130.07, 129.29, 128.91, 127.38, 120.11, 113.83, 50.10, 46.32, 44.57, 
37.67, 29.35, 28.26, 26.87 ppm. HRMS (ESI) calcd for C29H35N3O3S2 [M+H]+: 
538.2193, found: 538.2180 
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Acylsulfonamide SZ7TA5: was prepared following the general procedure B with 28% 
yield (49 mg). Rf = 0.31 in EtOAc. 1H NMR (400 MHz, CD3OD) δ 8.80 (s, 1H), 8.50 (s, 
1H), 8.22 (d, J = 8.0 Hz, 1H), 8.18 – 8.05 (m, 2H), 7.98 (d, J = 8.2 Hz, 1H), 7.17 – 7.01 
(m, 5H), 6.97 (s, 2H), 6.67 (s, 1H), 3.77 (s, 6H), 3.07 (t, J = 6.1 Hz, 2H), 2.94 (t, J = 6.2 
Hz, 2H). 13C NMR (101 MHz, CD3OD) δ 166.26, 161.22, 139.44, 138.34, 136.65, 
134.86, 133.71, 131.15, 131.02, 129.52, 129.10, 128.74, 126.28, 125.57, 105.83, 105.28, 
54.86, 41.97, 32.93 ppm. HRMS (ESI) calcd for C27H26N2O7S3 [M+H]+: 609.0794, 
found: 609.0772 
 
Acylsulfonamide SZ7TA6: was prepared following the general procedure B with 46% 
yield (79 mg). Rf = 0.5 in EtOAc. 1H NMR (400 MHz, CD3OD) δ 8.79 (s, 1H), 8.61 (s, 
1H), 8.47 (s, 1H), 8.37 (d, J = 7.4 Hz, 1H), 8.23 – 8.03 (m, 4H), 7.94 (d, J = 8.0 Hz, 1H), 
7.67 (t, J = 8.0 Hz, 1H), 7.15 – 6.95 (m, 6H), 3.04 (t, J = 7.0 Hz, 2H), 2.91 (t, J = 7.0 Hz, 
2H) ppm. 13C NMR (101 MHz, CD3OD) δ 164.42, 148.39, 139.47, 138.06, 136.70, 
134.89, 133.95, 133.63, 131.31, 131.01, 130.13, 129.54, 129.46, 129.22, 129.12, 128.74, 
127.36, 126.24, 125.61, 123.00, 41.99, 32.94 ppm. HRMS (ESI) calcd for C25H21N3O7S3 
[M+H]+: 572.0614, found: 572.0597 
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Acylsulfonamide SZ7TA7: was prepared following the general procedure B with 42% 
yield (145 mg). Rf = 0.48 in EtOAc : MeOH = 20:1. 1H NMR (400 MHz, CDCl3) δ 8.78 
(s, 1H), 8.45 (s, 1H), 8.27 (d, J = 8.7 Hz, 1H), 8.09 (d, J = 8.3 Hz, 1H), 7.98 (d, J = 8.7 
Hz, 1H), 7.95 – 7.83 (m, 4H), 7.72 (d, J = 8.0 Hz, 1H), 7.66 (d, J = 7.1 Hz, 1H), 7.43 – 
7.29 (m, 4H), 7.14 – 7.05 (m, 5H), 3.11 (m, 2H), 2.93 (t, J = 6.4 Hz, 2H) ppm. 13C NMR 
(101 MHz, CDCl3) δ 166.50, 138.81, 137.55, 136.87, 133.78, 133.36, 131.85, 131.09, 
130.43, 130.10, 129.80, 129.53, 129.29, 128.71, 128.18, 127.25, 127.17, 127.02, 126.17, 
125.88, 124.85, 124.55, 41.86, 34.12 ppm. HRMS (ESI) calcd for C29H24N2O5S3 
[M+H]+: 577.0920, found: 577.0905 
 
Sulfonamide 22: The sulfonamide 22 was obtained starting from sulfonyl azide SZ8 
(290 mg, 0.62 mmol) following the procedure described for synthesis of sulfonamide 14 
with 89% yield (243 mg). Rf = 0.33 in hexane : EtOAc = 1:1. 1H NMR (250 MHz, 
CDCl3) : 7.59 (d, J = 7.6 Hz, 2H), 7.22 – 7.00 (m, 7H), 6.39 (s, 1H), 5.99 (s, 1H), 5.28 
(bs, 2H), 4.34 (s, 1H), 3.62 – 3.51 (m, 4H), 3.34 (s, 3H), 3.11 (d, J = 13.9 Hz, 1H), 2.85 – 
2.67 (m, 2H), 2.55 – 2.42 (m, 1H), 2.36 – 2.21 (m, 1H) ppm. 13C NMR (63 MHz, CDCl3) 
δ 147.44, 147.06, 144.95, 143.84, 140.81, 129.97, 129.51, 129.10, 128.45, 127.52, 
126.78, 126.30, 111.75, 111.03, 68.20, 58.26, 55.80, 55.74, 47.26, 28.47 ppm. HRMS 
(ESI) calcd for C24H26N2O4S [M+H]+: 439.1686, found: 439.1682 
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Acylsulfonamide SZ8TA1: was prepared following the general procedure B with 50% 
yield (163 mg). Rf = 0.4 in hexane : EtOAc = 1:1. 1H NMR (400 MHz, CD3OD) : 8.17 
(d, J = 8.3 Hz, 2H), 7.77 (d, J = 7.8 Hz, 2H), 7.67 (d, J = 8.3 Hz, 2H), 7.63 – 7.55 (m, 
1H), 7.51 – 7.42 (m, 5H), 7.29 (s, 2H), 6.89 (s, 1H), 6.35 (s, 1H), 5.71 (s, 1H), 4.57 (d, J 
= 12.7 Hz, 1H), 4.35 (bs, 1H), 3.83 (s, 3H), 3.71 – 3.60 (m, 1H), 3.57 (s, 3H), 3.49 – 3.37 
(m, 2H), 3.23 (d, J = 5.4 Hz, 2H) ppm. 13C NMR (101 MHz, CD3OD) δ 166.83, 149.85, 
148.85, 141.35, 136.04, 135.70, 133.27, 132.08, 131.45, 130.70, 130.04, 129.21, 128.99, 
128.62, 128.09, 123.76, 111.17, 66.85, 56.59, 55.27, 55.19, 45.22, 23.57 ppm. HRMS 
(ESI) calcd for C31H30N2O5S [M+H]+: 543.1948, found: 543.1936 
 
Acylsulfonamide SZ8TA3: was prepared following the general procedure A with 14% 
yield (20 mg). Rf = 0.35 in EtOAc. 1H NMR (400 MHz, CDCl3) : 8.09 (bs, 2H), 7.82 (d, 
J = 7.2 Hz, 2H), 7.63 (bs, 2H), 7.47 – 7.34 (m, 6H), 7.24 (bs, 2H), 6.67 (s, 1H), 6.25 (s, 
1H), 4.51 (d, J = 10.1 Hz, 1H), 3.82 (s, 3H), 3.65 (s, 3H), 3.58 – 3.34 (m, 3H), 3.33 – 
3.06 (m, 3H), 2.60 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3) : 169.52, 161.45, 159.66, 
149.51, 148.72, 140.63, 135.02, 133.97, 132.17, 131.55, 131.41, 130.99, 130.28, 129.72, 
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129.22, 129.12, 126.89, 126.61, 122.50, 122.22, 110.54, 65.52, 55.88, 43.00, 23.67, 17.73 
ppm. HRMS (ESI) calcd for C35H33N3O5S2 [M+H]+: 640.1940, found: 640.1935 
 
Acylsulfonamide SZ8TA4: was prepared following the general procedure A with 18% 
yield (31 mg). Rf = 0.45 in EtOAc. 1H NMR (400 MHz, CDCl3) : 9.58 (bs, 1H), 7.98 
(bs, 2H), 7.56 (bs, 2H), 7.39 – 7.18 (m, 11H), 6.65 (s, 2H), 6.20 (s, 2H), 5.68 (s, 1H), 
4.45 – 4.25 (m, 2H), 4.07 – 3.96 (m, 3H), 3.84 (s, 3H), 3.83 (s, 3H), 3.60 (s, 6H), 3.38 
(bs, 3H), 3.13 – 3.03 (m, 4H) ppm. 13C NMR (101 MHz, CDCl3) : 165.34, 149.47, 
148.56, 140.50, 134.64, 131.67, 130.80, 130.16, 129.71, 129.25, 129.13, 128.63, 127.99, 
122.76, 121.64, 120.84, 110.84, 110.63, 66.50, 65.95, 56.20, 55.85, 54.09, 45.50, 23.51 
ppm. HRMS (ESI) calcd for C43H45N3O7S [M+H]+: 748.3057, found: 748.3062 
 
Acylsulfonamide SZ8TA5: was prepared following the general procedure B with 42% 
yield (152 mg). Rf = 0.58 in hexane : EtOAc = 1:3. 1H NMR (400 MHz, CD3OD) : 8.21 
– 8.12 (m, 2H), 7.69 – 7.63 (m, 2H), 7.49 – 7.43 (m, 3H), 7.30 – 7.25 (m, 2H), 6.94 – 
6.85 (m, 3H), 6.69 – 6.65 (m, 1H), 6.33 (s, 1H), 5.64 (s, 1H), 4.50 (d, J = 13.1 Hz, 1H), 
3.83 (s, 3H), 3.76 (s, 6H), 3.67 – 3.60 (m, 1H), 3.57 (s, 3H), 3.46 – 3.34 (m, 1H), 3.31 – 
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3.26 (m, 1H), 3.23 – 3.15 (m, 2H) ppm. 13C NMR (101 MHz, CD3OD) : 166.18, 161.04, 
149.68, 148.67, 141.13, 135.56, 133.58, 131.29, 130.51, 129.89, 129.20, 129.02, 128.84, 
123.41, 110.95, 110.88, 105.64, 104.85, 66.54, 56.29, 55.03, 54.95, 54.65, 23.20 ppm. 
HRMS (ESI) calcd for C33H34N2O7S [M+H]+: 603.2160, found: 603.2145 
 
Acylsulfonamide SZ8TA7: was prepared following the general procedure A with 48% 
yield (97 mg). Rf = 0.41 in hexane : EtOAc = 1:1. 1H NMR (400 MHz, CD3OD) δ 8.24 
(d, J = 8.1 Hz, 2H), 8.07 – 7.86 (m, 4H), 7.77 – 7.66 (m, 4H), 7.54 – 7.45 (m, 5H), 7.32 – 
7.26 (m, 1H), 6.90 (s, 1H), 6.34 (s, 1H), 5.68 (s, 1H), 4.58 (d, J = 12.9 Hz, 1H), 3.84 (s, 
3H), 3.70 – 3.62 (m, 1H), 3.55 (s, 3H), 3.48 – 3.40 (m, 1H), 3.35 – 3.30 (m, 1H), 3.26 – 
3.19 (m, 2H) ppm. 13C NMR (101 MHz, CD3OD) δ 168.17, 150.02, 148.99, 141.41, 
135.69, 135.18, 133.95, 133.65, 132.18, 131.79, 130.80, 130.52, 130.26, 129.33, 129.16, 
128.53, 127.42, 126.92, 126.55, 124.52, 124.28, 123.53, 121.83, 111.22, 111.08, 66.62, 
56.41, 55.29, 55.19, 45.10, 23.25 ppm. HRMS (ESI) calcd for C35H32N2O5S [M+H]+: 
593.2105, found: 593.2094 
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Acylsulfonamide SZ8TA8: was prepared following the general procedure A with 44% 
yield (50 mg). Rf = 0.63 in EtOAc : MeOH = 20:1. 1H NMR (400 MHz, CD3OD) δ 7.98 
(d, J = 8.2 Hz, 2H), 7.71 (d, J = 8.7 Hz, 2H), 7.54 (d, J = 8.2 Hz, 2H), 7.30 – 7.23 (m, 
3H), 7.14 (d, J = 8.2 Hz, 4H), 6.69 (s, 1H), 6.17 (s, 1H), 5.57 (s, 1H), 4.40 (d, J = 13.3 
Hz, 1H), 4.20 (s, 1H), 3.63 (s, 3H), 3.53 – 3.44 (m, 1H), 3.36 (s, 3H), 3.15 – 3.02 (m, 3H) 
ppm. 13C NMR (101 MHz, CD3OD) δ 165.65, 152.66, 149.86, 148.82, 141.39, 135.45, 
135.11, 131.81, 130.89, 130.55, 130.20, 129.29, 128.99, 123.64, 122.17, 120.53, 120.49 
(q, J = 259.81 Hz), 111.22, 111.14, 66.88, 56.53, 55.29, 55.22, 45.14, 23.42 ppm. HRMS 
(ESI) calcd for C32H29F3N2O6S [M+H]+: 627.1771, found: 627.1785 
 
Acylsulfonamide SZ8TA9: was prepared following the general procedure A with 49% 
yield (47 mg). Rf = 0.52 in EtOAc : MeOH = 20:1. 1H NMR (400 MHz, CD3OD) δ 8.13 
(d, J = 7.8 Hz, 2H), 7.73 – 7.65 (m, 3H), 7.44 (s, 3H), 7.31 (s, 2H), 7.25 (d, J = 3.2 Hz, 
1H), 6.88 (s, 1H), 6.58 (d, J = 2.0 Hz, 1H), 6.35 (s, 1H), 5.73 (s, 1H), 4.57 (d, J = 12.9 
Hz, 1H), 4.36 (s, 1H), 3.82 (s, 3H), 3.70 – 3.60 (m, 1H), 3.56 (s, 3H), 3.49 – 3.40 (m, 
1H), 3.23 (s, 2H) ppm. 13C NMR (101 MHz, CD3OD) δ 156.66, 149.87, 148.83, 147.32, 
145.55, 141.36, 135.47, 135.06, 131.77, 130.84, 130.19, 129.27, 128.89, 123.58, 122.05, 
118.06, 112.46, 111.18, 111.09, 66.81, 56.51, 55.29, 55.21, 45.10, 23.34 ppm. HRMS 
(ESI) calcd for C29H28N2O6S [M+H]+: 533.1741, found: 533.1735 
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Acylsulfonamide SZ9TA2: was prepared following the general procedure A with 60% 
yield (169 mg). Rf = 0.56 in hexane : EtOAc = 1:1. 1H NMR (400 MHz, CDCl3) : 8.08 
(d, J = 8.4 Hz, 2H), 7.85 (d, J = 8.0 Hz, 2H), 7.63 (d, J = 8.6 Hz, 2H), 7.56 (d, J = 8.4 Hz, 
2H), 7.51 (d, J = 8.0 Hz, 2H), 7.22 – 7.12 (m, 5H), 6.86 (d, J = 9.2 Hz, 2H), 3.77 (d, J = 
4.8 Hz, 4H), 3.32 (t, J = 5.8 Hz, 4H), 3.06 (t, J = 7.2 Hz, 2H), 2.79 (t, J = 7.2 Hz, 2H), 
1.47 (t, J = 5.6 Hz, 4H), 0.98 (s, 6H) ppm. 13C NMR (101 MHz, CDCl3) : 154.12, 
147.00, 136.96, 135.69, 130.03, 129.54, 128.96, 128.87, 128.72, 128.30, 127.46, 126.11, 
113.06, 57.87, 57.69, 52.65, 43.87, 37.79, 31.29, 28.53, 27.70, 27.59 ppm. HRMS (ESI) 
calcd for C36H40N6O5S3 [M+H]+: 733.2295, found: 733.2297 
 
Acylsulfonamide SZ9TA3: was prepared following the general procedure A with 45% 
yield (62 mg). Rf = 0.66 in EtOAc : MeOH = 20:1. 1H NMR (400 MHz, DMSO-d6) δ 
8.01 – 7.95 (m, 4H), 7.95 – 7.91 (m, 2H), 7.76 (d, J = 8.4, 2H), 7.66 (d, J = 8.2, 2H), 7.53 
– 7.49 (m, 3H), 7.19 – 7.15 (m, 4H), 7.09 – 7.04 (m, 1H), 3.91 (s, 4H), 3.21 (t, J = 7.1 
Hz, 2H), 2.73 (s, 2H), 2.55 (s, 3H) ppm. 13C NMR (101 MHz, DMSO-d6) δ 168.41, 
161.13, 159.47, 145.80, 143.06, 139.86, 136.90, 135.55, 132.49, 131.71, 130.99, 129.91, 
129.77, 129.33, 128.55, 128.21, 127.80, 126.85, 126.15, 124.67, 57.27, 57.14, 52.14, 
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29.03, 17.81 ppm. HRMS (ESI) calcd for C33H30N6O5S4 [M+H]+: 719.1233, found: 
719.1228 
 
Acylsulfonamide SZ9TA7: was prepared following the general procedure A with 69% 
yield (45 mg). Rf = 0.44 in hexane : EtOAc = 1:1. 1H NMR (400 MHz, CDCl3) : 8.44 (s, 
1H), 7.96 (d, J = 8.0 Hz, 2H), 7.74 – 7.68 (m, 3H), 7.60 – 7.51 (m, 3H), 7.35 (d, J = 8.0 
Hz, 2H), 7.18 – 6.93 (m, 10H), 3.37 (s, 2H), 3.31 (s, 2H), 2.86 (t, J = 6.4 Hz, 2H), 2.50 
(bs, 2H) ppm. 13C NMR (101 MHz, CDCl3) : 146.99, 143.43, 140.01, 136.83, 135.75, 
133.39, 131.40, 130.42, 129.47, 128.86, 128.82, 128.66, 127.93, 127.66, 127.36, 127.12, 
126.86, 126.06, 125.73, 124.34, 57.60, 57.39, 52.47, 31.14 ppm. HRMS (ESI) calcd for 
C33H29N5O5S3 [M+H]+: 672.1404, found: 672.1409 
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2.4.12 Mutant Bcl-XL ( R139ABcl-XL ) experiments: LC/MS-SIM analysis 
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Figure 2.6. Bcl-XL and mutant Bcl-XL templated incubations with SZ7 and TA2. The 
samples were incubated for six hours at 37 °C and subjected to LC/MS-SIM analysis 
with gradient system 1. A) Incubation of SZ7 and TA2 without Bcl-XL B) Incubation of 
SZ7 and TA2 with 2 M Bcl-XL C) Incubation of SZ7 and TA2 with 2 M mutant Bcl-
XL D) Synthetic SZ7TA2 as the reference. 
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Figure 2.7. Bcl-XL and mutant Bcl-XL templated incubations with SZ9 and TA1. The 
samples were incubated for six hours at 37 °C and subjected to LC/MS-SIM analysis 
with gradient system 1. A) Incubation of SZ9 and TA1 without Bcl-XL B) Incubation of 
SZ9 and TA1 with 2 M Bcl-XL C) Incubation of SZ9 and TA1 with 2 M mutant Bcl-
XL D) Synthetic SZ9TA1 as the reference. 
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Figure 2.8. Bcl-XL and mutant Bcl-XL templated incubations with SZ9 and TA5. The 
samples were incubated for six hours at 37 °C and subjected to LC/MS-SIM analysis 
with gradient system 1. A) Incubation of SZ9 and TA5 without Bcl-XL B) Incubation of 
SZ9 and TA5 with 2 M Bcl-XL C) Incubation of SZ9 and TA5 with 2 M mutant Bcl-
XL D) Synthetic SZ9TA5 as the reference. 
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2.4.13 Peptide control experiments: LC/MS-SIM analysis 
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Figure 2.9. Incubation of SZ9 and TA1 and suppressing Bcl-XL-templated incubations 
with Bim and mutant Bim. The samples were incubated for six hours at 37 °C and 
subjected to LC/MS-SIM analysis with gradient system 1. A) Incubation of SZ9 and TA1 
without Bcl-XL B) Incubation of SZ9 and TA1 with 2 M Bcl-XL C) Incubation of SZ9 
and TA1 with 2 M Bcl-XL and 20 M Bim D) Incubation of SZ9 and TA1 with 2 M 
Bcl-XL and 20 M mutant Bim E) Synthetic SZ9TA1 as the reference. 
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Figure 2.10. Incubation of SZ9 and TA5 and suppressing Bcl-XL-templated incubations 
with Bim and mutant Bim. The samples were incubated for six hours at 37 °C and 
subjected to LC/MS-SIM analysis with gradient system 2. A) Incubation of SZ9 and TA5 
without Bcl-XL B) Incubation of SZ9 and TA5 with 2 M Bcl-XL C) Incubation of SZ9 
and TA5 with 2 M Bcl-XL and 20 M Bim D) Incubation of SZ9 and TA5 with 2 M 
Bcl-XL and 20 M mutant Bim E) Synthetic SZ9TA5 as the reference. 
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Chapter 3 
Identification of Protein-Protein Interaction Modulators Targeting Mcl-1 via Sulfo-
Click Kinetic Target-Guided Synthesis 
3.1 Introduction 
The discovery of B-cell lymphoma-2 (Bcl-2) almost three decades ago has been 
considered as a major breakthrough in understanding the development of cancer, thus 
providing channels to deliver potential anti-cancer agents.1 This Bcl-2 family can be 
classified into two categories: pro-apoptotic and anti-apoptotic proteins. Although the 
complete mechanism through which these two types of proteins interact remains 
controversial, the anti-apoptotic proteins in the Bcl-2 family (e.g. Bcl-2, Bcl-XL, Mcl-1) 
have been established as the promising targets for drug discovery and development.2 
Initially, Bcl-2 and Bcl-XL were identified as the key players in regulation of apoptosis. 
As a result, majority of the research endeavors were aimed at development of small-
molecules disrupting the interactions between pro-apoptotic proteins and Bcl-2/Bcl-XL.3 
Remarkably, a few of these candidates have made it to the clinical trials.4 For example, 
ABT-263, an analogue of ABT-737, was developed by Abbott laboratories and is 
currently in phase I/II clinical trials.4c Despite being highly potent against Bcl-2 and Bcl-
XL (Ki <1 nM), these molecules exhibited weaker binding affinities against Mcl-1 (Ki = 
550 nM for ABT-263; Ki >1000 nM for ABT-737).4c Moreover, cancer cells have been 
reported to develop resistance against ABT-737 through up-regulation of Mcl-1.5
107 
 
Accordingly, down-regulation of Mcl-1 has resulted in restoring the sensitivity of cancer 
cells towards ABT-263 and ABT-737.4c, 6 Meanwhile, Willis et al.7 and Warr et al.8 have 
recently demonstrated that Mcl-1 also plays a crucial role in regulating the apoptotic 
pathway. For instance, the pro-apoptotic Bak interacts with Bcl-XL and Mcl-1 through 
BH3 domain, which is also essential for dimerization of Bak, eventually leading to 
apoptosis.7 Besides, Bak does not bind to the other members of the anti-apoptotic family, 
Bcl-2, Bcl-w and A1. In other words, antagonism of both, Bcl-XL and Mcl-1 by BH3-
only proteins is required for the Bak-assisted cell death.7 Strikingly, certain BH3-only 
proteins are known to heterodimerize with anti-apoptotic members with high selectivity. 
For example, Noxa binds strongly to Mcl-1 (but not Bcl-2 and Bcl-XL) and also triggers 
its destruction. Whereas, Bad binds to Bcl-XL and Bcl-2 but not Mcl-1.9 Collectively, 
these findings suggest that the small molecule inhibitors either targeting Mcl-1 
selectively or multiple members of the Bcl-2 family (Bcl-2, Bcl-XL and Mcl-1) 
simultaneously, hold great therapeutic potential. Consequently, several research groups 
have reported structurally diverse molecules as pan-active antagonists of the Bcl-2 family 
(Figure 3.1A),10 although a few Mcl-1-selective candidates are also available (Figure 
3.1B).9, 11  
Recently, Pellecchia and co-workers identified acylsulfonamides as potent 
inhibitors displaying nanomolar binding affinities against both, Bcl-XL and Mcl-1 using a 
fragment-based approach, termed as SAR by ILOE (structure activity relationship by 
interligand nuclear overhauser effect).10d Contrary to SAR by NMR, SAR by ILOE12 
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Figure 3.1. Inhibitors targeting multiple Bcl-2 family members or Mcl-1 selectively  
relies on identifying protein-assisted ligand-ligand NOEs (ILOEs) between two 
adjacently binding fragments at the binding site of the protein, which can be covalently 
linked, guided by molecular modeling studies along with appropriate synthetic methods 
to obtain a bidentate ligand (Figure 3.2B).10d Importantly, 15N labeled protein is not 
required for ILOE-based screening. Moreover, tedious HSQC experiments need not be 
performed, presenting advantages over the SAR by NMR approach.  
Initially, fragments binding to Bcl-XL, identified by Petros et al.13 through SAR 
by NMR screening, were chosen as model substrates. As anticipated, Bcl-XL-assisted 
ILOEs between hydrogens on the aromatic rings of acid 6 and methylene hydrogens of 
naphthalenol 7 were clearly recognized (Figure 3.2). Additionally, the majority of the 
109 
 
 
Figure 3.2. Comparison of SAR by NMR and SAR by ILOEs approaches 
ILOE signals were abolished when Bak BH3 peptide was added to the NMR sample, 
indicating that the fragments were targeting the binding site of Bcl-XL.10d ILOEs arising 
from nonspecific binding interactions can thus be clearly distinguished and corresponding 
fragments may not be considered useful. After establishing these experiments, Pellecchia 
et al. utilized this approach with diverse set of fragments to identify several 
acylsulfonamides as potent inhibitors of Bcl-XL and Mcl-1. Strikingly, this is the only 
example in the literature wherein acylsulfonamides were found to be active against Mcl-
1, since the Abbott candidates (ABT-737 and ABT-263) exhibited poor binding affinities 
against this target. Meanwhile, Manetsch and co-workers have established another 
fragment-based approach, kinetic target-guided synthesis (TGS) for the identification of 
protein-protein interaction modulators (PPIMs). They reported that the sulfo-click 
reaction, wherein sulfonyl azides react with thio acids generating acylsulfonamides, can 
be successfully employed to disrupt Bcl-XL-protein interactions.14  
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Figure 3.3. Kinetic TGS screening via sulfo-click chemistry against Bcl-XL  
A library of nine sulfonyl azides and nine thio acids (eighty one potential 
products), was incubated as binary mixtures at 37 °C for six hours in presence and 
absence of Bcl-XL and the samples were analyzed by liquid chromatography combined 
with mass spectrometry detection in the selected ion mode (LC/MS-SIM) for the product 
formation (Figure 3.3). Comparison of samples with and without Bcl-XL revealed that, of 
all eighteen fragments, only SZ4, SZ7, SZ9, TA1, TA2, and TA5 were selectively 
templated by Bcl-XL thereby yielding acylsulfonamides SZ4TA2, SZ7TA2, SZ9TA1, 
and SZ9TA5 in amplified amounts. Furthermore, these compounds showed IC50s in the 
low micromolar range, which underscores the utility of kinetic TGS as a valuable 
approach to PPIM discovery.14b Based on the reports from Pellecchia and Manetsch, the 
kinetic TGS approach can also be envisioned to be applied to Mcl-1 to discover 
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structurally diverse acylsulfonamides. Herein, we disclose our findings towards screening 
and identification of acylsulfonamides as PPIMs targeting Mcl-1 via sulfo-click kinetic 
TGS. 
3.2 Results and discussion 
3.2.1 Expansion of fragment library  
Inspired by the results obtained for Bcl-XL, the libraries of sulfonyl azides and 
thio acids were first expanded in order to explore a wider chemical space. Majority of the 
sulfonyl azides were synthesized using one of the following three reactions conditions: 
(a) alkylation of amines with 4-(bromomethyl)benzenesulfonyl azide,14b (b) treating the 
corresponding sulfonamides with triflyl azide (TfN3), a diazo transfer reagent,15 or (c) 
alkylation of amines with in situ generated 2-chloroethanesulfonyl azide (Scheme 3.1 A-
B).16 Thus, a set of twenty two sulfonyl azides were added to the previous library 
bringing up the total number of fragments to thirty one.  
The thio acids were derived from corresponding acid chlorides using sodium 
hydrosulfide (Scheme 3.1C). Although the synthetic procedure seems fairly 
straightforward, purification of the thio acids is problematic at times. Moreover, they are 
not stable over a reasonable period of time due to formation of by-products such as 
anhydride of thio acid. As a result, handling and storage of thio acids becomes difficult 
and they have to be freshly prepared before the kinetic TGS screening to obtain 
reproducible results. A method deprived of these limitations was recently reported, 
wherein the carboxylic acids were first coupled with 9-fluorenylmethanethiol providing 
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Scheme 3.1. Synthesis of sulfonyl azides, thio acids, thioesters and acylsulfonamides. 
Reaction conditions: (a) K2CO3, CH3CN:H2O (9:1), 12 h, rt (b) K2CO3, KI (cat.), 
CH3CN:H2O (9:1), 3 h, rt (c) TfN3, CuSO4, NaHCO3, H2O, toluene, t-BuOH, 24 to 48 h, 
rt (d) NaSH, acetone, H2O, 2 h, rt or NaSH, neat, 1 h, 0 °C to rt (e) EDCI, DMAP, DCM, 
2 h, rt (f) 3.5% DBU, DMF, 1 min, rt; RSO2N3, 1 min, rt (g) EDCI, DMAP, CH2Cl2, rt, 
24 to 48 h (h) (CH3)2CHOCOCl, N-methyl piperidine, THF, 0 °C, 30 min (i) LiAlHSeH, 
THF, 0 °C, 30 min (j) RSO2N3, THF, 0 °C to rt, 3 h 
corresponding thioesters, which upon deprotection quantitatively yield the thio acids.16 
Hence, the corresponding thioesters of the thio acids TA1-TA10 were synthesized as 
described above. The deprotection can be accomplished by treating the thioesters with (a) 
5% piperidine in DMF, or (b) 3.5% 1,8-Diazabicycloundec-7-ene (DBU) in DMF, or (c) 
5 equivalents of Cs2CO3. The reaction is completed in about an hour with Cs2CO3, 
whereas it takes two minutes when DBU or piperidine is used, making it highly 
efficient.16 After deprotection with piperidine, the thio acid generated can be diluted to a 
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stock solution in methanol and used for kinetic TGS experiments without further 
purification. Importantly, this process has been tailored towards synthesis of 
acylsulfonamides (Scheme 3.1D). In a one-pot approach, deprotection of thio ester with 
DBU or Cs2CO3 followed by addition of sulfonyl azide results in formation of 
corresponding acylsulfonamide in good to excellent yields.16 Alternatively, the 
acylsulfonamides can be synthesized by (a) reaction between sulfonamides and 
carboxylic acids using EDCI coupling conditions, or (b) the previously reported reaction 
between sulfonyl azides and selenocarboxylates which were produced from 
corresponding carboxylic acids and the selenating reagent LiAlHSeH (Scheme 3.1 E-F).17 
3.2.2 Kinetic TGS screening against Mcl-1 
 The entire library of fragments was incubated as binary mixtures (31 sulfonyl 
azides and 10 thio acids; 310 possible combinations) against Mcl-1 at 37 °C for six hours 
(Figure 3.4). As previously described, the thio acids TA1-TA10 were generated in situ 
from corresponding thio esters using 5% piperidine in DMF prior to the kinetic TGS 
screening. Based on previously optimized conditions for Bcl-XL, initially the screening 
was carried out at 2 µM concentration of Mcl-1. Unfortunately, no TGS hits were 
obtained under these conditions, while increasing the concentration by five-fold to 10 µM 
provided consistent results. Furthermore, these 310 binary mixtures were incubated in the 
phosphate buffer in the absence of Mcl-1. Subsequently, all the samples were analyzed 
using liquid chromatography in combination with mass spectrometry equipped with 
electrospray ionization in the positive selected ion mode (LC/MS-SIM) to detect 
corresponding acylsulfonamides. 
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Figure 3.4. Library of sulfonyl azides and thio acids utilized for kinetic TGS screening 
against Mcl-1 
Comparison of LC/MS-SIM data for samples in presence and absence of Mcl-1 
revealed that, out of forty one fragments, only eleven fragments (SZ9, SZ15, SZ17, 
SZ31, TA1, TA2, TA3, TA5, TA6, TA7, and TA8) leading to fourteen combinations 
were templated by the protein, since elevated amounts of those acylsulfonamides were 
observed in the Mcl-1 containing samples (Figure 3.5). To investigate whether these 
fragments were templated at the binding site of Mcl-1, a control experiment incorporating 
wildtype pro-apoptotic Bim BH3 peptide along with the fragments in the presence of 
Mcl-1 was designed. Suppression of the product formation is observed if the fragments 
compete with Bim BH3 peptide for the binding site. On the contrary, if the product 
formation results from non-specific binding, addition of Bim BH3 peptide to the 
incubation sample would not have any effect and such fragment combinations can 
obviously be ruled out. 
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Figure 3.5. LC/MS-SIM analysis of kinetic TGS incubations with fragments SZ15 and 
TA8 targeting Mcl-1. The samples were incubated for six hours at 37 °C and subjected to 
the LC/MS-SIM analysis. (A) Incubation sample containing fragments SZ15 and TA8 in 
the absence of Mcl-1. (B) Incubation sample containing fragments SZ15 and TA8 in the 
presence of 10 μM Mcl-1. (C) Incubation sample containing fragments SZ15 and TA8 in 
the presence of 10 μM Mcl-1 and 20 μM Bim BH3 peptide. (D) Synthetic SZ15TA8 as 
the reference compound. 
Consequently, some combinations (SZ9TA3, SZ15TA2, and SZ31TA2) could be 
abandoned based on the aforementioned control experiments, whereas other eleven 
combinations were confirmed as the kinetic TGS hits (Figure 3.6). 
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 Figure 3.6. Acylsulfonamides confirmed as kinetic TGS hits against Mcl-1 
3.2.3 Biological activity of the kinetic TGS hits 
 The acylsulfonamides confirmed as kinetic TGS hits were synthesized using 
synthetic procedures mentioned above and then tested for their ability to disrupt Mcl-
1/BH3 interactions using conventional fluorescence polarization assay utilizing GST-
Mcl-1 and fluorescein-labeled Bim BH3 peptide. Majority of these compounds displayed 
IC50 values in the single digit µM range when subjected to dose-response studies. 
Moreover, ligand efficiencies in the range of 0.16-0.18 were observed for these 
acylsulfonamides (Table 3.1). It is worth mentioning that, the ligand efficiencies between 
0.16-0.24 are theoretically predicted to be optimal for PPIMs.18 Interestingly, when all 
reactive fragments (SZ1-SZ31 and TA1-TA10) were tested in the fluorescence 
polarization assay at 100 μM concentration, less than 5% inhibition was detected except 
four sulfonyl azides: SZ4 (23%), SZ9 (13%), SZ15 (25%), and SZ27 (14%). These 
results are exciting since the high-quality inhibitors can be unambiguously identified 
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through the screening of fragments possessing weak binding affinities, remarkably 
reducing the synthetic efforts. To probe whether these molecules would display any 
biological activity against Bcl-XL, they were subjected to the fluorescence polarization 
assay designed using fluorescein-labeled GST-Bcl-XL and fluorescein-labeled Bak BH3 
peptide. Strikingly, comparison of IC50 values revealed that all of the compounds 
exhibited noticeable selectivity towards Mcl-1, evident from the selectivity indices 
ranging from 3 to 19 (Table 3.1).  
Table 3.1. Biological activity of acylsulfonamides against Mcl-1 and Bcl-XL 
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1 SZ15TA1 569.1 9.7 0.180 29.1 3.00 
2 SZ15TA3 666.3 5.8 0.162 36.4 6.27 
3 SZ15TA5 629.0 13.4 0.158 53.0 3.95 
4 SZ15TA6 614.1 11.7 nd 71.6 6.12 
5 SZ15TA8 653.1 7.6 0.162 47.0 6.18 
6 SZ17TA3 643.8 8.6 0.157 50.0 5.81 
7 SZ17TA8 630.7 8.4 0.161 76.0 9.05 
8 SZ31TA3 657.8 9.4 0.152 84.0 8.94 
9 SZ31TA6 605.7 6.2 0.169 20.4 3.29 
10 SZ31TA7 610.7 10.6 0.158 56.7 5.35 
11 SZ31TA8 644.7 5.9 0.162 111 18.81 
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3.2.4 Discussion 
 Recent advances in the field of fragment-based lead discovery have demonstrated 
that the PPIMs targeting the anti-apoptotic Bcl-2 family can be developed. Although 
highly potent molecules such as ABT-737 and ABT-263 were discovered as dual 
inhibitors of Bcl-2 and Bcl-XL through SAR by NMR approach, subsequent resistance 
developed by cancer cells has highlighted the role of Mcl-1 as another key regulator of 
apoptosis. Recently, the SAR by ILOEs approach was exploited leading to the 
identification of acylsulfonamides targeting Bcl-XL and Mcl-1 with binding affinities in 
the nanomolar range. Meanwhile, acylsulfonamides as PPIMs of Bcl-XL were also 
identified through the sulfo-click kinetic TGS, another fragment-based approach. Inspired 
by these results, we extended this approach for the identification of structurally diverse 
acylsulfonamides as Mcl-1 inhibitors. First, a library of thirty one sulfonyl azides and ten 
thio acids resulting in three hundred and ten acylsulfonamides was incubated as binary 
mixtures in the presence and absence of the target protein, Mcl-1. In an additional control 
experiment, Bim BH3 peptide was added to the incubation sample containing Mcl-1. 
Subsequent LC/MS-SIM analysis disclosed that only eleven acylsulfonamides were 
templated by the protein, designated as kinetic TGS hits. Also, the product formation 
through templation was suppressed by addition of Bim BH3 peptide suggesting that, the 
templation occurs at the binding site of Mcl-1. The kinetic TGS hits were synthesized and 
tested using fluorescence polarization assay. As expected, all the acylsulfonamides were 
found to possess respectable biological activity in the single digit micromolar range and 
also displayed optimal ligand efficiencies. 
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 Careful observation of all the acylsulfonamides identified through kinetic TGS 
screening provided some useful structural information. For example, acylsulfonamides 
derived from sulfonyl azides with bis-benzylic tertiary amines (SZ15, SZ17, and SZ31) 
were found to be most active against Mcl-1. Surprisingly, none of the alkyl sulfonyl 
azides (SZ22-SZ28) led to the kinetic TGS hits. Moreover, other sulfonyl azides, being 
comparatively smaller in size, were also found to be not templated by the protein target. 
On the other hand, thio acids TA3 and TA8 were found to be favored during the kinetic 
TGS screening, although thio acids TA1, TA5, TA6, and TA7 also featured in some of 
the PPIMs. Notably, structurally bulky (TA2 and TA4) as well as heterocyclic (TA9 and 
TA10) thio acids did not contribute to the kinetic TGS hits. It is noteworthy to mention 
that, the majority of the fragments showed less than 5% inhibition even at 100 µM 
concentration. Importantly, these acylsulfonamides exhibited striking selectivity towards 
Mcl-1. These results are highly valuable since identification of Mcl-1-selective inhibitors 
still remains a challenging task and has met with limited success. Collectively, these 
results can be regarded as preliminary structure activity relationship studies and therefore 
serve as a foundation for the future endeavors towards hit-to-lead optimization. 
3.3 Conclusions 
 Herein, we have demonstrated that the sulfo-click kinetic TGS approach can also 
be applied to discover acylsulfonamides with diversified scaffolds as inhibitors of Mcl-1. 
Based on our previous work on Bcl-XL, fragment libraries of sulfonyl azides and thio 
acids were screened against Mcl-1. Eleven acylsulfonamides were identified as kinetic 
TGS hits, which were confirmed using peptide control experiments. Interestingly, certain 
fragments from the library (SZ15, SZ17, SZ31, TA3, and TA8) were found to be 
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predominantly templated by the protein target. Furthermore, the kinetic TGS hits 
displayed IC50 values in the single digit nanomolar range, underlining that the most 
potent compounds of the library were identified during the screening. Besides, these 
acylsulfonamides were found to be selective towards Mcl-1, presenting a route to 
generate Mcl-1-selective inhibitors. Based on these findings, this strategy can be 
envisioned to be applied to other challenging protein-protein interaction targets such as 
MDM2/p53, TNF/TNFR1 and IL-2/IL-2Rα. 
3.4 Experimental section 
3.4.1 General information 
 All reagents and solvents were purchased from commercial sources and used 
without further purification. All reactions were run under an Argon atmosphere unless 
otherwise indicated. Prior to use of solvents in reactions, they were purified by passing 
the degassed solvents through a column of activated alumina and transferred by an oven 
dried syringe or cannula. Thin layer chromatography was performed on Merck TLC 
plates (silica gel 60 F254). 1H NMR and 13C NMR were recorded on a Varian Inova 400 
(400 MHz) or a Bruker Avance DPX 250 (250 MHz) instrument. The purification of 
designated compounds was carried out using reverse phase HPLC system (Waters Prep 
LC 4000 system with Waters 996 photo-diode array detector, Agilent column Eclipse 
XDB-C18, 5 µm, 9.4 mm  250 mm). The compounds were eluted using a gradient 
elution of A:B (80:20 to 0:100) over 40 min at a flow rate of 5.0 mL/min, where solvent 
A was H2O (0.05% TFA) and solvent B was CH3CN (0.05% TFA). The HRMS data were 
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measured on an Agilent 1100 Series MSD/TOF with electrospray ionization. The LC/MS 
data were measured on an Agilent 1100 LC/MSD-VL with electrospray ionization.  
The gradient used for LC/MS-SIM analysis is shown below: 
Table 3.2. Elution gradient system employed for the LC/MS-SIM analysis 
Time % B* Flow rate Time % B* Flow rate 
0.00 10.0 2.0 mL min-1 4.60 100.0 3.0 mL min-1 
0.60 10.0 2.0 mL min-1 4.61 100.0 2.0 mL min-1 
4.09 100.0 2.0 mL min-1 4.62 10.0 2.0 mL min-1 
4.10 100.0 3.0 mL min-1 5.20 10.0 2.0 mL min-1 
* eluent A: H2O (0.05% TFA); eluent B: CH3CN (0.05% TFA) 
The sulfonyl azides14, 16 SZ1-SZ11, SZ16, SZ18, SZ19, SZ21, SZ23, SZ28 and the 
thioesters16 TE1-TE3, TE5, TE7, and TE8 have been previously reported. 
3.4.2 General protocol for incubations of Mcl-1with reactive fragments  
 In a 96-well plate, one thio acid building block (1 L of a 2 mM solution in 
methanol) and one sulfonyl azide building block (1 L of a 2 mM solution in methanol) 
were added to a solution of Mcl-1 (98 L of a 10 M Mcl-1 solution in buffer (58 mM 
Na2HPO4, 17 mM NaH2PO4, 68 mM NaCl, 1 mM NaN3, pH = 7.40)). The 96-well plate 
was sealed and incubated at 37 °C for six hours. The incubation samples were then 
subjected to Liquid Chromatography combined with mass spectrometry analysis in the 
Selected Ion Mode (LC/MS-SIM, Kinetex PFP preceded by a Phenomenex C18 guard 
column, electrospray ionization and mass spectrometric detection in the positive SIM, 
tuned to the expected molecular mass of the product). The TGS hit compound was 
identified by the mass and the retention time. As a control, identical building block 
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combinations were incubated in buffer without Mcl-1 and subjected to LC/MS-SIM 
analysis. Comparison of the LC/MS-SIM chromatograms of these control incubations 
with the chromatograms of the Mcl-1 containing incubations allows us to determine 
whether the protein is templating the corresponding amidation reaction. Furthermore, 
synthetically prepared acylsulfonamide was subjected to LC/MS-SIM analysis and the 
retention time was compared with the one identified in the Mcl-1 containing incubation. 
3.4.3 General protocol for the control incubations of Mcl-1 with reactive fragments and 
Bim BH3 peptide   
 For the Mcl-1 containing incubation sample showing acylsulfonamide formation, 
control incubation with Bim peptide has been undertaken to demonstrate that the 
templation reaction occurs at the desired binding site. Thus, in a 96-well plate, one thio 
acid (1 L of a 2 mM solution in methanol) and one sulfonyl azide (1 L of a 2 mM 
solution in methanol) were added to a solution of Mcl-1 (97 L of a 10 M Mcl-1 
solution in buffer). Finally, Bim BH3 peptide (1 L of a 2 mM solution in DMSO) was 
added and the incubation sample in a sealed 96-well plate was incubated at 37 °C for six 
hours. This incubation sample was then subjected to LC/MS-SIM analysis along with the 
Mcl-1 containing sample without the Bim BH3 peptide. 
3.4.4 General procedure A for the synthesis of sulfonyl azides  
 A mixture of 4-(bromomethyl)benzenesulfonyl azide (276 mg, 1 mmol), 
corresponding amine (1 mmol), and potassium carbonate (276 mg, 2 mmol) in 
acetonitrile and water (9:1; 6 mL), was stirred at room temperature for 12 hours. After 
treating with ethyl acetate (20 mL) and water (20 mL), the system was extracted with 
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ethyl acetate (20 mL 3). The combined organic layers were dried over anhydrous 
sodium sulfate and concentrated. The sulfonyl azide was then obtained by flash 
chromatography. 
 The sulfonyl azides SZ12-SZ15, SZ17, and SZ31 were synthesized using this 
procedure. In case of SZ12, corresponding aniline was used, whereas corresponding 
phenol was used for the synthesis of SZ13 and SZ14. Also, the reaction temperature was 
maintained at 66 °C for the sulfonyl azides SZ12-SZ14. 
3.4.5 General procedure B for the synthesis of sulfonyl azides 
 The sulfonyl azides were synthesized starting from corresponding amines, in situ 
generated 2-chloroethanesulfonyl azide and potassium carbonate, using a previously 
reported procedure.16 
 The sulfonyl azides SZ22, and SZ24-SZ27 were synthesized using this procedure. 
3.4.6 General procedure C for the synthesis of sulfonyl azides 
 The sulfonyl azides were synthesized starting from corresponding sulfonamides 
using triflyl azide, a diazo transfer reagent, following the previously reported procedure.15 
The synthesis of the sulfonamides used has been described later in this document. 
 The sulfonyl azides SZ29-SZ30 have been synthesized using this procedure. 
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3.4.7 Synthesis of fragments 
 
Sulfonyl azide SZ12: Yield = 67%. Rf = 0.35 in hexanes : EtOAc = 3:1. 1H NMR (400 
MHz, CDCl3) : 1H NMR (600 MHz, CDCl3) δ 7.94 (d, J = 8.3 Hz, 2H), 7.61 (d, J = 8.2 
Hz, 2H), 7.57 (dd, J = 8.1, 1.8 Hz, 1H), 7.40 (t, J = 2.1 Hz, 1H), 7.30 (t, J = 8.2 Hz, 1H), 
6.86 (dd, J = 8.2, 2.2 Hz, 1H), 4.64 (s, 1H), 4.56 (s, 2H) ppm. 13C NMR (101 MHz, 
CDCl3) : 148.2, 146.4, 130.2, 128.4, 128.3, 128.2, 127.8, 118.9, 113.0, 106.9, 47.5 ppm. 
HRMS (ESI) calcd for C13H11N5O4S [M+K]+: 372.0163, found: 372.0145 
 
Sulfonyl azide SZ13: Yield = 40%. Rf = 0.44 in hexanes : EtOAc = 3:1. 1H NMR (400 
MHz, CDCl3) : 7.94 – 7.84 (m, 3H), 7.68 – 7.34 (m, 5H), 4.50 (s, 2H) ppm. 13C NMR 
(101 MHz, CDCl3) : 143.3, 141.2, 134.4, 134.2, 129.2, 128.7, 127.9, 126.0, 125.2, 53.8 
ppm. HRMS (ESI) calcd for C13H10N4O5S [M+NH4]+: 352.0716, found: 352.0719  
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Sulfonyl azide SZ14: Yield = 45%. Rf = 0.21 in hexanes : EtOAc = 3:1.   1H NMR (400 
MHz, CDCl3) : 8.10 (dd, J = 8.6, 3.4 Hz, 1H), 7.91 – 7.82 (m, 4H), 7.51 (d, J = 7.4 Hz, 
5H), 7.38 (d, J = 2.1 Hz, 1H), 6.93 (dd, J = 8.7, 1.9 Hz, 1H), 6.77 (d, J = 3.8 Hz, 1H) 4.49 
(s, 2H) ppm. 13C NMR (101 MHz, CDCl3) : 177.2, 163.9, 156.5, 152.9, 143.0, 134.6, 
132.0, 131.2, 129.2, 129.0, 128.7, 127.6, 126.3, 122.8, 119.5, 112.2, 107.7, 53.8 ppm. 
HRMS (ESI) calcd for C22H15N3O5S [M+H]+: 434.0805, found: 434.0796 
 
Sulfonyl azide SZ15: was synthesized starting from SZ6 and 1-chloro-2-(chloromethyl)-
3-fluorobenzene. Yield =54%. Rf = 0.62 in hexanes : EtOAc = 5:1.  1H NMR (400 MHz, 
CDCl3) : 7.80 (d, J = 8.1 Hz, 2H), 7.54 (d, J = 8.1 Hz, 2H), 7.22 – 7.11 (m, 7H), 6.96 – 
6.89 (m, 1H), 3.87 (s, 2H), 3.75 (s, 2H), 3.07 (t, J = 7.6 Hz, 2H), 2.79 (t, J = 7.6 Hz, 2H) 
ppm. 13C NMR (101 MHz, CDCl3) : 162.1 (d, J = 249.0 Hz), 147.9, 136.8, 136.5, 136.0, 
129.6, 129.5, 129.1 (d, J = 26.0 Hz), 127.3, 126.1, 125.6, 124.2 (d, J = 16.8 Hz), 114.1 
(d, J = 23.3 Hz), 58.0, 53.7, 49.6, 31.3 ppm. HRMS (ESI) calcd for C22H20ClFN4O2S2 
[M+H]+: 491.0779, found: 491.0771 
 
Amine 6: A mixture of 2-(phenylthio)ethanamine (500 mg, 3.3 mmol), 1-(chloromethyl)-
3-methoxybenzene (517 mg, 3.3 mmol) and potassium carbonate (911 mg, 6.6 mmol) in 
acetonitrile and water (9:1, 20 mL), was stirred at room temperature for 12 hours. After 
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adding ethyl acetate (20 mL) and water (20 mL), the system was extracted with ethyl 
acetate (20 mL 3). The combined organic phase was dried over anhydrous sodium 
sulfate and concentrated. Intermediate 6 was obtained by flash chromatography in 37% 
yield. Rf = 0.2 in hexanes : EtOAc = 1:1. 1H NMR (400 MHz, CDCl3) : 7.40 – 7.15 (m, 
6H), 6.94 – 6.87 (m, 2H), 6.81 (d, J = 8.5 Hz, 1H), 3.79 (s, 3H), 3.78 (s, 2H), 3.09 (t, J = 
6.1 Hz, 2H), 2.87 (t, J = 6.2 Hz, 2H), 1.72 (s, 1H) ppm. 13C NMR (101 MHz, CDCl3) : 
159.7, 141.7, 135.8, 129.4, 129.3, 128.8, 126.0, 120.2, 113.4, 112.4, 55.0, 53.2, 47.4, 34.1 
ppm. HRMS (ESI) calcd for C16H19NOS [M+H]+: 274.1260, found: 274.1257 
 
Sulfonyl azide SZ17: Yield = 82%. Rf = 0.43 in hexanes : EtOAc = 4:1.   1H NMR (400 
MHz, CDCl3) : 7.86 (d, J = 8.3 Hz, 2H), 7.61 (d, J = 8.2 Hz, 2H), 7.28 – 7.12 (m, 6H), 
7.00 – 6.95 (m, 2H), 6.82 (dd, J = 8.1, 1.7 Hz, 1H), 3.81 (s, 3H), 3.69 (s, 2H), 3.63 (s, 
2H), 3.07 (t, J = 7.2 Hz, 2H), 2.77 (t, J = 7.2 Hz, 2H) ppm. 13C NMR (101 MHz, CDCl3) 
: 159.7, 147.8, 140.2, 136.7, 136.2, 129.6, 129.3, 128.8, 128.7, 127.4, 125.8, 121.0, 
114.3, 112.5, 58.4, 57.7, 55.1, 52.8, 31.3 ppm. HRMS (ESI) calcd for C23H24N4O3S2 
[M+H]+: 469.1368, found: 469.1378  
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Sulfonyl azide SZ20: To a solution of 2-methylbenzene-1-sulfonyl chloride (1 g, 5.24 
mmol) in aqueous ethanol (24 mL) was added sodium azide (682 mg, 10.5 mmol) and the 
reaction mixture was stirred at room temperature for 2.5 hours. The reaction mixture was 
treated with water, extracted with ethyl acetate (30 mL 3). The combined organic phase 
was dried over anhydrous sodium sulfate and concentrated. The sulfonyl azide SZ20 was 
obtained after flash column chromatography. Yield = 89%. Rf = 0.64 in hexanes : EtOAc 
= 4:1. 1H NMR (250 MHz, CDCl3) δ 8.06 – 7.96 (m, 1H), 7.62 – 7.52 (m, 1H), 7.42 – 
7.32 (m, 2H), 2.65 (s, 3H) ppm. 13C NMR (63 MHz, CDCl3) : 138.6, 136.9, 134.8, 
133.2, 129.5, 126.6, 20.5 ppm.  
 
Sulfonyl azide SZ22: Yield = 18%. Rf = 0.63 in hexanes : EtOAc = 2:1 (stained with 
Ninhydrin).  1H NMR (400 MHz, CDCl3) δ 3.56 – 3.47 (m, 1H), 3.43 – 3.25 (m, 2H), 
2.96 – 2.83 (m, 2H), 2.22 – 2.13 (m, 1H), 2.04 – 1.98 (m, 1H), 1.84 – 1.68 (m, 2H), 1.67 
– 1.53 (m, 5H), 1.28 – 1.06 (m, 4H), 1.03 – 0.89 (m, 2H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 66.2, 54.0, 52.7, 46.8, 42.0, 33.1, 32.4, 30.2, 25.9, 25.8, 25.7 ppm. HRMS (ESI) 
calcd for C11H20N4O2S [M+H]+: 273.1380, found: 273.1375 
 
Sulfonyl azide SZ24: Yield = 38%. Rf = 0.73 in hexanes : EtOAc = 1:1.  1H NMR (400 
MHz, CDCl3) δ 7.32 – 7.11 (m, 5H), 3.47 (t, J = 6.3 Hz, 2H), 2.91 (d, J = 11.1 Hz, 2H), 
128 
 
2.83 (t, J = 6.3 Hz, 2H), 2.52 (d, J = 7.0 Hz, 2H), 1.97 (m, 2H), 1.66 (d, J = 12.6 Hz, 2H), 
1.60 – 1.48 (m, 1H), 1.38 – 1.23 (m, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 140.5, 
129.2, 128.3, 126.0, 53.9, 53.8, 52.5, 43.2, 37.8, 32.2 ppm. HRMS (ESI) calcd for 
C14H20N4O2S [M+H]+: 309.1380, found: 309.1373 
 
Sulfonyl azide SZ25: Yield = 42%. Rf = 0.45 in hexanes : EtOAc = 1:4.  1H NMR (400 
MHz, CDCl3) δ 6.82 (s, 1H), 6.72 (m, 2H), 5.91 (s, 2H), 3.48 (t, J = 6.3 Hz, 2H), 3.39 (s, 
2H), 2.87 (t, J = 6.3 Hz, 2H), 2.56 – 2.42 (m, J = 22.7 Hz, 8H) ppm. 13C NMR (101 
MHz, CDCl3) δ 147.7, 146.7, 131.9, 122.2, 109.4, 107.9, 100.9, 62.6, 53.5, 53.0, 52.8, 
52.2 ppm. HRMS (ESI) calcd for C14H19N5O4S [M+H]+: 354.1231, found: 354.1226 
 
Sulfonyl azide SZ26: Yield = 60%. Rf = 0.54 in hexanes : EtOAc = 4:1.  1H NMR (400 
MHz, CDCl3) δ 7.38 – 7.23 (m, 10H), 3.65 (s, 4H), 3.34 (dd, J = 8.3, 6.1 Hz, 2H), 3.05 
(dd, J = 8.3, 6.2 Hz, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 138.1, 129.0, 128.7, 127.7, 
58.8, 53.8, 47.6 ppm. HRMS (ESI) calcd for C16H18N4O2S [M+H]+: 331.1223, found: 
331.1218 
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Sulfonyl azide SZ27: Yield = 40%. Rf = 0.44 in hexanes : EtOAc = 2:1.  1H NMR (400 
MHz, CDCl3) δ 7.35 – 7.21 (m, 5H), 6.61 (s, 1H), 6.18 (s, 1H), 4.61 (s, 1H), 3.85 (s, 3H), 
3.61 (s, 3H), 3.49 – 3.40 (m, 1H), 3.39 – 3.30 (m, 1H), 3.18 – 2.94 (m, 4H), 2.89 – 2.72 
(m, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 147.9, 147.4, 142.5, 129.6, 129.1, 128.5, 
127.9, 126.3, 111.6, 110.9, 67.7, 55.9, 55.9, 54.1, 48.8, 47.3, 28.0 ppm. HRMS (ESI) 
calcd for C19H22N4O4S [M+H]+: 403.1435, found: 403.1435 
 
Sulfonyl azide SZ29: Yield = 35%. Rf = 0.51 in hexanes : EtOAc = 4:1.  1H NMR (400 
MHz, CDCl3) δ 7.69 (d, J = 8.8 Hz, 2H), 7.49 (d, J = 8.2 Hz, 2H), 7.21 (d, J = 8.2 Hz, 
2H), 6.64 (d, J = 8.8 Hz, 2H), 4.91 (t, J = 5.3 Hz, 1H), 4.38 (d, J = 5.4 Hz, 2H) ppm. 13C 
NMR (101 MHz, CDCl3) δ 152.8, 136.6, 132.2, 130.0, 129.0, 125.2, 121.8, 112.3, 47.0 
ppm.  
 
Sulfonyl azide SZ30: Yield = 50%. Rf = 0.48 in hexanes : EtOAc = 4:1.  1H NMR (400 
MHz, CDCl3) δ 7.69 (d, J = 8.6 Hz, 2H), 7.17 (d, J = 8.4 Hz, 2H), 6.70 – 6.59 (m, 4H), 
4.73 (s, 1H), 4.24 (d, J = 4.8 Hz, 2H), 3.35 (q, J = 6.9 Hz, 4H), 1.16 (t, J = 7.0 Hz, 6H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 153.3, 147.7, 130.1, 129.1, 124.1, 123.6, 112.1, 
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112.1, 47.4, 44.6, 12.7 ppm. HRMS (ESI) calcd for C17H21N5O2S [M+H]+: 360.1489, 
found: 360.1490 
 
Sulfonyl azide SZ31: Yield = 81%. Rf = 0.64 in hexanes : EtOAc = 2:1.  1H NMR (400 
MHz, CDCl3) δ 7.87 (d, J = 8.3 Hz, 2H), 7.60 (d, J = 8.3 Hz, 2H), 7.22 (d, J = 4.3 Hz, 
4H), 7.19 – 7.12 (m, 1H), 6.92 (s, 1H), 6.80 – 6.73 (m, 2H), 5.94 (s, 2H), 3.68 (s, 2H), 
3.55 (s, 2H), 3.09 – 3.03 (m, 2H), 2.78 – 2.72 (m, 2H) ppm. 13C NMR (101 MHz, CDCl3) 
δ 147.8, 147.8, 146.8, 136.8, 136.2, 132.4, 129.6, 128.8, 128.8, 127.4, 125.9, 121.9, 
109.1, 107.9, 100.9, 58.3, 57.6, 52.6, 31.3 ppm. HRMS (ESI) calcd for C23H22N4O4S2 
[M+H]+: 483.1155, found: 483.1159 
 
Sulfonamide 7: Sodium borohydride (60 mg, 1.5 mmol) was added slowly to the 
solution of sulfonyl azide SZ15 (540 mg, 1.1 mmol) in methanol at 0 °C. The system was 
stirred for 30 min at room temperature, quenched by solid NH4Cl and the solvent was 
removed under reduced pressure to obtain crude product. The sulfonamide 7 (484 mg, 
95%) was obtained by flash chromatography. Rf = 0.33 in hexanes : EtOAc = 2:1.  1H 
NMR (400 MHz, CDCl3) : 7.79 (d, J = 8.2 Hz, 2H), 7.42 (d, J = 8.1 Hz, 2H), 7.21 – 
7.09 (m, 7H), 6.97 – 6.88 (m, 1H), 5.23 (bs, 2H), 3.83 (s, 2H), 3.68 (s, 2H), 3.06 – 2.99 
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(m, 2H), 2.78 – 2.71 (m, 2H) ppm. 13C NMR (101 MHz, CDCl3) : 162.1 (d, J = 248.2 
Hz), 145.1, 140.5, 136.5, 136.0, 129.5, 129.4, 129.2, 129.0, 128.9, 126.2, 126.0, 125.6, 
124.4 (d, J = 17.2 Hz), 114.1 (d, J = 23.4 Hz), 58.0, 53.3, 49.5, 31.1 ppm. HRMS (ESI) 
calcd for C22H22ClFN2O2S2 [M+H]+: 465.0868, found: 465.0866 
 
Sulfonamide 8: The sulfonamide 8 was obtained starting from the sulfonyl azide SZ17 
following the procedure described for the synthesis of sulfonamide 7 in 97% yield. Rf = 
0.5 in hexanes : EtOAc = 1:1.  1H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 8.4 Hz, 2H), 
7.51 (d, J = 8.3 Hz, 2H), 7.24 – 7.10 (m, 6H), 6.96 – 6.91 (m, 2H), 6.80 (dd, J = 8.3, 2.5 
Hz, 1H), 5.08 (s, 2H), 3.81 (s, 3H), 3.65 (s, 2H), 3.60 (s, 2H), 3.07 – 3.01 (m, 2H), 2.78 – 
2.72 (m, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 159.8, 145.2, 140.6, 140.6, 136.4, 
129.5, 129.4, 129.0, 128.9, 126.5, 126.0, 121.2, 114.5, 112.6, 58.5, 58.0, 55.3, 52.9, 31.5 
ppm. HRMS (ESI) calcd for C23H26N2O3S2 [M+H]+: 443.1458, found: 443.1446 
Br
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0 oC to rt 9  
Sulfonamide 9: To a solution of 4-bromobenzaldehyde (200 mg, 1.08 mmol) and 
4-aminobenzenesulfonamide (186 mg, 1.08 mmol) in MeOH (7 mL) was added sodium 
sulfate (1 g) and acetic acid (50 µL) and the resulting mixture was stirred at room 
temperature. After 3 hours, sodium sulfate was removed, reaction mixture was cooled to 
0 °C and the sodium borohydride (123 mg, 3.24 mmol) was added carefully. The system 
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was stirred for 30 min at room temperature, quenched by solid NH4Cl and the solvent 
was removed under reduced pressure. The sulfonamide 9 was obtained after flash 
chromatography in 45% yield. Rf = 0.59 in DCM : MeOH = 10:1.   1H NMR (400 MHz, 
DMSO-d6) δ 7.55 – 7.47 (m, 4H), 7.29 (d, J = 8.3 Hz, 2H), 7.03 (t, J = 6.1 Hz, 1H), 6.91 
(s, 2H), 6.62 (d, J = 8.8 Hz, 2H), 4.32 (d, J = 6.1 Hz, 2H) ppm. 13C NMR (101 MHz, 
DMSO-d6) δ 151.0, 139.0, 131.2, 130.5, 129.3, 127.3, 119.7, 111.2, 45.2 ppm. HRMS 
(ESI) calcd for C13H13BrN2O2S [M+Na]+: 362.9773, found: 362.9759 
 
Sulfonamide 10: The sulfonamide 10 was obtained following the procedure described 
for the synthesis of sulfonamide 9 in 65% yield. Rf = 0.28 in hexanes : EtOAc = 1:1.  1H 
NMR (400 MHz, DMSO-d6) δ 7.49 (d, J = 8.8 Hz, 2H), 7.13 (d, J = 8.6 Hz, 2H), 6.88 (s, 
2H), 6.79 (t, J = 5.6 Hz, 1H), 6.66 – 6.60 (m, 4H), 4.16 (d, J = 5.6 Hz, 2H), 3.29 (q, J = 
6.9 Hz, 4H), 1.06 (t, J = 7.0 Hz, 6H) ppm. 13C NMR (101 MHz, DMSO-d6) δ 151.4, 
146.5, 129.9, 128.4, 127.2, 125.1, 111.6, 111.0, 45.6, 43.7, 12.4 ppm. HRMS (ESI) calcd 
for C17H23N3O2S [M+H]+: 334.1584, found: 334.1584 
 
Sulfonamide 11: The sulfonamide 11 was obtained starting from sulfonyl azide SZ31 
following the procedure described for sulfonamide 7 in 92% yield. Rf = 0.2 in hexanes : 
133 
 
EtOAc = 2:1.  1H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 8.3 Hz, 2H), 7.48 (d, J = 8.3 
Hz, 2H), 7.23 – 7.10 (m, 5H), 6.89 – 6.87 (m, 1H), 6.75 – 6.72 (m, 2H), 5.92 (s, 2H), 5.23 
(s, 2H), 3.62 (s, 2H), 3.50 (s, 2H), 3.04 – 2.99 (m, 2H), 2.73 – 2.69 (m, 2H) ppm. 13C 
NMR (101 MHz, CDCl3) δ 147.7, 146.7, 145.0, 140.5, 136.2, 132.6, 129.2, 128.9, 128.8, 
126.4, 125.8, 121.9, 109.1, 107.9, 100.9, 58.2, 57.7, 52.6, 31.3 ppm. HRMS (ESI) calcd 
for C23H24N2O4S2 [M+H]+: 457.1250, found: 457.1240 
3.4.8 Synthesis of 9-fluorenylmethyl thioesters  
 All the 9-fluorenylmethyl thioesters were synthesized from the corresponding 
carboxylic acids following the reported procedure.16 The carboxylic acids were 
commercially available, while 2-(6,7-dimethoxy-1-phenyl-3,4-dihydroisoquinolin-2(1H)-
yl)acetic acid was synthesized as reported previously.14b 
 
Thioester TE4: Yield = 51%. Rf = 0.2 in hexanes : EtOAc = 10:1.  1H NMR (600 MHz, 
CDCl3) δ 7.76 (t, J = 6.5 Hz, 2H), 7.64 (dd, J = 7.3, 3.9 Hz, 2H), 7.39 (t, J = 7.4 Hz, 2H), 
7.34 – 7.26 (m, 7H), 6.62 (s, 1H), 6.13 (s, 1H), 4.54 (s, 1H), 4.15 (t, J = 5.8 Hz, 1H), 3.87 
(s, 3H), 3.61 (s, 3H), 3.46 (d, J = 5.9 Hz, 2H), 3.33 (d, J = 16.5 Hz, 1H), 3.16 (d, J = 16.5 
Hz, 1H), 3.06 – 3.00 (m, 1H), 2.89 – 2.84 (m, 1H), 2.69 – 2.60 (m, 2H) ppm. 13C NMR 
(151 MHz, CDCl3) δ 201.4, 147.6, 147.2, 145.9, 145.7, 143.0, 141.3, 129.7, 128.4, 127.7, 
127.7, 127.6, 127.1, 126.5, 124.9, 124.9, 119.9, 119.8, 111.7, 111.0, 67.5, 63.9, 55.9, 
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55.9, 49.2, 47.0, 31.4, 28.5 ppm. HRMS (ESI) calcd for C33H31NO3S [M+K]+: 560.1656, 
found: 560.1656 
 
Thioester TE6: Yield = 80%. Rf = 0.71 in hexanes : EtOAc = 3:1.  1H NMR (400 MHz, 
CDCl3) δ 8.70 (t, J = 1.9 Hz, 1H), 8.36 (ddd, J = 8.2, 2.2, 1.0 Hz, 1H), 8.19 – 8.15 (m, 
1H), 7.76 (d, J = 7.4 Hz, 2H), 7.71 (d, J = 7.5 Hz, 2H), 7.58 (t, J = 8.0 Hz, 1H), 7.41 (t, J 
= 7.2 Hz, 2H), 7.38 – 7.32 (m, 2H), 4.29 (t, J = 5.7 Hz, 1H), 3.78 (d, J = 5.8 Hz, 2H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 189.7, 148.3, 145.1, 141.2, 138.2, 132.7, 129.8, 
128.0, 127.5, 127.3, 124.7, 122.2, 120.1, 46.5, 33.0 ppm. HRMS (ESI) calcd for 
C21H15NO3S [M+H]+: 362.0845, found: 362.0848 
 
Thioester TE9: Yield = 84%. Rf = 0.75 in hexanes : EtOAc = 2:1.  1H NMR (400 MHz, 
CDCl3) δ 7.78 – 7.71 (m, 4H), 7.55 – 7.54 (m, 1H), 7.44 – 7.31 (m, 4H), 7.18 – 7.16 (m, 
1H), 6.50 (dd, J = 3.6, 1.7 Hz, 1H), 4.26 (t, J = 6.0 Hz, 1H), 3.68 (d, J = 6.0 Hz, 2H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 180.3, 150.9, 146.3, 145.6, 141.2, 127.9, 127.3, 
124.8, 120.0, 115.7, 112.3, 46.9, 31.7 ppm. HRMS (ESI) calcd for C19H14O2S [M+Na]+: 
329.0607, found: 329.0611 
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Thioester TE10: Yield = 75%. Rf = 0.63 in hexanes : EtOAc = 3:1.  1H NMR (400 MHz, 
CDCl3) δ 8.32 – 8.29 (m, 1H), 7.76 (d, J = 7.6 Hz, 2H), 7.68 (d, J = 7.5 Hz, 2H), 7.44 – 
7.39 (m, 2H), 7.37 – 7.31 (m, 2H), 6.84 (m, 1H), 4.27 (t, J = 5.7 Hz, 1H), 3.74 (d, J = 5.8 
Hz, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 179.6, 164.4, 150.7, 144.9, 141.1, 128.0, 
127.3, 124.6, 120.1, 105.9, 46.3, 32.2 ppm. HRMS (ESI) calcd for C18H13NO2S 
[M+Na]+: 330.0559,  found: 330.0558 
3.4.9 General procedure A for the synthesis of acylsulfonamides 
 The acylsulfonamides were synthesized from corresponding sulfonamides, 
carboxylic acids in the presence of EDCI following a reported procedure.14b 
 The acylsulfonamides SZ15TA1, SZ15TA3, SZ15TA5, SZ15TA6, SZ15TA8, 
and SZ17TA3 were synthesized using this procedure. 
3.4.10 General procedure B for the synthesis of acylsulfonamides 
 The acylsulfonamides were prepared according to a reported procedure wherein, 
the thioesters were first deprotected to generate corresponding thio acids in situ, followed 
by the addition of the sulfonyl azide.16 
 The acylsulfonamides SZ17TA8, SZ31TA3, SZ31TA6, SZ31TA7, and 
SZ31TA8 were synthesized using this procedure. 
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3.4.11 Synthesis of acylsulfonamides 
 
Acylsulfonamide SZ15TA1: Yield = 61%. Rf = 0.6 in DCM : MeOH = 20:1. 1H NMR 
(600 MHz, DMSO) δ 7.88 – 7.84 (m, 4H), 7.56 (t, J = 7.3 Hz, 1H), 7.49 (d, J = 8.1 Hz, 
2H), 7.44 (t, J = 7.7 Hz, 2H), 7.32 – 7.26 (m, 2H), 7.15 (t, J = 7.8 Hz, 3H), 7.09 (d, J = 
7.4 Hz, 2H), 7.01 (t, J = 7.2 Hz, 1H), 3.80 (s, 2H), 3.72 (s, 2H), 3.11 – 3.06 (m, 2H), 2.66 
– 2.62 (m, 2H) ppm. 13C NMR (101 MHz, CD3CN) : 166.3, 163.1 (d, J = 249.0 Hz), 
160.9, 160.5, 141.3, 138.0, 137.3, 134.5, 134.0, 133.7 (d, J = 10.0 Hz), 132.4, 132.3, 
131.0, 130.3, 129.7, 129.2, 128.1, 127.1, 115.7 (d, J = 22.5 Hz), 58.2, 53.8, 49.8, 28.7 
ppm. HRMS (ESI) calcd for C29H26ClFN2O3S2 [M+H]+: 569.1136, found: 569.1144 
 
Acylsulfonamide SZ15TA3: Yield = 55%. Rf = 0.29 in DCM : MeOH = 20:1. 1H NMR 
(600 MHz, DMSO) δ 7.88 – 7.84 (m, 2H), 7.71 (d, J = 8.0 Hz, 2H), 7.45 – 7.40 (m, 3H), 
7.32 – 7.25 (m, 4H), 7.17 – 7.10 (m, 3H), 7.03 – 6.95 (m, 3H), 3.76 (s, 2H), 3.63 (s, 2H), 
3.04 – 2.98 (m, 2H), 2.60 – 2.55 (m, 2H), 2.52 (s, 3H) ppm. 13C NMR (63 MHz, CDCl3) 
: 169.9, 160.4 (d, J = 145.0 Hz), 160.3, 140.0, 137.0 (d, J = 12.5 Hz), 136.9, 133.0, 
132.6 (d, J = 10.3 Hz), 132.1, 131.8, 131.1, 130.9, 129.5, 129.4, 129.3, 127.7, 127.1, 
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126.4, 122.1, 117.2, 116.9, 115.0 (d, J = 22.5 Hz), 57.6, 52.8, 49.0, 28.9, 17.8 ppm. 
HRMS (ESI) calcd for C33H29ClFN3O3S3 [M+H]+: 666.1116, found: 666.1097 
 
Acylsulfonamide SZ15TA5: Yield = 44%. Rf = 0.57 in DCM : MeOH = 20:1. 1H NMR 
(600 MHz, DMSO) δ 7.72 (d, J = 8.0 Hz, 2H), 7.45 – 7.39 (m, 1H), 7.33 – 7.22 (m, 4H), 
7.16 – 7.10 (m, 3H), 7.05 – 7.00 (m, 4H), 6.98 (t, J = 7.4 Hz, 1H), 6.45 (s, 1H), 3.75 (s, 
2H), 3.68 (s, 6H), 3.62 (s, 2H), 3.04 – 2.98 (m, 2H), 2.61 – 2.55 (m, 2H) ppm. 13C NMR 
(101 MHz, CDCl3) : 165.0, 162.4 (d, J = 226.0 Hz), 161.0, 140.2, 136.8, 136.1, 133.0, 
132.9, 132.6, 131.2, 131.0, 129.5, 129.4, 127.8, 126.4, 116.3 (d, J = 17.0 Hz), 115.0 (d, J 
= 22.7 Hz), 106.3, 105.9, 57.6, 55.7, 52.8, 49.0, 28.6 ppm. HRMS (ESI) calcd for 
C31H30ClFN2O5S2 [M+H]+: 629.1342, found: 629.1343 
 
Acylsulfonamide SZ15TA6: Yield = 61%. Rf = 0.24 in DCM : MeOH = 20:1. 1H NMR 
(600 MHz, DMSO) δ 8.63 (s, 1H), 8.24 (t, J = 6.3 Hz, 2H), 7.78 – 7.72 (m, 2H), 7.61 (t, J 
= 7.9 Hz, 1H), 7.45 – 7.38 (m, 2H), 7.34 – 7.22 (m, 5H), 7.15 – 7.09 (m, 3H), 7.04 – 6.94 
(m, 1H), 3.75 (s, 2H), 3.64 (s, 2H), 3.04 – 2.99 (m, 2H), 2.62 – 2.55 (m, 2H) ppm. 13C 
NMR (101 MHz, CDCl3) : 163.7, 162.5 (d, J = 207.0 Hz), 161.0, 148.2, 140.0, 136.8, 
134.3, 133.2, 132.8, 131.3, 130.7, 130.1, 129.4, 127.7, 126.4, 123.6, 116.7 (d, J = 18.0 
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Hz), 115.0 (d, J = 22.0 Hz), 57.7, 52.8, 49.0, 28.7 ppm. HRMS (ESI) calcd for 
C29H25ClFN3O5S2 [M+Na]+: 636.0800, found: 636.0804 
 
Acylsulfonamide SZ15TA8: Yield = 82%. Rf = 0.52 in DCM : MeOH = 20:1. 1H NMR 
(400 MHz, CDCl3) : 1H NMR (400 MHz, CDCl3) δ 8.00 (d, J = 8.8 Hz, 2H), 7.94 (s, 
2H), 7.84 (d, J = 8.3 Hz, 2H), 7.19 (d, J = 8.3 Hz, 2H), 7.10 – 7.04 (m, 4H), 7.04 – 7.00 
(m, 2H), 6.98 – 6.90 (m, 3H), 6.89 – 6.82 (m, 1H), 3.75 (s, J = 1.2 Hz, 2H), 3.53 (s, 2H), 
2.95 – 2.88 (m, 2H), 2.68 – 2.60 (m, 2H) ppm. 13C NMR (101 MHz, CDCl3) : 164.3, 
162.2 (d, J = 250.0 Hz), 161.4 (d, J = 37.0 Hz), 152.9, 139.8, 137.8, 136.8, 133.2, 132.3 
(d, J = 9.5 Hz), 131.0, 130.5, 129.6, 129.3, 129.2, 127.4, 126.2, 120.5, 120.3 (q, J = 
259.25 Hz), 117.6 (d, J = 16.1 Hz), 114.8 (d, J = 22.6 Hz), 57.4, 52.7, 48.8, 28.7 ppm. 
HRMS (ESI) calcd for C30H25ClF4N2O4S2 [M+H]+: 653.0953, found: 653.0935 
 
Acylsulfonamide SZ17TA3: Yield = 80%. Rf = 0.26 in DCM : MeOH = 20:1. 1H NMR 
(600 MHz, DMSO) δ 7.88 – 7.84 (m, 2H), 7.75 (d, J = 7.8 Hz, 2H), 7.44 – 7.41 (m, 3H), 
7.36 (d, J = 7.8 Hz, 2H), 7.21 – 7.12 (m, 3H), 7.09 (d, J = 8.0 Hz, 2H), 7.01 (t, J = 7.2 
Hz, 1H), 6.94 – 6.88 (m, 2H), 6.76 (d, J = 7.9 Hz, 1H), 3.70 (s, 3H), 3.59 (s, 2H), 3.55 (s, 
2H), 3.12 – 3.06 (m, 2H), 2.61 – 2.55 (m, 2H), 2.53 (s, 3H) ppm. 13C NMR (101 MHz, 
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CD3OD) δ 170.7, 163.2, 161.7, 161.2, 143.3, 136.1, 134.1, 133.6, 132.8, 132.5, 132.1, 
131.8, 131.6, 130.5, 130.3, 130.0, 128.8, 127.9, 125.6, 124.2, 117.4, 117.0, 59.3, 58.0, 
56.0, 52.5, 28.8, 17.9 ppm. HRMS (ESI) calcd for C34H33N3O4S3 [M+H]+: 644.1706, 
found: 644.1737 
 
Acylsulfonamide SZ17TA8: Yield = 68%. Rf = 0.46 in DCM : MeOH = 20:1. 1H NMR 
(600 MHz, DMSO) δ 7.95 (d, J = 8.8 Hz, 2H), 7.81 (d, J = 8.2 Hz, 2H), 7.44 (d, J = 8.1 
Hz, 2H), 7.31 (d, J = 8.3 Hz, 2H), 7.19 (t, J = 7.8 Hz, 1H), 7.14 – 7.07 (m, 4H), 6.98 (t, J 
= 7.2 Hz, 1H), 6.93 – 6.88 (m, 2H), 6.76 (d, J = 6.1 Hz, 1H), 3.70 (s, 3H), 3.62 (s, 2H), 
3.57 (s, 2H), 3.12 – 3.06 (m, 2H), 2.61 – 2.55 (m, 2H) ppm. 13C NMR (101 MHz, CDCl3) 
δ 164.5, 161.9, 161.5, 160.6, 153.1, 140.7, 134.7, 132.5, 131.7, 131.3, 130.8, 130.6, 
129.6, 129.6, 128.1, 123.0, 120.6, 120.4 (q, J = 259.8 Hz), 116.6, 115.9, 58.2, 57.0, 55.4, 
51.3, 28.3 ppm. HRMS (ESI) calcd for C31H29F3N2O5S2 [M+H]+: 631.1543, found: 
631.1534 
 
Acylsulfonamide SZ31TA3: Yield = 60%. Rf = 0.4 in DCM : MeOH = 20:1. 1H NMR 
(600 MHz, DMSO) δ 7.88 – 7.84 (m, 2H), 7.77 – 7.72 (m, 2H), 7.44 – 7.41 (m, 3H), 7.35 
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(d, J = 7.9 Hz, 2H), 7.16 (t, J = 7.5 Hz, 2H), 7.10 (d, J = 7.8 Hz, 2H), 7.02 (t, J = 7.1 Hz, 
1H), 6.90 (s, 1H), 6.80 – 6.75 (m, 2H), 5.94 (s, 2H), 3.57 (s, 2H), 3.48 (s, 2H), 3.10 – 
3.04 (m, 2H), 2.58 – 2.54 (m, 2H), 2.53 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 
170.0, 161.5, 159.8, 149.6, 148.8, 140.8, 134.8, 132.6, 132.1, 131.8, 131.6, 131.5, 129.6, 
129.6, 129.4, 128.2, 127.2, 125.6, 122.5, 121.2, 110.9, 109.1, 102.0, 58.1, 56.8, 50.8, 
28.5, 17.9 ppm. HRMS (ESI) calcd for C34H31N3O5S3 [M+Na]+: 680.1318, found: 
680.1344 
 
Acylsulfonamide SZ31TA6: Yield = 65%. Rf = 0.27 in DCM : MeOH = 20:1. 1H NMR 
(600 MHz, DMSO) δ 8.63 (s, 1H), 8.25 (d, J = 7.6 Hz, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.77 
(t, J = 7.8 Hz, 2H), 7.58 (t, J = 7.9 Hz, 1H), 7.51 – 7.41 (m, 2H), 7.36 (d, J = 7.9 Hz, 2H), 
7.15 (t, J = 7.6 Hz, 2H), 7.10 (d, J = 7.8 Hz, 2H), 7.00 (t, J = 7.2 Hz, 1H), 6.80 – 6.74 (m, 
2H), 5.94 (s, 2H), 3.57 (s, 2H), 3.47 (s, 2H), 3.08 (d, J = 6.9 Hz, 2H), 2.55 (d, J = 6.9 Hz, 
2H) ppm. 13C NMR (101 MHz, CD3OD) δ 164.9, 149.4, 148.6, 148.3, 141.1, 135.4, 
134.0, 132.8, 131.6, 131.0, 130.1, 129.3, 129.0, 127.6, 127.3, 125.5, 123.1, 122.2, 110.7, 
108.6, 101.9, 58.1, 56.6, 50.9, 27.6 ppm. HRMS (ESI) calcd for C30H27N3O7S2 [M+H]+: 
606.1363, found: 606.1360 
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Acylsulfonamide SZ31TA7: Yield = 50%. Rf = 0.54 in DCM : MeOH = 20:1. 1H NMR 
(400 MHz, CDCl3) δ 8.15 (d, J = 7.9 Hz, 1H), 8.05 (d, J = 7.8 Hz, 2H), 7.84 (d, J = 8.0 
Hz, 1H), 7.75 (d, J = 7.7 Hz, 1H), 7.60 (d, J = 6.5 Hz, 1H), 7.52 – 7.37 (m, 5H), 7.20 – 
7.13 (m, 5H), 6.85 (s, 1H), 6.73 – 6.68 (m, 2H), 5.90 (s, 2H), 3.60 (s, 2H), 3.48 (s, 2H), 
3.03 – 2.94 (m, 2H), 2.73 – 2.65 (m, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 167.2, 
147.9, 146.9, 146.6, 137.6, 136.4, 133.8, 132.7, 130.7, 130.2, 129.2, 129.1, 128.6, 128.0, 
126.9, 126.1, 125.1, 124.6, 122.1, 109.3, 108.1, 101.1, 58.4, 57.9, 52.8, 31.6 ppm. HRMS 
(ESI) calcd for C34H30N2O5S2 [M+Na]+: 633.1488, found: 633.1506 
 
Acylsulfonamide SZ31TA8: Yield = 62%. Rf = 0.57 in DCM : MeOH = 20:1. 1H NMR 
(400 MHz, DMSO) δ 7.99 – 7.90 (m, 3H), 7.75 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.2 Hz, 
2H), 7.24 (d, J = 8.1 Hz, 2H), 7.18 – 7.08 (m, 4H), 7.00 (t, J = 7.1 Hz, 1H), 6.81 – 6.74 
(m, 2H), 5.95 (s, 2H), 3.57 (s, 2H), 3.48 (s, 2H), 3.11 – 3.04 (m, 2H), 2.59 – 2.52 (m, 2H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 164.4, 153.1, 149.6, 148.8, 140.6, 134.9, 132.6, 
131.6, 131.5, 130.6, 129.6, 129.6, 128.1, 125.6, 121.2, 120.6, 120.4 (q, J = 259.6 Hz), 
110.8, 109.1, 102.0, 58.1, 56.9, 50.8, 28.5 ppm. HRMS (ESI) calcd for C31H27F3N2O6S2 
[M+H]+: 645.1335, found: 645.1352 
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3.4.12 Peptide control experiments: LC/MS-SIM analysis 
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Figure 3.7. Incubation of SZ15 and TA1 and suppressing Mcl-1-templated incubations 
with Bim BH3 peptide. The samples were incubated for six hours at 37 °C and subjected 
to the LC/MS-SIM analysis. A) Incubation of SZ15 and TA1 without Mcl-1 B) 
Incubation of SZ15 and TA1 with 10 M Mcl-1 C) Incubation of SZ15 and TA1 with 10 
M Mcl-1 and 20 M Bim D) Synthetic SZ15TA1 as the reference. 
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Figure 3.8. Incubation of SZ15 and TA3 and suppressing Mcl-1-templated incubations 
with Bim BH3 peptide. The samples were incubated for six hours at 37 °C and subjected 
to the LC/MS-SIM analysis. A) Incubation of SZ15 and TA3 without Mcl-1 B) 
Incubation of SZ15 and TA3 with 10 M Mcl-1 C) Incubation of SZ15 and TA3 with 10 
M Mcl-1 and 20 M Bim D) Synthetic SZ15TA3 as the reference. 
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Figure 3.9. Incubation of SZ15 and TA5 and suppressing Mcl-1-templated incubations 
with Bim BH3 peptide. The samples were incubated for six hours at 37 °C and subjected 
to the LC/MS-SIM analysis. A) Incubation of SZ15 and TA5 without Mcl-1 B) 
Incubation of SZ15 and TA5 with 10 M Mcl-1 C) Incubation of SZ15 and TA5 with 10 
M Mcl-1 and 20 M Bim D) Synthetic SZ15TA5 as the reference. 
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Figure 3.10. Incubation of SZ15 and TA6 and suppressing Mcl-1-templated incubations 
with Bim BH3 peptide. The samples were incubated for six hours at 37 °C and subjected 
to the LC/MS-SIM analysis. A) Incubation of SZ15 and TA6 without Mcl-1 B) 
Incubation of SZ15 and TA6 with 10 M Mcl-1 C) Incubation of SZ15 and TA6 with 10 
M Mcl-1 and 20 M Bim D) Synthetic SZ15TA6 as the reference. 
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Figure 3.11. Incubation of SZ17 and TA3 and suppressing Mcl-1-templated incubations 
with Bim BH3 peptide. The samples were incubated for six hours at 37 °C and subjected 
to the LC/MS-SIM analysis. A) Incubation of SZ17 and TA3 without Mcl-1 B) 
Incubation of SZ17 and TA3 with 10 M Mcl-1 C) Incubation of SZ17 and TA3 with 10 
M Mcl-1 and 20 M Bim D) Synthetic SZ17TA3 as the reference. 
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Figure 3.12. Incubation of SZ17 and TA8 and suppressing Mcl-1-templated incubations 
with Bim BH3 peptide. The samples were incubated for six hours at 37 °C and subjected 
to the LC/MS-SIM analysis. A) Incubation of SZ17 and TA8 without Mcl-1 B) 
Incubation of SZ17 and TA8 with 10 M Mcl-1 C) Incubation of SZ17 and TA8 with 10 
M Mcl-1 and 20 M Bim D) Synthetic SZ17TA8 as the reference. 
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Figure 3.13. Incubation of SZ31 and TA3 and suppressing Mcl-1-templated incubations 
with Bim BH3 peptide. The samples were incubated for six hours at 37 °C and subjected 
to the LC/MS-SIM analysis. A) Incubation of SZ31 and TA3 without Mcl-1 B) 
Incubation of SZ31 and TA3 with 10 M Mcl-1 C) Incubation of SZ31 and TA3 with 10 
M Mcl-1 and 20 M Bim D) Synthetic SZ31TA3 as the reference. 
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Figure 3.14. Incubation of SZ31 and TA6 and suppressing Mcl-1-templated incubations 
with Bim BH3 peptide. The samples were incubated for six hours at 37 °C and subjected 
to the LC/MS-SIM analysis. A) Incubation of SZ31 and TA6 without Mcl-1 B) 
Incubation of SZ31 and TA6 with 10 M Mcl-1 C) Incubation of SZ31 and TA6 with 10 
M Mcl-1 and 20 M Bim D) Synthetic SZ31TA6 as the reference. 
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Figure 3.15. Incubation of SZ31 and TA7 and suppressing Mcl-1-templated incubations 
with Bim BH3 peptide. The samples were incubated for six hours at 37 °C and subjected 
to the LC/MS-SIM analysis. A) Incubation of SZ31 and TA7 without Mcl-1 B) 
Incubation of SZ31 and TA7 with 10 M Mcl-1 C) Incubation of SZ31 and TA7 with 10 
M Mcl-1 and 20 M Bim D) Synthetic SZ31TA7 as the reference. 
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Figure 3.16. Incubation of SZ31 and TA8 and suppressing Mcl-1-templated incubations 
with Bim BH3 peptide. The samples were incubated for six hours at 37 °C and subjected 
to the LC/MS-SIM analysis. A) Incubation of SZ31 and TA8 without Mcl-1 B) 
Incubation of SZ31 and TA8 with 10 M Mcl-1 C) Incubation of SZ31 and TA8 with 10 
M Mcl-1 and 20 M Bim D) Synthetic SZ31TA8 as the reference. 
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Chapter 4 
A Simple Base-Mediated Amidation of Aldehydes with Azides 
4.1 Introduction 
The amide bond serves as one of the nature’s most fundamental functional 
groups. Indeed, it is an integral component of a large number of organic and biological 
molecules such as pharmaceuticals, natural products, peptides, and proteins. 
Traditionally, the amide functionality is incorporated through a reaction of an amine with 
either an activated carboxylic acid (generally acid halides or anhydrides) or by an 
activation using carbodiimide coupling reagents. However, several innovative approaches 
have been developed in the past decade, which include the Staudinger reaction,1 the α-
bromo nitroalkane-amine coupling,2 the native chemical ligation,3 the thio acid-azide 
amidation,4 the alkyne-sulfonyl azide coupling,5 the coupling of acyltrifluoroborates with 
hydroxylamines6 or azides,7 the Au/DNA-catalyzed amidation from alcohols and 
amines,8 the aminocarbonylation of aryl halides,9 and the Pd catalyzed coupling of aryl 
halides with isocyanides.10 Additionally, numerous one-pot oxidative amidation methods 
have been reported wherein, aldehydes,11 alcohols12 or alkynes13 are oxidized using 
transition metal catalysts and treated with amines yielding corresponding amides. 
Meanwhile, some environmentally benign metal-free amidation procedures employing 
silyl reagents14 or oxidants like sodium chlorite,15 peroxide16 have also been exploited.  
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Another important approach to amides is the Schmidt reaction,17 involving 
ketones and hydrazoic acid. Aube and co-workers have reported an intramolecular 
Schmidt reaction of cyclic ketones to construct N-substituted lactams in which hydrazoic 
acid was replaced by an alkyl azide.18 An interesting extension of this reaction, known as 
the Boyer reaction,19 was first reported19a in 1950s, wherein, two aromatic aldehydes 
were reacted with β-phenylethyl azide under harsh acidic conditions generating the 
corresponding amides in moderate yields. Strikingly, this reaction failed to afford the 
desired amide when benzyl or n-butyl azide was used. The reaction of benzyl azide is of 
particular interest since it leads to amidomethylarenes. In fact, a variety of therapeutic 
agents such as Picotamide,20 Raltegravir21 and others22 are comprised of an 
amidomethylarene moiety. Recently, Molander et al. reported a synthetic route to 
generate these types of molecules via a C-C bond forming reaction between 
amidomethyltrifluoroborates and aryl or heteroaryl chlorides (Scheme 4.1).22c  
 
Scheme 4.1. Synthesis of amidomethylarenes 
Implementing a one-pot approach, a series of reactions were performed starting 
from 2-(chloromethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane and various acid 
chlorides to obtain the corresponding amidomethyltrifluoroborates, which were 
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subsequently treated with the aryl or heteroaryl chlorides under standard Pd catalyzed 
cross-coupling conditions leading to the amidomethylarenes. Although a wide range of 
substrates were tolerated under the reported reaction conditions, a tedious 4-step 
sequence to access amidomethyltrifluoroborates demanding long reaction times, high 
temperatures and the Pd catalyst required in the following C-C bond formation are the 
drawbacks associated with this approach. Therefore, a simple, convenient method 
deprived of the aforementioned disadvantages would be of great interest. We herein 
unveil a straightforward protocol starting from azides and aromatic aldehydes to 
synthesize amidomethylarenes under mild basic conditions (Scheme 4.2). 
 
Scheme 4.2. Reaction between azides and aromatic aldehydes yielding amides 
4.2 Results and discussion 
4.2.1 Optimization of the reaction conditions 
Initially, the reaction conditions were screened using benzyl azide and 
benzaldehyde as the model substrates. The summary of these results is presented in Table 
4.1. Surprisingly, among the non-nucleophilic bases tested, t-BuOK alone produced the 
desired amide. From the set of the solvents explored, polar aprotic solvents such as THF, 
DMF, and DMSO proved to be suitable for this transformation, DMF offering the best 
results. In the course of further optimization, increasing the amount of t-BuOK to 2 eq 
was found to significantly improve the yield of the product. Furthermore, the reaction 
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was completed in 15 min at room temperature making it a highly efficient and practical 
synthetic route. 
Table 4.1. Optimization of the reaction conditionsa  
 
Entry Base Solvent Yield (%)b 
1 DIPEA DMF - 
2 Cs2CO3 DMF - 
3 DBU DMF - 
4 t-BuOK DMF 50 
5 t-BuOK THF 40 
6 t-BuOK DMSO 23 
7 t-BuOKc DMF 72 
    
a General reaction conditions: 1a (0.5 mmol), 2a (0.6 mmol), base (0.75 mmol), solvent 
(2.5 mL), 15 min; b Isolated yield based on 1a; c t-BuOK (1.0 mmol). 
4.2.2 Scope of the reaction regarding the aldehydes 
Having the reaction conditions optimized, the scope of the reaction involving 
benzyl azide and a diverse array of aldehydes was first examined (Table 4.2). Aromatic 
aldehydes bearing electron-donating groups afforded excellent yields although an excess 
amount of the base was required in some cases (3ad, 3aj, and 3al). Changing the position 
of methoxy substituent on the aromatic ring from para to meta did not affect the yield 
(3ab and 3ac). However, the amidation reaction with the sterically challenging 
2-methoxybenzaldehyde offered a moderate amount of the product (3ad). Substrates such 
as 3-methylbenzaldehyde, 4-(methylthio)benzaldehyde, [1,1'-biphenyl]-4-carbaldehyde 
and 1-naphthaldehyde led to the formation of desired products 3ae-3ah in good to 
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excellent yields. Functional moieties like 1,3-dioxolane (3ai) and N,N-dimethylamine 
(3aj) were well tolerated as well. Heterocyclic substrates such as furan and indole 
derivatives provided excellent results (3ak and 3al). 
Table 4.2. Reaction of benzyl azide with various aromatic aldehydesa,b 
 
a Reaction conditions: 1a (0.5 mmol), 2 (0.6 mmol), t-BuOK (1.0 mmol), DMF (2.5 mL), 
15 min; b Isolated yields based on 1a; c t-BuOK (2.0 mmol). 
Among aldehydes with electron-withdrawing substituents, 4-chlorobenzaldehyde 
exhibited great compatibility (3am) whereas, lower yield was obtained when 
4-cyanobenzaldehyde was used (3an). Cinnamaldehyde, despite being a Michael 
acceptor, did undergo the reaction (3ao) albeit with poor yield. Unfortunately, the 
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aliphatic aldehydes are not appropriate starting materials under these reaction conditions 
due to the presence of a more acidic α-proton. 
4.2.3 Scope of the reaction regarding the azides 
These encouraging results prompted us to expand the scope of this reaction with 
respect to the azides (Table 4.3). Benzyl azides consisting of electron-withdrawing 
substituents were successfully converted to the amides 3ba, 3ca, and 3da in moderate to 
substantial yields. Especially, the reaction of an azide incorporated on a heteroaryl moiety 
proceeded smoothly resulting in amide 3da. Benzyl azides containing electron-donating 
substituents were found to be suitable substrates for this reaction (3ea and 3fa). It is 
noteworthy to mention that an azide with both electron-donating and withdrawing 
functionalities furnished the amide 3ga in 77% yield. Substrates with sterical hindrance 
participated well under these reaction conditions (3ha and 3ia). In pursuit of substrates 
other than the substituted benzyl azides, we discovered that the α-azido amides also take 
part in this reaction efficiently providing moderate yields for the corresponding diamides 
3ja, 3ka, and 3la. An acid labile Boc group was obviously unaffected (3la) under these 
conditions, offering an advantage over the Boyer reaction. Aromatic and other aliphatic 
azides failed to generate corresponding amides under the reaction conditions described 
herein.  
4.2.4 Control experiments and the plausible mechanism 
 Intrigued by the outcome of this study, we decided to delve into the mechanistic 
details of this reaction. A control experiment was designed wherein t-BuOK was added to 
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a solution of azide 1a in DMF resulting in a deprotonation followed by the loss of 
molecular nitrogen leading to benzylideneamide 5 (Scheme 4.3). 
Table 4.3. Reaction of various azides with benzaldehydea,b 
R N3 + PhCHO
DMF, rt
1b-l 2a 3ba-la
3ba (78%)
t-BuOK
3ea (58%)
3ia (60%)3ha (78%)
3ca (52%) 3da (65%)
R N
H
Ph
O
N
H
Ph
O
Cl
N
H
Ph
O
N
H
Ph
O
N
H
Ph
O
F3C N
H
Ph
O
N
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N
H
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O
Ph
N
H
Ph
O
N
O
N
Ph
3ja (56%)
N
H
Ph
O
N
O
N
Boc
N
H
Ph
O
O N
H
Cl
Ph
O
O
O
3fa (75%) 3ga (77%)
3ka (76%) 3la (45%)
N
O
N
H
Ph
O
Ph
 
a Reaction conditions: 1 (0.5 mmol), 2a (0.6 mmol), t-BuOK (1.0 mmol), DMF (2.5 mL), 
15 min; b Isolated yields based on 1. 
After 10 minutes of stirring, aldehyde 2a was added to the reaction mixture. 
Interestingly, the desired amide 3aa was formed only in trace amounts. On the contrary, 
when a mixture of azide 1a and aldehyde 2a in DMF was treated with t-BuOK, amide 
3aa was obtained in 72% yield (Table 4.2). 
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Scheme 4.3. Control experiments to investigate the reaction mechanism. Reaction 
conditions: 1a (0.5 mmol), 2a (0.6 mmol), t-BuOK (1.0 mmol), DMF (2.5 mL), 15 min. 
This implies that the intermediate benzylideneamide 5 loses its reactivity towards 
aldehyde, failing to generate an amide. Whereas, if the reactive species 4 formed by 
addition of t-BuOK reacts with the aldehyde prior to the elimination of molecular 
nitrogen, an amide is obtained suggesting that, the nucleophilic attack of outermost 
nitrogen atom in species 4 on the carbonyl carbon of aldehyde is crucial for the reaction 
to proceed. Based on these results, a plausible mechanism is proposed in the Scheme 4.4. 
The first step would involve a deprotonation of benzyl azide, generating a highly reactive 
species 4. One of the resonance forms of species 4 (4-B) can readily react with the 
benzaldehyde 2a leading to an intermediate 6 followed by a 1,5-hydride shift resulting in 
triazenide 7. An intramolecular nucleophilic attack on the carbonyl carbon would produce 
8, which would be converted to the amide 3aa through retro [2+2] cycloaddition or 
stepwise loss of molecular nitrogen.  
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Scheme 4.4. Plausible reaction mechanism of amidation 
4.2.5 Discussion 
 Although a lot of synthetic methods to access amides are available, the amide 
bond formation starting from azide and aldehydes seems to be surprisingly less explored. 
For instance, the Boyer reaction was reported in 1950s wherein, two aromatic aldehydes 
reacted with alkyl azides under harsh acidic conditions yielding amides. While exploring 
various reactions for a different application, we serendipitously discovered a reaction 
between a set of alkyl azides (substituted benzyl azides and α-azido amides) and aromatic 
aldehydes under mild basic conditions which resulted in the formation of corresponding 
amides. Among various bases investigated, only potassium tert-butoxide (t-BuOK) was 
suitable to carry out the desired transformation, whereas DMF was the solvent of choice. 
A wide range of electronically and sterically diverse aromatic aldehydes were tolerated 
and the corresponding amides were obtained in good to excellent yields. Unfortunately, 
aliphatic aldehydes are not suitable under these conditions due to the presence of a more 
acidic α-proton. With these encouraging results, scope of the reaction with respect to 
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azides was then investigated. In addition to various substituted benzyl azides, α–azido 
amides were found to undergo the reaction as well. Aromatic and other aliphatic azides 
however, did not take part in the reaction. This implies that an electron-stabilizing group 
on the azides is required for this reaction to proceed. 
Mechanistically, the initial step involves deprotonation of benzyl azide, followed 
by the nucleophilic attack of the terminal nitrogen on the carbonyl carbon of aldehyde. 
Other key steps include 1,5-hydride shift resulting in a triazenide intermediate, 
intramolecular nucleophilic attack on the carbonyl carbon and loss of molecular nitrogen 
finally leading to the amide. Experiments to gain additional mechanistic insights are 
currently in progress.  
4.3 Conclusion 
In summary, a simple, yet highly efficient methodology has been developed for 
the synthesis of amides starting from benzyl azides or α-azido amides and aromatic 
aldehydes. A wide variety of substrates were shown to deliver the desired product in 
moderate to excellent yields, demonstrating the scope of this reaction. Besides, innocuous 
by-products (molecular nitrogen and t-BuOH), short reaction time, ambient temperature 
and easily accessible starting materials make it an attractive alternative to the 
contemporary synthetic routes. Notably, biologically valuable amidomethylarenes could 
be easily synthesized using this method.  
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4.4 Experimental section 
4.4.1 General information 
 All reagents and solvents were purchased from commercial sources and used 
without further purification. All reactions were run under an Argon atmosphere unless 
otherwise indicated. Prior to use of solvents in reactions, they were purified by passing 
the degassed solvents through a column of activated alumina and transferred by an oven-
dried syringe or cannula. Thin layer chromatography was performed on Merck TLC 
plates (silica gel 60 F254). 1H NMR and 13C NMR were recorded on a Varian Inova 400 
(400 MHz) or a Bruker Avance DPX-250 (250 MHz) instrument. The HRMS data were 
measured on an Agilent 1100 Series MSD/TOF with electrospray ionization. 
The azides 1a,23 1b,24 1d,25 1e,26 1f,27 1i,28 1j,29 1l,30 and an aldehyde 2n31 were 
synthesized as previously reported in the literature. 
4.4.2 Synthesis of azides 
 
1-(azidomethyl)-3-(trifluoromethyl)benzene (1c): To a solution of 1-(bromomethyl)-3-
(trifluoromethyl)benzene (1.0 g, 4.18 mmol) in DMSO (15 mL), was added sodium azide 
(326 mg, 5.0 mmol, 1.2 eq) and the resulting reaction mixture was stirred overnight at 70 
°C. The reaction was then treated with H2O (40 mL) and extracted with EtOAc (30 mL  
2). The combined organic layers were washed with brine (30 mL  3), dried with Na2SO4 
and concentrated under reduced pressure. The azide 1c was then obtained by flash 
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chromatography. Yield = 76%. Rf = 0.31 in hexanes. 1H NMR (400 MHz, CDCl3) δ 7.61 
– 7.55 (m, 2H), 7.51 – 7.48 (m, 2H), 4.42 (s, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 
136.74, 131.48, 131.42 (q, J = 32.5 Hz), 129.53, 125.25 (q, J = 3.7 Hz), 124.94 (q, J = 
3.7 Hz), 124.12 (q, J = 272.4 Hz), 54.31 ppm. 
 
5-(azidomethyl)-6-chlorobenzo[d][1,3]dioxole (1g): The azide 1g was prepared 
following the procedure described for the synthesis of azide 1c. Yield = 73%. Rf = 0.62 in 
hexanes : EtOAc = 5:1. 1H NMR (400 MHz, CDCl3) δ 6.86 (s, 1H), 6.82 (s, 1H), 5.98 (s, 
2H), 4.36 (s, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 148.47, 147.14, 126.41, 126.12, 
110.29, 109.85, 102.22, 52.35 ppm. 
N3
1h  
2-(azidomethyl)-1,1'-biphenyl (1h): The azide 1h was synthesized following the 
procedure described for the synthesis of azide 1c. Yield = 83%. Rf = 0.22 in hexanes. 1H 
NMR (400 MHz, CDCl3) δ 7.47 – 7.43 (m, 2H), 7.42 – 7.37 (m, 4H), 7.36 – 7.30 (m, 
3H), 4.28 (s, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 142.42, 140.45, 132.99, 130.64, 
129.76, 129.39, 128.53, 127.99, 127.65, 52.80 ppm. 
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2-azido-1-(4-benzylpiperidin-1-yl)ethanone (1k): The azide 1k was prepared following 
the procedure described for the synthesis of azide 1c, starting from 1-(4-benzylpiperidin-
1-yl)-2-chloroethanone.32 Yield = 54%. Rf = 0.3 in hexanes : EtOAc = 2:1. 1H NMR (250 
MHz, CDCl3) δ 7.36 – 7.09 (m, 5H), 4.58 (d, J = 13.3 Hz, 1H), 3.92 (s, 2H), 3.61 (d, J = 
13.7 Hz, 1H), 3.05 – 2.87 (m, 1H), 2.67 – 2.47 (m, 3H), 1.90 – 1.65 (m, 3H), 1.19 (q, J = 
11.8 Hz, 2H) ppm. 13C NMR (63 MHz, CDCl3) δ 165.20, 139.61, 128.95, 128.20, 125.98, 
50.47, 45.11, 42.66, 42.31, 37.83, 32.18, 31.43 ppm. HRMS (ESI) calcd for C14H18N4O 
[M+H]+: 259.1553, found: 259.1557 
4.4.3 General procedure for the synthesis of amides 
To a mixture of the azide (0.5 mmol) and an aldehyde (0.6 mmol, 1.2 eq) in DMF (2.5 
mL) at room temperature, t-BuOK (1.0 or 2.0 mmol, 2 or 4 eq) was carefully added and 
bubbling was observed immediately. After the completion of reaction, (monitored by 
TLC) water (10 mL) was added and the pH was adjusted to 7.0 using saturated NH4Cl 
solution. The reaction mixture was extracted with EtOAc (20 mL  2) and the combined 
organic layers were washed with brine (30 mL  3), dried with Na2SO4 and concentrated 
under reduced pressure. The product was purified by flash chromatography. 
4.4.4 Synthesis of amides 
 
N-benzylbenzamide (3aa): Yield = 72%. Rf = 0.41 in hexanes : EtOAc = 2:1. 1H NMR 
(400 MHz, CDCl3) δ 7.78 (d, J = 7.6 Hz, 2H), 7.46 – 7.37 (m, 2H), 7.31 (t, J = 7.6 Hz, 
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2H), 7.28 – 7.20 (m, 4H), 4.52 (d, J = 5.8 Hz, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 
167.68, 138.49, 134.37, 131.39, 128.59, 128.43, 127.68, 127.30, 127.16, 43.87 ppm. 
HRMS (ESI) calcd for C14H13NO [M+H]+: 212.1070, found: 212.1068 
 
N-benzyl-4-methoxybenzamide (3ab): Yield = 81%. Rf = 0.31 in hexanes : EtOAc = 
2:1. 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.7 Hz, 2H), 7.35 – 7.18 (m, 5H), 7.07 (s, 
1H), 6.84 – 6.77 (m, 2H), 4.52 (d, J = 5.8 Hz, 2H), 3.76 (s, 3H) ppm. 13C NMR (101 
MHz, CDCl3) δ 167.16, 162.19, 138.74, 128.99, 128.65, 127.79, 127.35, 126.75, 113.71, 
55.41, 43.94 ppm. HRMS (ESI) calcd for C15H15NO2 [M+H]+: 242.1176, found: 
242.1172 
 
N-benzyl-3-methoxybenzamide (3ac): Yield = 81%. Rf = 0.35 in hexanes : EtOAc = 
2:1. 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.36 (m, 1H), 7.32 (d, J = 0.5 Hz, 1H), 7.32 – 
7.29 (m, 3H), 7.29 – 7.28 (m, 1H), 7.28 – 7.24 (m, 2H), 7.03 – 6.97 (m, 1H), 6.61 (s, 1H), 
4.59 (d, J = 5.7 Hz, 2H), 3.80 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 167.42, 
159.99, 138.35, 136.02, 129.71, 128.91, 128.03, 127.74, 118.89, 117.92, 112.57, 55.59, 
44.29 ppm. HRMS (ESI) calcd for C15H15NO2 [M+H]+: 242.1176, found: 242.1175 
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N-benzyl-2-methoxybenzamide (3ad): Yield = 45%. Rf = 0.39 in hexanes : EtOAc = 
2:1. 1H NMR (400 MHz, CDCl3) δ 8.22 (dd, J = 7.8, 1.8 Hz, 2H), 7.43 – 7.37 (m, 1H), 
7.36 – 7.28 (m, 4H), 7.27 – 7.21 (m, 1H), 7.04 (t, J = 7.5 Hz, 1H), 6.91 (d, J = 8.4 Hz, 
1H), 4.66 (d, J = 5.7 Hz, 2H), 3.83 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 165.33, 
157.48, 138.77, 132.79, 132.20, 128.57, 127.42, 127.16, 121.19, 111.37, 55.87, 43.66 
ppm. HRMS (ESI) calcd for C15H15NO2 [M+H]+: 242.1176, found: 242.1177 
 
N-benzyl-3-methylbenzamide (3ae): Yield = 75%. Rf = 0.51 in hexanes : EtOAc = 2:1. 
1H NMR (400 MHz, CDCl3) δ 7.67 – 7.56 (m, 3H), 7.29 – 7.16 (m, 7H), 4.51 (d, J = 5.9 
Hz, 2H), 2.28 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 167.84, 138.57, 138.06, 
134.31, 132.01, 128.43, 128.19, 127.86, 127.55, 127.11, 124.14, 43.71, 21.17 ppm. 
HRMS (ESI) calcd for C15H15NO [M+H]+: 226.1226, found: 226.1230 
 
N-benzyl-4-(methylthio)benzamide (3af): Yield = 83%. Rf = 0.37 in hexanes : EtOAc = 
2:1. 1H NMR (400 MHz, CDCl3) δ 7.71 – 7.67 (m, 2H), 7.34 – 7.25 (m, 5H), 7.23 – 7.20 
(m, 2H), 6.42 (s, 1H), 4.61 (d, J = 5.7 Hz, 2H), 2.48 (s, 3H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 167.00, 143.65, 138.44, 130.63, 128.92, 128.05, 127.74, 127.57, 125.58, 44.25, 
15.21 ppm. HRMS (ESI) calcd for C15H15NOS [M+H]+: 258.0947, found: 258.0951 
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N-benzyl-[1,1'-biphenyl]-4-carboxamide (3ag): Yield = 74%. Rf = 0.49 in hexanes : 
EtOAc = 2:1. 1H NMR (400 MHz, CDCl3) δ 7.86 (d, J = 7.1 Hz, 2H), 7.58 (t, J = 6.5 Hz, 
4H), 7.44 (t, J = 6.4 Hz, 2H), 7.41 – 7.22 (m, 6H), 6.96 (s, 1H), 4.62 (d, J = 4.5 Hz, 2H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 167.34, 144.40, 140.11, 138.48, 133.18, 129.04, 
128.87, 128.47, 128.12, 127.99, 127.73, 127.31, 44.23 ppm. HRMS (ESI) calcd for 
C20H17NO [M+H]+: 288.1383, found: 288.1384 
N-benzyl-1-naphthamide (3ah): 
 
Yield = 67%. Rf = 0.49 in hexanes : EtOAc = 2:1. 1H NMR (400 MHz, CDCl3) δ 8.24 (d, 
J = 7.7 Hz, 1H), 7.80 (d, J = 8.1 Hz, 2H), 7.51 – 7.40 (m, 3H), 7.34 – 7.21 (m, 6H), 6.85 
(s, 1H), 4.52 (d, J = 5.8 Hz, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 169.49, 138.34, 
134.19, 133.62, 130.51, 130.18, 128.68, 128.26, 127.75, 127.43, 126.99, 126.33, 125.46, 
125.00, 124.62, 43.85 ppm. HRMS (ESI) calcd for C18H15NO [M+H]+: 262.1226, found: 
262.1224 
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N-benzylbenzo[d][1,3]dioxole-5-carboxamide (3ai): Yield = 86%. Rf = 0.32 in hexanes 
: EtOAc = 2:1. 1H NMR (400 MHz, CDCl3) δ 7.32 – 7.26 (m, 7H), 6.76 (dd, J = 8.0, 0.5 
Hz, 1H), 6.52 (s, 1H), 5.97 (s, 2H), 4.56 (d, J = 5.7 Hz, 2H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 166.84, 150.49, 148.11, 138.48, 128.89, 128.76, 128.01, 127.69, 121.76, 
108.12, 107.86, 101.83, 44.28 ppm. HRMS (ESI) calcd for C15H13NO3 [M+H]+: 
256.0968, found: 256.0966 
N
H
O
N3aj  
N-benzyl-4-(dimethylamino)benzamide (3aj): Yield = 83%. Rf = 0.26 in hexanes : 
EtOAc = 2:1. 1H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 9.0 Hz, 2H), 7.35 – 7.25 (m, 
5H), 6.64 (d, J = 9.0 Hz, 2H), 6.26 (s, 1H), 4.61 (d, J = 5.7 Hz, 2H), 2.99 (s, 6H) ppm. 
13C NMR (101 MHz, CDCl3) δ 167.44, 152.63, 139.05, 128.81, 128.63, 128.01, 127.49, 
121.25, 111.21, 44.04, 40.27 ppm. HRMS (ESI) calcd for C16H18N2O [M+H]+: 255.1492, 
found: 255.1500 
 
N-benzylfuran-2-carboxamide (3ak): Yield = 86%. Rf = 0.48 in hexanes : EtOAc = 1:1. 
1H NMR (400 MHz, CDCl3) δ 7.33 (s, 1H), 7.30 – 7.18 (m, 4H), 7.06 (d, J = 3.2 Hz, 2H), 
6.43 – 6.37 (m, 1H), 4.53 (d, J = 5.9 Hz, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 
158.39, 147.89, 143.96, 138.17, 128.58, 127.73, 127.39, 114.18, 111.99, 42.99 ppm. 
HRMS (ESI) calcd for C12H11NO2 [M+H]+: 202.0863, found: 202.0862 
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N-benzyl-5-bromo-1-methyl-1H-indole-3-carboxamide (3al): Yield = 72%. Rf = 0.25 
in hexanes : EtOAc = 1:1. 1H NMR (400 MHz, CDCl3) δ 8.19 – 8.16 (m, 1H), 7.51 (s, 
1H), 7.36 – 7.25 (m, 6H), 7.16 – 7.13 (m, 1H), 6.22 (s, 1H), 4.63 (d, J = 5.8 Hz, 2H), 3.71 
(s, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 164.69, 138.99, 136.00, 132.47, 128.90, 
127.97, 127.60, 127.56, 125.78, 123.53, 115.27, 111.51, 110.43, 43.65, 33.59 ppm. 
HRMS (ESI) calcd for C17H15BrN2O [M+H]+: 343.0441, found: 343.0440 
 
N-benzyl-4-chlorobenzamide (3am): Yield = 80%. Rf = 0.55 in hexanes : EtOAc = 2:1. 
1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 8.5 Hz, 2H), 7.38 – 7.25 (m, 7H), 6.54 (s, 1H), 
4.59 (d, J = 5.7 Hz, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 166.53, 138.17, 137.98, 
132.95, 129.02, 128.63, 128.10, 127.90, 44.41 ppm. HRMS (ESI) calcd for C14H12ClNO 
[M+H]+: 246.0680, found: 246.0678 
 
N-benzyl-4-cyanobenzamide (3an): Yield = 37%. Rf = 0.35 in hexanes : EtOAc = 2:1. 
1H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 8.4 Hz, 2H), 7.62 (d, J = 8.4 Hz, 2H), 7.33 – 
7.25 (m, 5H), 7.00 (s, 1H), 4.56 (d, J = 5.7 Hz, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 
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165.85, 138.36, 137.75, 132.49, 128.95, 127.93, 127.91, 118.14, 115.10, 44.37 ppm. 
HRMS (ESI) calcd for C15H12N2O [M+H]+: 237.1022, found: 237.1023 
 
N-benzylcinnamamide (3ao): Yield = 19%. Rf = 0.38 in hexanes : EtOAc = 2:1. 1H 
NMR (400 MHz, CDCl3) δ 7.63 (d, J = 15.6 Hz, 1H), 7.43 (dd, J = 6.4, 2.8 Hz, 2H), 7.35 
– 7.22 (m, 8H), 6.52 (s, 1H), 6.47 (d, J = 15.6 Hz, 1H), 4.50 (d, J = 5.8 Hz, 2H) ppm. 13C 
NMR (101 MHz, CDCl3) δ 166.14, 141.36, 138.40, 134.97, 129.79, 128.92, 128.83, 
128.16, 127.95, 127.62, 120.80, 43.93 ppm. HRMS (ESI) calcd for C16H15NO [M+H]+: 
238.1226, found: 238.1223 
 
N-(2-chlorobenzyl)benzamide (3ba): Yield = 78%. Rf = 0.5 in hexanes : EtOAc = 2:1. 
1H NMR (400 MHz, CDCl3) δ 7.78 – 7.74 (m, 2H), 7.49 – 7.33 (m, 5H), 7.23 – 7.18 (m, 
2H), 6.75 (s, 1H), 4.69 (d, J = 6.0 Hz, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 167.55, 
135.79, 134.42, 133.84, 131.76, 130.48, 129.73, 129.17, 128.75, 127.32, 127.17, 42.20 
ppm. HRMS (ESI) calcd for C14H12ClNO [M+H]+: 246.0680, found: 246.0677 
 
N-(3-(trifluoromethyl)benzyl)benzamide (3ca): Yield = 52%. Rf = 0.37 in hexanes : 
EtOAc = 2:1. 1H NMR (400 MHz, CDCl3) δ 7.80 – 7.75 (m, 2H), 7.57 – 7.46 (m, 4H), 
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7.45 – 7.37 (m, 3H), 6.75 (s, 1H), 4.65 (d, J = 5.9 Hz, 2H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 167.79, 139.56, 134.21, 131.96, 131.37 (q, J = 1.3 Hz), 131.22 (q, J = 32.2 Hz), 
129.42, 128.85, 127.19, 124.70 – 124.50 (m, two quartets being merged, J = 3.8 Hz), 
124.20 (q, J = 272.4 Hz), 43.73 ppm. HRMS (ESI) calcd for C15H12F3NO [M+H]+: 
280.0944, found: 280.0949 
N
Cl
N
H
O
3da  
N-((6-chloropyridin-3-yl)methyl)benzamide (3da): Yield = 65%. Rf = 0.33 in hexanes 
: EtOAc = 1:1. 1H NMR (400 MHz, CDCl3) δ 8.24 (s, 1H), 7.77 – 7.72 (m, 2H), 7.61 (dd, 
J = 8.2, 2.4 Hz, 1H), 7.49 – 7.43 (m, 1H), 7.40 – 7.34 (m, 2H), 7.21 (d, J = 8.2 Hz, 1H), 
7.08 (s, 1H), 4.53 (d, J = 6.0 Hz, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 167.96, 
150.68, 149.07, 138.83, 133.88, 133.37, 132.06, 128.82, 127.19, 124.48, 40.85 ppm. 
HRMS (ESI) calcd for C13H11ClN2O [M+H]+: 247.0633, found: 247.0635 
 
N-(3-methylbenzyl)benzamide (3ea): Yield = 58%. Rf = 0.45 in hexanes : EtOAc = 2:1. 
1H NMR (400 MHz, CDCl3) δ 7.80 – 7.76 (m, 2H), 7.50 – 7.44 (m, 1H), 7.42 – 7.36 (m, 
2H), 7.24 – 7.19 (m, 1H), 7.15 – 7.06 (m, 3H), 6.58 (s, 1H), 4.57 (d, J = 5.7 Hz, 2H), 2.32 
(s, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 167.49, 138.63, 138.30, 134.59, 131.65, 
128.83, 128.83, 128.71, 128.49, 127.16, 125.10, 44.27, 21.55 ppm. HRMS (ESI) calcd 
for C15H15NO [M+H]+: 226.1226, found: 226.1231 
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N-(3-methoxybenzyl)benzamide (3fa): Yield = 75%. Rf = 0.32 in hexanes : EtOAc = 
2:1. 1H NMR (400 MHz, CDCl3) δ 7.80 – 7.75 (m, 2H), 7.51 – 7.44 (m, 1H), 7.42 – 7.36 
(m, 2H), 7.27 – 7.22 (m, 1H), 6.93 – 6.86 (m, 2H), 6.81 (dd, J = 8.2, 2.5 Hz, 1H), 6.60 (s, 
1H), 4.58 (d, J = 5.7 Hz, 2H), 3.77 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 167.56, 
160.09, 139.98, 134.53, 131.70, 129.97, 128.74, 127.15, 120.26, 113.65, 113.17, 55.41, 
44.23 ppm. HRMS (ESI) calcd for C15H15NO2 [M+H]+: 242.1176, found: 242.1179 
 
N-((6-chlorobenzo[d][1,3]dioxol-5-yl)methyl)benzamide (3ga): Yield = 77%. Rf = 0.4 
in hexanes : EtOAc = 2:1. 1H NMR (400 MHz, CDCl3) δ 7.77 – 7.73 (m, 2H), 7.49 – 
7.43 (m, 1H), 7.41 – 7.35 (m, 2H), 6.91 (s, 1H), 6.80 (s, 1H), 6.70 (s, 1H), 5.92 (s, 2H), 
4.57 (d, J = 6.0 Hz, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 167.56, 147.91, 147.04, 
134.39, 131.77, 129.03, 128.75, 127.16, 125.61, 110.30, 110.03, 102.03, 42.08 ppm. 
HRMS (ESI) calcd for C15H12ClNO3 [M+H]+: 290.0578, found: 290.0583 
 
N-([1,1'-biphenyl]-2-ylmethyl)benzamide (3ha): Yield = 78%. Rf = 0.53 in hexanes : 
EtOAc = 2:1. 1H NMR (400 MHz, CDCl3) δ 7.63 – 7.60 (m, 2H), 7.49 – 7.40 (m, 4H), 
7.38 – 7.32 (m, 7H), 7.29 – 7.26 (m, 1H), 6.26 (s, 1H), 4.61 (d, J = 5.6 Hz, 2H) ppm. 13C 
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NMR (101 MHz, CDCl3) δ 167.20, 141.89, 140.95, 135.61, 134.51, 131.57, 130.44, 
129.15, 129.03, 128.67, 128.65, 128.03, 127.73, 127.58, 127.02, 42.27 ppm. HRMS 
(ESI) calcd for C20H17NO [M+H]+: 288.1383, found: 288.1383 
 
N-(naphthalen-1-ylmethyl)benzamide (3ia): Yield = 60%. Rf = 0.47 in hexanes : 
EtOAc = 2:1. 1H NMR (400 MHz, CDCl3) δ 8.07 – 8.04 (m, 1H), 7.89 – 7.85 (m, 1H), 
7.81 (d, J = 8.1 Hz, 1H), 7.75 – 7.71 (m, 2H), 7.55 – 7.45 (m, 3H), 7.45 – 7.39 (m, 2H), 
7.38 – 7.32 (m, 2H), 6.48 (s, 1H), 5.05 (d, J = 5.3 Hz, 2H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 167.36, 134.46, 134.09, 133.58, 131.68, 131.66, 128.98, 128.91, 128.71, 
127.15, 127.04, 126.91, 126.22, 125.59, 123.68, 42.54 ppm. HRMS (ESI) calcd for 
C18H15NO [M+H]+: 262.1226, found: 262.1225 
 
N-(2-oxo-2-(4-phenylpiperazin-1-yl)ethyl)benzamide (3ja): Yield = 56%. Rf = 0.17 in 
hexanes : EtOAc = 1:1. 1H NMR (400 MHz, CDCl3) δ 7.86 – 7.81 (m, 2H), 7.52 – 7.46 
(m, 1H), 7.45 – 7.39 (m, 2H), 7.35 (s, 1H), 7.30 – 7.25 (m, 2H), 6.93 – 6.88 (m, 3H), 4.28 
(d, J = 4.0 Hz, 2H), 3.83 – 3.79 (m, 2H), 3.62 – 3.58 (m, 2H), 3.21 – 3.15 (m, 4H) ppm. 
13C NMR (101 MHz, CDCl3) δ 167.38, 166.74, 150.89, 134.05, 131.85, 129.47, 128.74, 
127.26, 121.02, 116.99, 49.77, 49.53, 44.58, 42.22, 41.90 ppm. HRMS (ESI) calcd for 
C19H21N3O2 [M+H]+: 324.1707, found: 324.1716 
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N-(2-(4-benzylpiperidin-1-yl)-2-oxoethyl)benzamide (3ka): Yield = 76%. Rf = 0.14 in 
hexanes : EtOAc = 2:1. 1H NMR (400 MHz, CDCl3) δ 7.86 – 7.81 (m, 2H), 7.51 – 7.46 
(m, 1H), 7.45 – 7.37 (m, 3H), 7.31 – 7.24 (m, 2H), 7.23 – 7.17 (m, 1H), 7.14 – 7.10 (m, 
2H), 4.62 – 4.52 (m, 1H), 4.29 – 4.12 (m, 2H), 3.80 – 3.70 (m, 1H), 2.96 (tt, J = 15.6, 8.0 
Hz, 1H), 2.65 – 2.52 (m, 3H), 1.84 – 1.67 (m, 3H), 1.26 – 1.11 (m, 2H) ppm. 13C NMR 
(101 MHz, CDCl3) δ 167.30, 166.26, 139.79, 134.13, 131.73, 129.20, 128.67, 128.51, 
127.22, 126.31, 44.85, 42.97, 42.69, 41.85, 38.24, 32.36, 31.73 ppm. HRMS (ESI) calcd 
for C21H24N2O2 [M+H]+: 337.1911, found: 337.1904 
 
tert-butyl 4-(2-benzamidoacetyl)piperazine-1-carboxylate (3la): Yield = 45%. Rf = 
0.12 in hexanes : EtOAc = 1:1. 1H NMR (400 MHz, CDCl3) δ 7.83 – 7.76 (m, 2H), 7.46 
(ddd, J = 6.4, 3.7, 1.3 Hz, 1H), 7.42 – 7.37 (m, 2H), 7.31 (s, 1H), 4.22 (d, J = 4.0 Hz, 
2H), 3.63 – 3.56 (m, 2H), 3.48 – 3.37 (m, 6H), 1.43 (s, 9H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 167.39, 166.95, 154.55, 133.94, 131.85, 128.71, 127.23, 80.70, 44.45, 42.05, 
41.89, 28.50 ppm. HRMS (ESI) calcd for C18H25N3O4 [M+Na]+: 370.1737, found: 
370.1738 
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